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ABSTRACT OF THE DISSERTATION 
THE 4-AZA-S-RIBOSYL-L-HOMOCYSTEINE DERIVATIVES AND THE RELATED  
GAMMA-LACTAM AND AZAHEMIACETAL ANALOGS: 
SYNTHESIS, INHIBITION AND QUORUM SENSING ACTIVITY 
by 
Venkata Malladi 
Florida International University, 2011 
Miami, Florida 
Professor Stanislaw F. Wnuk, Major Professor. 
Quorum sensing (QS) is a population-dependent signaling process bacteria use to control 
multiple processes including virulence, critical for establishing infection. There are two major 
pathways of QS systems. Type 1 is species specific or intra-species communication in which N-
acylhomoserine lactones (Gram-negative bacteria) or oligopeptides (Gram-positive bacteria) are 
employed as signaling molecules (autoinducer one). Type 2 is inter-species communication in 
which S-4,5-dihydroxy-2,3-pentanedione (DPD) or its borate esters are used as signaling 
molecules. The DPD is biosynthesized by LuxS enzyme from S-ribosylhomocysteine (SRH). 
Recent increase in prevalence of bacterial strains resistant to antibiotics emphasizes the need 
for the development of new generation of antibacterial agents. Interruption of QS by small 
molecules is one of the viable options as it does not affect bacterial growth but only virulence, 
leading to less incidence of microbial resistance. Thus, in this work, inhibitors of both N-
acylhomoserine lactone (AHL) mediated intra-species and LuxS enzyme, involved in inter-
species QS are targeted.  
The γ-lactam and their reduced cyclic azahemiacetal analogs, bearing the additional 
alkylthiomethyl substituent, were designed and synthesized targeting AHL mediated QS systems 
in P. aeruginosa and Vibrio harveyi. The γ-lactams with nonylthio or dodecylthio chains acted as 
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inhibitors of las signaling in P. aeruginosa with moderate potency. The cyclic azahemiacetal with 
shorter propylthio or hexylthio substituent were found to strongly inhibit both las and rhl 
signaling in P. aeruginosa at higher concentrations. However, lactam and their azahemiacetal 
analogs were found to be inactive in V. harveyi QS systems. 
The 4-aza-S-ribosyl-L-homocysteine (4-aza-SRH) analogs and 2-deoxy-2-substituted-S-
ribosyl-L-homocysteine analogs were designed and synthesized targeting Bacillus subtilis LuxS 
enzyme. The 4-aza-SRH analogs in which oxygen in ribose ring is replaced by nitrogen were 
further modified at anomeric position to produce pyrrolidine, lactam, nitrone, imine and 
hemiaminal analogs. Pyrrolidine and lactam analogs which lack anomeric hydroxyl, acted as 
competitive inhibitors of LuxS enzyme with KI value of 49 and 37 µM respectively. The 2,3-
dideoxy lactam analogs were devoid of activity. Such findings attested the significance of 
hydroxyl groups for LuxS binding and activity. Hemiaminal analog of SRH was found to be a 
time-dependent inhibitor with IC50 value of 60 µM.  
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1. INTRODUCTION 
 1.1. Quorum sensing 
Quorum sensing (QS) is a cell density dependent bacterial communication phenomenon. The 
term, ‘quorum’ is defined as “the minimum bacterial behavioral unit required inducing this 
communication”.1 Observation of autoinduction of luminescence in V. fisheri was the first 
example of involvement of QS.2 Later, many examples of bacteria employing QS (both Gram 
positive and Gram negative) for interspecies and intraspecies communication were reported. Such 
conversations allow bacteria which are single-celled organisms to control crucial functions in 
united communities such as symbiosis, motility, virulence, antibiotic production, biofilm 
formation, exchange of DNA and many other processes; and thereby receive some of the benefits 
of multicelluar organisms. Bacteria secrete chemical molecules called autoinducers (AIs) to 
induce QS.3-5 At low cell density, the concentration of this chemical is also low. When cell 
density increases, the concentration increases to a point critical for induction of genes responsible 
for community behaviors.3-5 
There are two major pathways of QS systems. Type 1 is species specific or intra-species 
communication in which acyl homoserine lactones (Gram-negative bacteria) and oligopeptides 
(Gram-positive bacteria) are employed as autoinducers (referred as AI-1s). On the other hand 
type 2 is inter-species signaling system in which borate diester of cyclized 
dihydroxypentanedione or R-tetrahydroxytetrahydrofuran (R-THMF) are used as autoinducers 
(referred as AI-2) (Figure 2).6 
1.1.1. Intraspecies quorum sensing  
1.1.1.1. Gram negative bacteria 
  The major intraspecies signaling molecules among Gram negative bacteria are AHL 
analogs.6 QS in marine luminescent V. fisheri was the first report of AHL involvement as 
Acyl homoserine lactones (AHLs) 
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autoinducer molecules.7,8 These sensor molecules can be distinct to each species or could be 
shared among other bacteria.  
The AHLs contain a long fatty acid chain connected to a homoserine lactone through an 
amide bond. The AHLs are synthesized from SAM and acylated acyl carrier protein (acyl-ACP) 
by inducer synthases (LuxI like proteins) at low basal levels.9 At high cell densities, as the AHL 
reaches the threshold concentration, it binds to the cognate receptors (LuxR-like proteins) which 
reside in cytoplasm. Thereafter the AHL:LuxR complex undergoes homodimerization followed 
by multimerization. Subsequently, the multimer binds to 20 bp-element called lux-type-box and 
activates transcription of target genes required for community behaviors (Figure 1).10,11 Details of 
different LuxI/LuxR type of systems present in various Gram negative bacteria along with their 
functions are included in Table 1.6 
 
Figure 1. Model of AHL biosynthesis and quorum sensing in a bacterial cell.10 
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The LuxR type proteins share 18-23% sequence homology. The conserved residues required 
for binding were identified to be Ala38 (Gly in LasR and VanR), Tyr53 (Cys in AhyR), Tyr57, 
Asp70 and Thr129 (Ser in AhyR, LasR. LuxR, RhlR and VanR).12 Recently, the crystal structure 
of Agrobacterium tumefaciens TraR in complex with its inducing ligand, 3-oxo-C8-AHL bound to 
target DNA was solved by Allesandro et al.13 From the crystallographic studies, the binding 
pocket of TraR was found to have hydrophobic and aromatic residues to accommodate the fatty 
acid side chain. Also, hydrogen bonding between Trp57 and carbonyl of lactone, Asp70 and 
amide nitrogen and Tyr53 and side chain amide carbonyl were observed.13 
Table 1. Representative AHLs along with their regulators and corresponding functions 
Bacterium Signala LuxI/LuxR QS phenotype 
 
Agrobacterium  
hydrophilia 
 
C4-AHL 
 
AhyI/AhyR 
 
Exoprotease production 
 
A. tumefaciens 
 
3-oxo-C8-AHL 
 
TraI/R 
 
Ti plasmid conjugation 
 
Burkholderia 
cenocepacia 
 
C8-AHL, C6-AHL 
 
CciI/R;CepI/R 
 
Biofilm, swarming motility 
 
Erwinia carotovora 
 
3-oxo-C6-AHL 
 
ExpI/R; 
CarI/R 
 
Carbapenem, exoenzymes,virulence 
 
Psuedomonas 
aeruginosa 
 
3-oxo-C12-AHL 
 
LasI/R 
 
Exoenzymes, pyocyanin and biofilm 
 
formation 
 
3-oxo-C4-AHL 
 
RhlI/R 
 
Serratia liquefaciens 
 
C4-AHL 
 
SwrI/R 
 
Extracellular proteases, swarming 
 
Vibrio fisheri 
 
3-oxo-C6-AHL 
 
LuxI/R 
 
bioluminescence 
 
Vibrio harveyi 
 
3-hydrdoxy-C4-
AHL 
 
LuxLM/N 
 
bioluminescence 
aAHL abbreviations/nomenclature used in the entire text 
Recently, a third chemical class of QS signal (CAI-1as AI-1) in V. cholerae was also 
discovered. It is identified as (S)-3-hydroxytridecane-4-one (Figure 2). While other bacteria 
produce biofilms and virulence factors at high cell density through QS, V. cholerae, in contrast at 
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high population of bacteria, represses the factors regulating their production by employing CAI-1 
and AI-2.14 
A fourth type of QS system was observed in P. aeruginosa known as 4QS pathway (4-
quinolone signal). It is modulated by using 2-heptyl-3-hydroxy-4-quinolone as an autoinducer 
(Figure 2) and detected by QscR receptor. Three signaling pathways exist in P. aeruginosa. Two 
QS mediated systems (lasR and rhlR) use AHL and the third uses a 4-quinolone derivative. The 
LasI/R synthesizes and detects N-(3-oxo-dodecanoyl)-L-homoserine lactone (3-oxo-C12-AHL) 
while RhlI/R synthesizes and detects N-butanoyl-L-homoserine lactone (C4-AHL) (Figure 2). 
These two signaling systems regulate 6% of the gene expression in P. aeruginosa. The QscR is an 
orphan receptor which lacks LuxI of its own and recognizes AHL produced by LasI and RhLI 
systems. It represses QS activity.15 Together, the three QS systems act in a complex hierarchical 
partially redundant manner to control virulence, secondary metabolite production and various 
host immune responses.16 
1.1.1.2. Gram positive bacteria 
Gram positive bacteria use oligopeptides as autoinducers to mediate two component QS 
regulatory system.17 These two components are: (i) receptor for binding to AI-1s and (ii) 
response-regulatory protein. The latter is involved in gene regulation upon activation along with 
AI-1 production through a positive feedback loop. When AI-1 binds to the sensor receptor, a 
histidine sensor kinase protein is activated which auto phosphorylate the histidine residue.18 The 
phosphorylated protein transfers the phosphoryl group to the conserved aspartate residue in the 
cognate response regulator leading to the activation of several genes responsible for bacterial 
QS.18,19 
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O
O
N
H
R
O
A. Acylhomoserine lactones (AI-1)
R group
O
OH
O
O
P. aeruginosa (LasI)
P. aeruginosa (RhlI)
V. fisheri (LuxI)
A. tumefaciens (TraI)
V. harveyi (LuxLM)
B. Oligopeptides (AI-1)
ADPITROWGD B. subtilis (ComX)
ERGMT B. subtilis (CSF)
EMRLSKFRDFILQRKK S. pneumoniae (CSP)
YSTCDFIM
S
O
GVNACSSLF
S
O
INCDFLL
S
O
YSTCYFIM
S
O
S. aeureus (AgrD)
AIP-I AIP-II
AIP-III AIP-IV
C. Furanones (AI-2)
O O
B
O
CH3
HO
HO
HO OH
AI-2 in V. harveyi (LuxS)
OHO
OH
CH3
HO
 AI-2 in S. typhimurium (LuxS)
D. Tridecane (AI-1)
OH
O
CAI-1 in V. cholera (CqsA)
N
H
E. 4-Quonilone (AI-1)
O
OH
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Figure 2. Representative structures of autoinducers (respective synthases mentioned in 
parenthesis) A. AHLs used by Gram negative bacteria B. Oligopeptides used by Gram positive 
bacteria. C. AI-2s recognized by V. harveyi and S. typhimurium. D. AI-1 autoinducer used in V. 
cholerae  E. PQS autoinducer used by P. aeruginosa. 
1.1.2. Interspecies quorum sensing 
While AHLs are the chemical lexicon of Gram negative bacteria and oligo peptides for Gram 
positive bacteria, for communication within the species, derivatives of 4,5-dihdroxy-2,3-
  
 
6 
pentanedione (DPD), referred as AI-2  is the common signaling molecule for both Gram positive 
and negative bacteria.20-23 
 Vibrio harveyi, a Gram negative bioluminescent marine bacterium, is the paradigm for the 
interspecies communication, as involvement of AI-2 was extensively studied and demonstrated in 
this organism. It uses AHL mediated QS for regulation of bioluminescence. In a series of 
biochemical and genetic experiments conducted by Bassler et al. to study QS in V. harveyi, the 
bacterial mutant cultures, in spite of lacking the AHL synthase (LuxM) and cognate receptor 
(LuxN),24,25 were observed to induce bioluminescence. Such findings suggested a second class of 
signaling molecules, apart from AHL. That was the first example of association of AI-2 as QS 
mediator. However,  apart from AHLS and AI-2 QS systems, another new class of QS molecule 
called CAI-1 (whose structure is unknown but speculated to be related to CAI-1 in V. cholerae 
((S)-3-hydroxytridecane-4-one)) was also shown to mediate QS (Figure 2).14 These three QS 
systems work convergently to control production of bioluminescence26 virulence factors such as 
metalloprotease production, type III secretion27 and siderophore production.28 
An overview of QS system of V. harveyi
V. harveyi recognizes and secretes three types of autoinducers: (1) the AI-1 (N-(3-
hydroxybutyryl)- -homoserine lactone) referred as HAI-1, is synthesized by LuxM, (2) the AI-2 
(borate ester of 4,5-dihydroxy-2,3-pentanedione27 (DPD) is synthesized by LuxS (it will be 
discussed  in detail in later sections), and (3) cholera autoinducer 1 (CAI-1) is synthesized by 
CqsA enzyme.14 Membrane bound histidine kinases detect the autoinducers (Figure 3).29 The 
HAI-1 is detected by the LuxN histidine kinase.27,30 The AI-2 is detected by the periplasmic 
protein LuxP in complex with the LuxQ histidine kinase,24,27,31 while CAI-1 is detected by the 
CqsS histidine kinase.14,27,32 These proteins are bifunctional as they can act as kinases and 
phosphatases depending on cell density.28 In the absence autoinducers, i.e., at low cell density, 
these proteins get phosphorylated and subsequently transfer the phosphate to LuxO via LuxU. 
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Phosphorylated LuxO along with σ54 activates production of five sRNAs.33,34 These in turn bind 
with chaperon Hfq to destabilize mRNA encoding the transcriptional regulator, LuxRvh.35 
Therefore no LuxRvh is produced at low cell density. At high cell density, when AIs are released, 
the cognate receptors turn themselves into phosphatases and reverse the sequence of 
phosphorylation leading to up regulation of LuxRvh which regulates for more than 50 genes 
including those encoding luciferase26 and virulence factors (Figure 3).36,37 
1.1.2.1. The signaling pathway for auto inducer of type 2 (AI-2) 
In order to study the enzymes involved in the AI-2 signaling, Schaudre et al. made mutants of 
V. harveyi, E. coli and S. typhimurium. In all the mutants of bacteria, luxS gene was observed to 
be highly conserved.38 The involvement of luxS  in AI-2 signaling was confirmed by observation 
of the fact that bacterial cultures lacking luxS gene failed to produce AI-2 activity.38 The luxS 
gene was found to be present in more than 60 bacterial species (both Gram positive and negative) 
supporting the hypothesis of AI-2 as inter species signal. 
A.                                                                     B. 
.   
Figure 3. A. Vibrio harveyi signal transduction at low cell density: B. Vibrio harveyi signal 
transduction at high cell density.29  
 
The key to identification of biosynthetic pathway of AI-2 was unraveled when luxS gene was 
observed to be located downstream of pfs and metk.39 The gene metk encodes for enzyme, S-
Biosynthesis of AI-2 
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adenosyl-L-methionine synthetase which catalyzes production of S-adenosyl-L-methionine 
(SAM) from ATP and methionine.40 The SAM acts as a methyl donor in the biosynthesis and/or 
modification of DNA, RNA and various proteins and produces S-adenosylhomocysteine (SAdH). 
Through negative feedback inhibition, SAdH inactivates SAM-dependent methyltransferase. 
Therefore, SAdH should be transformed into a nontoxic metabolite for the successful operation of 
SAM dependent methylation reactions.41 Eukaryotes employ the enzyme, SAdH hydrolase to 
convert S- SAdH to adenine and homocysteine (Hcy) whereas prokaryotes follow a two-step 
strategy using Pfs enzyme and LuxS.42 In the first step Pfs catalyzes depurination of SAdH to 
give adenine and S-ribosyl-L-homocysteine (SRH) (Scheme 1). In the second step, LuxS converts 
SRH to homocysteine and 4,5-dihydroxy- 2,3-pentanedione (DPD) by a nonredox pathway. 
Subsequently, homocysteine undergoes methylation and reenters the catalytic cycle.43 It was 
hypothesized that LuxS catalyzes the final step of converting SRH into DPD which ultimately 
leads to production of AI-2 activity. This hypothesis was proved by conducting series of 
experiments with the use of cell lysates, purifies Pfs, LuxS and substrates like SAM, SAdH and 
SRH.44
O
A
OHHO
SHO2C
NH2
SAdH
O
OHHO
SHO2C
NH2
OH
SRH
Pfs Nucleosidase
LuxS
SHHO2C
NH2
homocysteine
OH
O
O
OH
+
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O
A
OHHO
SHO2C
NH2
SAM
transmethylase
A: adenine
 
Scheme 1. Biosynthesis of 4,5-dihydroxy- 2,3-pentanedione (DPD) (precursor to AI-2) 
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The DPD is a highly unstable molecule. It undergoes dehydration and cyclization reactions to 
give a mixture of interconvertible furanones. But none of these sugar derivatives, including DPD, 
showed bioluminescence comparable to AI-2 activity in V. harveyi bioassay. Such result clearly 
shows that LuxS in vitro mixtures contain an elusive chemical (AI-2) which is distinct from the 
rest of the furanones.44 Bassler et al. successfully solved the structure of AI-2 from the crystal 
structure of V. harveyi AI-2 sensing protein, LuxP in complex with AI-2 (depicted in Figure 4 
along with network of hydrogen bonds) and 11B NMR studies. It was found to be borate diester of 
S-THMF (2S,4S)-2-methyl-2,3,3,4-tetrahydroxyterahydrofuran). The proposed formation of AI-2 
from DPD involves (i) cyclization and hydration of DPD to give the furanone derivative, S-
THMF (ii) complexation of S-THMF with borate to form AI-2 (Scheme 2).22 
The structure of AI-2  
DPD
O O
B
O
O
CH3
HO
HO
HO
HO OH
OH
CH3O
(S-THMF borate): AI-2 in   
             V. harveyi
B(OH)4-
OHO
OH
CH3O
OHO
OH
CH3HO
HO
OHO
OH
CH3HO
HO
2H2O
(S-THMF)
O
O
OH
OH
(2S,4S)-2-methyl-2,3,3,4-
tetrahydroxytetrahydrofuran
(2R,4S)-2-methyl-2,3,3,4-
tetrahydroxytetrahydrofuran
(2S,4S)-2,4-dihydroxy-methyl-
2-methyldihydrofuran-3-one
(R-THMF): AI-2 in S. typhimurium
(S-DHMF)
(2R,4S)-2,4-dihydroxy-methyl-
2-methyldihydrofuran-3-one
(R-DHMF)
(2S,4S)-2-methyl-2,3,3,4-
tetrahydroxytetrahydrofuran-borate
 
Scheme 2. Formation of AI-2 from 4,5-dihydroxy-2,3-pentanedione (DPD).45 
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The crystal structure of Salmonella typhimurium LsrB (AI-2 binding protein) bound AI-2, 
revealed a chemically different form of AI-2 compared to V. harveyi (Scheme 2).45 While V. 
harveyi uses S-THMF-borate as AI-2, S. typhimurium uses R-THMF ((2R,4S)-2-methyl-2,3,3,4-
tetrahydroxytetrahydrofuran). S. typhimurium being a gut pathogen has no access to boron, so it is 
conceivable that it uses nonboron compound as a sensing molecule. These findings support the 
validity of DPD as a precursor to AI-2 sensor and establish its role in interspecies 
communication. 
A.       B.  
 
Figure 4. Crystal structure of V. harveyi LuxP with AI-2 at the binding site (Figure 4A)22 and 
crystal structure of Salmonella typhimurium LsrB with AI-2 at the binding site (Figure 4B).45 
 
1.2.2.2. S-ribosylhomocysteinase (LuxS) 
Currently four homologues of LuxS (Deinococcus radiodurans, Haemophilus influenzae, 
Helicobacter pylori and Bacillus subtilis) have been resolved by X-ray crystallography at 
resolution of 1.2 to 2.4 A°.46-48 All LuxS proteins are homodimers. Each subunit is a single 
polypeptide chain which share a novel α-β fold consisting of four-stranded antiparallel β-sheet 
bordered by 3 α helices on one side and a short 310 helix on the other side.46-48 The LuxS sequence 
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alignment from 26 species, revealed 23 repeated amino acid residues, some of which are part of 
the active center. In the crystal, as well as in solution, LuxS is present as symmetric homodimer 
with two symmetric active sites. The dimeric interface contains a complex network of H bonding, 
ionic and hydrophobic interactions.47 
The LuxSBs (LuxS present in Bacillus subtilis) is a single polypeptide with 157 amino acids 
per each monomer.46 Initially, the structure of LuxS was determined with Zn2+ at the active site, 
coordinated by three conserved residues viz His-54, His-58, Cys-126 and water molecule (Figure 
5). Because of the presence of zinc, a molecule of water and the motif HXXEH, similar to the 
protease-binding motif found in thermolysin and other zinc dependent hydrolases, LuxS was 
proposed to perform a similar enzymatic role. The function of the metal as a Lewis acid was 
established from the crystal structure of LuxS with the 2-keto intermediate, 3 (Scheme 3).49 The 
proposed metal mediated catalysis was confirmed by the dramatic change in electronic absorption 
spectrum of cobalt ion when the natural substrate, SRH was added to the Co-LuxSBs (from peaks 
at 530, 570, 650 nm to none).50 
 Interestingly, Cys84 which is highly conserved in the active site, was found oxidized to 
cysteine sulfonic acid and cysteine sulfinic acids leading to rapid inactivation of LuxS, suggesting 
complexation of metal ion to Cys84 in catalysis.46,47 A ligand combination (two His, one Cys, one 
water molecule and Fe2+) similar to LuxS was also reported in peptide deformylase which also 
underwent inactivation by an identical route.51,52 These findings along with the studies done by 
Pei et al. on purified LuxS enzyme, suggested that native metal ion in LuxS was Fe2+ instead of 
Zn2+.50 However, the Zn and the Co coordinated proteins were found to be more stable to aerobic 
oxidation compared to native iron bound LuxS. Substitution of Co2+ or Fe2+ for Zn2+ gave a 
variant with a 10-fold increase in catalytic activity in vitro.50 
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Figure 5. Crystal structure of LuxSBs in complex with 2-keto intermediate.49 
The crystal structure of LuxSBs in complex with SRH at 2.2 A° and homocysteine at 2.3 A° 
respectively, was determined by Baker et al.46 “The homocysteine moiety of SRH is bound in an 
extended conformation with the amino and carboxyl groups stabilized by hydrogen bonds with 
five neighboring residues from helix α1 and strand β3 (Arg65, Asp78, Ile79, Ser80 and Gly127 
and Lys35 of neighboring subunit). The ribose moiety appears to be in the C2ˈ-endo 
conformation and the ribose O2 and O3 hydroxyl groups can be seen involved in long ion-dipole 
interactions with the Zn2+ ion.23  In addition, the O2 and O3 ribose hydroxyl groups are stabilized 
by hydrogen bonds with the oxygen atoms of oxidized Cys84”.46,53 
Active site of LuxS (Figure 5) 
The proposed catalytic mechanism of LuxS involves consecutive aldose-ketose and ketose-
ketose isomerizations and subsequent β-elimination to release Hcy and DPD (Scheme 3).54 In the 
Mechanism of S-ribosylhomocysteinase (LuxS) 
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first catalytic step, the aldehyde form of SRH binds to the metal ion, to increase the acidity at C2 
so that, Cys84 in LuxSBs acting as acid/base, could abstract the hydrogen at C2 to form enediolate, 
2. Assisted by the second base /acid (probably Glu57), the metal ion migrates from C1 to C2 
position, followed by reprotonation at C1 by Cys84 to give 2-keto intermediate 3 (Scheme 3). 
The second step is repetition of the isomerization reactions as in first step, to give 3-keto 
intermediate, 5. In the third step, base/acid abstracts proton at C4 with elimination of 
homocysteine to give an enol intermediate which ultimately tautomerizes to DPD.49,50,53,54 The 
LuxS-catalyzed cleavage of the C5–S thioether bond in SRH is dramatically different from that 
proposed in the reversible mechanism for SAdHase. While SAdHse cleaves the thioether bond in  
SAdH by using enzyme-bound NAD+ (redox reaction), LuxS cleaves thioether bond in a 
nonredox fashion using enzyme bound water, acid-base pairs and a metal ion via a series of 
isomerization steps.41,55  
The proposed mechanism was validated by conducting various studies: (i) existence of proton 
transfer reactions were confirmed by studies with D2O,50 (ii) involvement of keto intermediates, 3 
and 5 was established using real time by 13C NMR spectroscopy.54 Involvement of keto 
intermediates as chemically and kinetically competent substrates was further proved by the 
synthesis of 2 and 3-keto intermediates, 3 and 5 and testing against LuxS,54,56 (iii) the 
intermediacy of 3 in catalysis and the function of metal ion as Lewis acid was proved by the 
crystal structure of 2-ketone intermediate 3 bound to a catalytically inactivated LuxS mutant 
(Cys84),49 and (iv) the stereochemical and regiochemical specificity of the proton transfer 
reactions catalyzed by Cys84 and Glu57 was elucidated by deuterium labeled SRH studies in 
LuxSBs and the conversion of intermediate 3 to 5 was found to be partially rate limiting,53,54 and 
(v) the role of Glu57 and Cys84 as general acids/bases (Scheme 3) was confirmed by the site-
directed mutagenesis.50 
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 Recent studies done by Pei et al. using [3-F]SRH and [3-Br]SRH as substrates for LuxSBs 
suggested involvement of Tyr-89 and His-11 along with Glu57 and Cys84 in keto-isomerization 
steps (part of proton relay system).56 
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Scheme 3. LuxS catalyzed conversion of SRH into Homocysteine and DPD as proposed by Pei et 
al.54 
 
1.2. Applications of QS modulation 
Recent increase in prevalence of bacterial strains resistant to antibiotics emphasizes the need 
for the development of new generation of antibacterial agents. Since some of the pathogenic 
bacteria use QS to regulate virulence, antibiotic resistance and biofilm formation, blocking 
bacterial QS offers a novel therapeutic strategy.6,19,57-63 Over the past decade, several new 
components in QS signal transduction pathways (both intra and interspecies) were identified 
expanding the range of new approaches available to modulate QS. Interruption of QS, which 
regulates virulence or biofilm formation, does not result in either bacteriostatic or bactericidal 
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effect. It only attenuates the virulence but does not affect bacterial growth. Such behavior has the 
advantage of putting less selective pressure on bacteria resulting in lower incidence of microbial 
resistance. An important bacterial behavior regulated by QS, is biofilm formation, which is one of 
the causes of antibiotic therapy failure. Biofilm can be described as “an assemblage of microbial 
cells that is irreversibly associated (not removed by gentle rinsing) with a surface and enclosed in 
a matrix of primarily polysaccharide material” 64 which makes bacterial cells less permeable to 
antibiotics. P. aeruginosa, one of the human opportunistic pathogen survives in the host by 
formation of biofilms causing hindrance to the entry of antibiotics into the cells and makes 
therapy ineffective. Thus, inhibition of biofilm formation should make the bacteria more 
susceptible to antibiotics. Therefore, QS inhibitors can act as adjuvants to antibiotic therapy.65,66 
The importance of QS inhibition in regulating bacterial pathogenicity and other community 
related behaviors can be further underscored by the natural evolution of bacterial quorum 
quenching enzymes to prevent these population based activities of bacteria competing for energy 
and nutrients.67,68 
(1) inhibition of synthesis of autoinducer molecules, (2) inhibition of  binding of autoinducer 
to sensor proteins, (3) inhibition of molecular targets downstream of autoinducer synthesis, (4) 
sequestration of autoinducer via molecular traps,61 (5) degradation of autoinducer,67-69 and (6) 
inhibition of autoinducer transport and release.6 
General strategies for manipulation of QS include: 
1.2.1. Modulation of intraspecies communication mediated by acylhomoserine lactones (AHLs) 
 Interception of the AHL (LuxI/LuxR) pathway can be achieved by three general approaches: 
(1) Inhibition of AHL synthases (LuxI), (2) degradation of AHLs, (3) inhibition of ligand-
receptor binding (AHL-LuxR) 
1.2.1.1. Inhibitors targeting the synthases 
The AHLs are synthesized by proteins called LuxIs or its homologues from SAM and 
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acyl carrier proteins. Therefore inhibition of enzymes which utilize SAM can also inhibit AHL 
mediated QS. The SAM is also the substrate for methyl transferases which are involved in crucial 
biochemical processes. Consequently, AHL synthases which alter the SAM metabolism can have 
undesired effects on the ubiquitous SAM pathway. Hence, inhibitors of synthases were not 
developed until recently. With the recent availability of crystal structures of LuxI type of proteins, 
design of ligands which specifically target AHL synthases without interfering with other SAM 
requiring enzymes might be undertaken.70-72 
1.2.1.2. Inhibitors targeting the ligand 
 The second method to interrupt AHL pathway is degradation of the AHL ligand itself by 
using several methods such as, specific enzymes (acylases or lactonases), oxidizing agents and 
pH (lactones are hydrolyzed at basic pH). So far the quorum quenching approach has been 
utilized in protecting plants from infectious bacterium.73,74 
1.2.1.3. Inhibitors targeting the receptor 
 The final method of interruption of AHL mediated QS, is inhibiting the AHL binding to its 
transcriptional regulators or LuxR type proteins. Significant research has been done in designing 
AHL analogs as LuxR inhibitors.75 According to the review published by Wang et al.6 AHL 
inhibitors can be classified based on the structural modification on the AHL signal as: inhibitors 
(1) with alteration of the acyl side chain, (2) with modification on the γ-lactone ring, (3) with 
simultaneous modification on both acyl side chain and lactone ring, and (4) inhibitors structurally 
unrelated to AHL.6  
As there is 70-80% sequence homology at the ligand binding domain of the LuxR-type of 
proteins and some species share identical AHLs, cross QS communication from one species to 
another is expected. The AHLs with short acyl chain length tend to act as antagonists in species 
(1) Inhibitors with modification on the acyl side chain of AHLs  
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which use long chain AHL. The C4-AHL, an agonist for RhlR (cognate receptor for P. 
aeruginosa), AhyR (cognate receptor for A. hydrophilia) and SwrR (cognate receptor for S. 
liquefaciens) is an antagonist for LuxR (receptor for V. fisheri).76 Winan et al. studied activities of 
AHL mimics against TraR in A. tumefaciens WCF47∆-traI derivative harbouring lacZ fusion as 
their reporter strain. The C8-AHL, a natural ligand for CciR in Burkholderia cenocepacia, was the 
most potent inhibitor identified in this study (Table 1).77  
Eberhard et al.76 and Greenberg et al.78 independently studied the effect of synthetic AHLs 
having various side chain and lactone ring modifications of 3-Oxo-C6-AHL which regulates 
LuxR system in V. fisheri. Compound 7 with chain length of C7 and lacking carbonyl at C3 was 
found to be an inhibitor. From these studies, the authors suggested: (1) the 3-oxo group is 
required for agonistic activity, (2) chain length longer than C5 results in inhibitory activity, (3) 
introducing unsaturation into acyl chains results in only moderate agonistic activity, suggesting 
the requirement of flexibility for binding (Figure 6). 
Douthea and co-workers have synthesized a series of AHL analogs by introducing steric bulk 
at the side chain79 and replacing the amide bond with either sulfonamide80or urea81 functionality. 
They tested the compounds in a strain harboring LuxR and lux box from V. fisheri and the 
luciferase gene cluster luxCDABE from Photorhabdus luminescens which produces luminescence 
upon addition of exogenous AHL. In the first study, the effect of steric bulk on binding to LuxR 
was studied. The cyclopentyl analaogue 8 with ED50 = 0.25 µM (equal to the natural substrate) 
was the most potent agonist while the phenyl substituted 9 and 10 with IC50 = 2 µM were the most 
potent antagonists identified in the study (Figure 6).79 Among sulfonamide group and urea series, 
none had agonistic activity. The most active inhibitors from sulfonamide series are 11 (IC50 = 2 
µM) and 12 (IC50 = 3 µM) and from urea series are 13 (IC50 = 1 mM) and 14 (IC50 = 1.1 mM ). 
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Figure 6. AHL mimics modified at the acyl side chain.6  
The data from Douthea and co-workers studies suggest: (1) addition of bulky substituent is well 
tolerated by LuxR leading to inhibition, but more than one ring can render the molecule inactive 
(napthyl is inactive), (2) replacement of amide with urea or sulfonamide results in loss of agonism 
and can confer antagonism, (3) reduction of acyl side chain close to C6 or less can render 
antagonistic properties, (4) presence of amide isosters, sulfonyl and urea groups are tolerated as 
they make hydrogen bond contacts at the LuxR binding domain, and (5) flattening of lactone ring 
(15) by introducing unsaturation results in loss of activity (Figure 6).80,81 
Neilson et al. reported a series of AHL mimics containing sulfonyl, sulfoxide and thioether 
groups on the acyl chain  (Figure 6).82 As LuxR system in V. fisheri accepts ligands with wider 
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structural diversity than P. aeruginosa LasR,  initial screening was performed in V. fisheri using a 
quorum sensing inhibitor selector system (QSIS) constructed by Rasmussn et al.73 Compounds 
active in this screening were later tested in P. aeruginosa las system in which lasB promoter is 
fused to gfp (encodes for green fluorescence protein). Compounds with the thioether group were 
found to be potent inhibitors while sulfoxide analogs were weak inhibitors and sulfonyls were 
inactive. Among the synthesized thioether AHL mimics, compounds 16 and 17 displayed strong 
antagonism with IC50 = 6 µM and IC50 = 50 µM (Figure 6). 
Blackwell et al. prepared a library of AHL derivatives having various long chain and phenyl 
substituents and tested in V. fisheri ES114 ∆ -luxI reporter strain. Of the compounds tested, 3-
nitro-phenyl acetonyl lactone, 18 was found to be a super agonist with EC50 = 0.3 µM in 
comparison to the natural ligand, 3-oxo-C12 with EC50 = 3 µM (Figure 6). Interestingly phenyl 
acetonyl lactones, 19 (IC50 = 0.6 µM), 20 (IC50 = 0.9 µM), 21 (IC50 = 1.0µM), 22 (IC50 = 1.1µM), 
24 (IC50 = 1.4µM)  and 23 (IC50 = 3.7µM) with electron-withdrawing groups (EWG) at the para 
position were identified to be inhibitors.83 They also reported indole derivative of AHL, 25 as 
antagonist of TraR in A. tumefaciens and LasR in P. aeruginosa, reduced biofilm formation in P. 
aeruginosa (Figure 6).63 
On the basis of these results, Blackwell et al. prepared various AHL analogs with diverse 
structural modifications in order to understand structure activity relationship of AHL analogs in 
QS systems of reporter strains viz., A. tumefaciens WCF47 (lacks traI) harboring a plasmid-born 
PtraI-lacZ fusion (pCF372), E. coli DH5R harboring the LasR expression vector pJN105L and a 
plasmid-born PlasI-lacZ fusion (pSC11) and V. fisheri ES114 lacking luxI.84 Compounds 26 to 31 
are the most potent antagonists, identified from this study (Figure 7A).84 The structure and 
activity correlations observed can be summarized as: (1) TraR ligand binding site is most 
compact and lipophilic of the three tested. Hence subtle changes in the ligand structure results in 
dramatic change in activities, (2) AHLs with acyl chain length of not more than eight atoms and 
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aromatic group with electron withdrawing groups or long chains can antagonize all three 
receptors, (3) carbon spacer length between lactone moiety and aromatic ring should not be less 
than one, to confer inhibitory activity, (4) D-AHL 31 was also capable of inducing antagonism in 
LasR (as the natural ligand was L-AHL), and (5) LuxR antagonists derived from phenyl AHLs 
are agonists at higher concentrations (compound 21).84 
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Figure 7. (A) AHL antagonists identified across A. tumefaciens, E. coli and V. fisheri strains and 
their corresponding IC50 values.84 (B) Isothiocyanate analogs as irreversible inhibitors of LasR.85 
 
Meijler et al. designed and synthesized electrophilic AHL analogs as probes to covalently 
modify Cys79, found at the active site of LasR. Among the analogs tested isothiocyanate analogs 
(32-34) were found to modify the binding pocket covalently and inhibit QS controlled activities 
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(Figure 7B). When tested for inhibition in reporter strain PAO-JP2 (lasI/rhlI deleted) harboring 
plasmid pKD201containing a lasI coupled to luxCDBE luminescence system86, compound 33 
displayed partial agonism.85 
 (2) Inhibitors with modification of the lactone ring
In order to explore the effect of modification of the lactone ring functionality on the AHL 
mediated LuxR type of receptors, analogs with replacement of the lactone ring with saturated and 
unsaturated rings of various sizes were designed.  
   
Suga et al. reported a library of antagonists of LasR and RhlR in P. aeruginosa fluorescent 
strain PAO-JP2 which lacks genes encoding AHL synthases (LasI for 3-oxo-C12-AHL and RhlI 
for 3-oxo-C4-AHL).87  All of the inhibitors had acyl side chain identical to the natural ligand (3-
oxo-C12-AHL in case of LasR and 3-oxo-C4-AHL in case of RhlR) and lactone carbonyl group 
replaced with amine, alcohol and ketones groups which are capable of hydrogen bonding (Figure 
8). The 3-oxo-C12-AHL cyclopentanone derivative 35 had agonistic activity against LasR 
signaling protein, comparable to native substrate at 400 µM and its C4 side chain counterpart 36 
activated RhlR at 100 µM.  The cyclopentanol analog 37 had agonistic activity comparable to 3-
oxo-C12-AHL at 50 µM when tested against LasR. The 3-oxo-C12-cyclohexanone derivative 39 
inhibited LasR at 100 µM by 35% and its C4 counterpart, 40 inhibited RhlR systems by 60% at 
50 µM when competing with 1µM 3-oxo-C12-AHL and 10 µM 3-oxo-C4-AHL respectively. 
Cyclohexanone analog 39 also inhibited QS mediated pyocyanin, elastase B and biofilm 
production.87 Based on the initial results, eight non-AHL analogs with lactone ring replaced by 
aromatic group were reported. Compound 43 (Figure 9) was found to inhibit LasR system and 
also elastase B production in P. aeruginosa.88 
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Figure 8. P. aeruginosa AHLs and their ring modified analogs.87 
Moroshi and co-workers reported acyl cyclopentane derivatives as inhibitors of Serratia 
marcescens QS.89 Serratia marcescens is a Gram negative pathogen which regulates prodigiosin 
production, swarming motility and biofilm formation using AHL mediated QS.90,91 It uses N-
hexanoyl homoserine lactone (C6-AHL) and N-(3-oxo-hexanoyl) homoserine lactone (3-oxo-C6-
AHL) as QS signals.92 The N-nonanoyl-cyclopetylamide 44a lacking the lactone ring was found 
to inhibit prodiogiosin production at four fold concentration relative to the natural agonist (Figure 
9). Kato et al. reported N-decanoyl cyclopentyl amide, 44b as inhibitor of P. aeruginosa QS. It 
inhibited 3-oxo-C12-AHL mediated lasB-lacZ expression with IC50 value of 80 µM and 3-oxo-C4-
AHL mediated rhlA-lacZ expression with 90 µM (Figure 9).93  
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Figure 9.  Cyclcopentanone, phenol analogs (43-44b)89 and thiolactone and caprolactam analogs 
(45-46).78   
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Eberhard et al. 76 and Greenberg et al.78 independently studied the effect of synthetic AHLs 
having various side chain and lactone ring modifications in V. fisheri LuxR system. TheAHL 
mimics with replacement of lactone ring with thiolactone 45 and caprolactam 46 were prepared 
(Figure 9). Thiolactone 45 had only moderate activity but caprolactam 46 was inactive, probably 
because of the lack of sensor binding. However, the detailed studies on lactam analogs with 
various ring sizes were not explored in this study 
In an effort to find more potent QS inhibitors, AHL analogs modified at both lactone and acyl 
side chain were also prepared. Psedomonas aeruginosa produces 3-oxo-C12-AHL as the AI-1 to 
coordinate QS related behaviors like virulence factor production and also host 
immunomodulatory responses. Spring and co-workers described the total synthesis of 3-oxo-C12-
AHL and also reported four 3-oxo-C12-AHL analogs 47-48b having various nonhydrolysable 
cyclic ketone and lactone rings along with changes at the acyl side chain as LasR inhibitors.94,95 
Cyclic ketones, 48a, 48b were found to reduce immunomodulatory responses (for e.g., TNFα 
factor and nitric oxide production) (Figure 10).  
 (3) Inhibitors with modifications on the lactone ring and acyl side chain  
N
H
O
O
O
F F
8
n
HN
H
OO
N8
47 48a n = 1
48b n = 2  
Figure 10. P. aeruginosa AHLs analogs with modification at lactone ring and acyl side chain.95 
Muh et al. screened a library of 200,000 compounds using ultra-high-throughput-cell based 
screening and identified two LasR inhibitors having a phenyl (49) and tetrazole ring (50) 
connected to 12 carbon aliphatic chain similar to 3-oxo-C12-AHL (Figure 11).96 Phenyl analog 49 
and tetrazole analog 50 inhibited both production of pyocyanin and elastase B in strain PAO-1-
MW1 (which lacks lasI and rhlI genes) with IC50 value of 10 µM and 30 nM, respectively. 
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Figure 11. Inhibitors of LasR identified through high-throughput-cell based screening.96 
Muh et al. discovered the triphenyl compound, 51 and its analog 52 (which is structurally 
distinct to the natural ligand) mimicking the activity of 3-oxo-C12-AHL against LasR protein (51 
had EC50 of 0.014 µM and 52 had EC50 of 0.054 µM) from the ultra-high-throughput-cell based 
screening (Figure12).97  
4. Inhibitors structurally unrelated to AHL 
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Figure 12. Triphenyl, nonnative agonists of 3-oxo-C12-AHL mediated QS.97 
De Nys et al. isolated halogenated furanones 53-60 from red alga Delisisa pulchra (Figure 
13).98 These furanones were the first example of small molecules identified to inhibit AHL 
mediated QS.99 Compounds 53 and 54 were found to reduce QS-mediated behaviors like 
swarming motility in S. liquefaciens mutants lacking AHL synthase acitivity.99 Bromofuranones 
were proposed to inhibit QS by destabilization of LuxR protein.100 Compound 56 displayed 
concentration-dependent inhibition of bioluminescence production in E. coli (pSB403) by 
interrupting binding of its auto inducer, 3-oxo-C6-AHL to LuxR. Compound 58 and 60 were able 
to reduce P. aeruginosa infection in pulmonary model.101,102 
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Figure 13. Halogenated bromofuranones as AHL mediated QS modulators.98 
Several butenolides found in Streptomyces antibioticus demonstrated antimicrobial activity 
against P. aeruginosa and weak inhibition of chitinase in Serratia marcescens. On the basis of 
preliminary biological results and their structural resemblance to furanones, Nielsen et al. 
prepared synthetic butenolides and tested for anti QS activity.103 From the library of compounds 
tested on GFP-fused E. coli (pJBA89) QS (that responds to 3-oxo-C12-AHL to induce QS-
mediated fluorescence), compounds with short side chain displayed maximum inhibition 
compared to long chain derivatives. Compound 61 was the most effective inhibitor with IC50 = 
2.4 µM, while 62 had IC50 = 3.5 µM and 63 had IC50 = 3.1 µM (Figure 14). 
Using QS inhibitor selector system (QSISI), Nielsen et al. discovered anti-QS properties of 
garlic extracts. Garlic components 64 and 65 were shown to have LuxR antagonistic activities 
(Figure 14).82 
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Figure 14. Butenolide analogs (61-63)103 and inhibitors from garlic (64-65).82 
  
 
26 
1.2.2. Modulation of interspecies communication  
Inhibition of AHL mediated intraspecies communication among Gram negative bacteria have 
been studied over two decades. With recent discovery of AI-2 pathway which was found in more 
than half of the bacterial species, interspecies communication can also be inhibited giving unique 
advantage of simultaneous inhibition of communication among multiple species. Moreover, 
bacteria which are devoid of AI-2 pathway, can still recognize the foreign AI-2 and induce QS.104 
Interspecies regulation of QS can be achieved by: (1) inhibiting LuxS which synthesizes DPD, (2) 
inhibiting the sensor receptor for AI-2 (LuxP in case of V. harveyi and LsrB in case of S. 
typhimurium and E. coli), (3) inhibiting enzymes downstream of AI-2 biosynthesis (e.g., 5’-
Methylthioadenosine/AdoHcy nucleosidase (MTAN) inhibitors). 
1.2.2.1. Inhibition of LuxS enzyme  
The luxS gene is conserved in more than 60 microbial species including many Gram positive 
and negative human pathogenic bacteria such as Vibrio cholerae (causative agent of cholera), 
Salmonella typhimurium (salmonellosis), Shigella  flexneri (shigellosis), Streptococcus 
pneumonia (pneumonia, meningitis and arthritis), Neisseria meningitidis (meningitis), 
Clostridium perfringens (food poisoning) and Borrelia burgdorferi (lyme disease).6 The LuxS 
enzyme is reported to be involved in cross talk among bacteria for regulating various community 
related behaviors like virulence factor production, biofilm formation, toxin production etc.5 Many 
examples or cases of involvement of LuxS/AI-2 in bacterial pathogenicity are reported recently 
and the list is growing. Mutations of luxS gene resulted in interference in expression of virulence 
factors and in some cases rendering the bacteria avirulent.105-107 As LuxS enzyme is a bacterial 
enzyme inhibition of which might cause less toxicity in humans. All of these factors/facts validate 
LuxS inhibitors as viable targets, to serve as broad spectrum antibacterial agents. 
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Reported LuxS Inhibitors
 As SRH is a most important intermediate in the synthesis of AI-2 and LuxS is present in 
many species, researchers aimed at making SRH analogs as inhibitors of LuxS. The crystal 
structure and mechanism of LuxS catalysis was identified recently. However, the inhibitors of 
LuxS are limited. Recently Zhou et al. reported the first examples of LuxS inhibitors, S-
(anhydroribosyl)-L-homocysteine (66) and S-(homoribosyl)-L-cysteine (67).59 The 1-deoxySRH 
66 was reported to act by inhibiting the first mechanistic step in enzyme catalysis and compound 
67 by inhibiting the final step of β-elimination (Figure 15). Pei et al. prepared a series of 
structural analogs with planar hydroxamate group which mimic the unstable enediolate 
intermediate formed during the isomerizations. Hydroxamates 68 and 69 were the most potent 
inhibitors reported to date with KI values of 0.72 and 0.37µM respectively.58  These results also 
proposed that homocysteine moiety is essential for binding and activity. On the basis of the 
similarities between substrates of mammalian SAHase and bacterial LuxS enzyme, as well as 
differences in mechanism of the two enzymes, our lab designed and synthesized SRH analogs 
with 6-(fluoro)vinyl unit in place of the C5 and sulfur atoms which acted as weak/moderate 
inhibitor of LuxS enzyme.108 Compound 70 acted as a competitive inhibitor with KI value of 96 
μM. Recently our lab in collaboration with Pei lab reported [3-F]SRH, 71 and [3-Br]SRH, 72 as 
time-dependent reversible inhibitors of LuxS. It was rationalized that covalent inhibition will be 
observed by nucleophilic attack of active site cysteine at the C3 position, with removal of halide. 
But time-dependent inhibition was observed because of the enzyme catalyzed elimination of 
halide ions via E1cb mechanism (Figure 15).56 Recent studies in our laboratory focused on design 
and synthesis of 3-deoxy and 3-deoxy-3-substituted SRH analogs. These 3-fluoro and 3-O-methyl 
SRH analogs (lacking enolizable hydroxyl group at C3) were designed as mechanism based LuxS 
inhibitors.109 Among the 3-modified SRH analogs, xylo analog, 73 was found to be most potent 
slow binding inhibitor with KI value of 4.2 and KI * value of 0.43, while compound 74 and 75 
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were moderately potent slow binding inhibitors with KI * value of 2.8 and 8.8, respectively. 
These findings are consistent with the time-dependent inhibition proposed for [3-F] SRH, 71 and 
[3-Br] SRH, 72 (Figure 15).109 
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Figure 15. Reported LuxS enzyme inhibitors  
Halogenated furanones isolated from red alga D. pulchra were reported to clear P. aeruginosa 
infection in mouse pulmonary infection models and inhibit B. anthracis growth and expression of 
virulence genes. However the mechanism of QS antagonism was elusive.110 Recently Zhou et al. 
reported the mechanism of their action to be the time-dependent modification of LuxS enzyme. 
On the basis of experimental findings, an addition elimination mechanism was proposed for the 
covalent inhibition of LuxS by bromofuranone 53 (Figure 15).111  
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1.2.2.2. 5’-Methylthioadenosine/AdoHcy nucleosidase (MTAN) inhibitors 
The 5’-Methylthioadenosine/AdoHcy nucleosidase (MTAN) is a dual substrate-specific 
microbial enzyme encoded by pfs gene.70 It catalyzes deadenylation of SAH to form adenine and 
SRH, the substrate for LuxS and also deadenylation of 5'-methylthioadenosine (MTA) to 5'-
methylthioribose (MTR) (Scheme 4). The MTA is synthesized from S-adenosylmethionine and 
acylated acyl carrier protein by AHL synthase. It is a feedback inhibitor of AHL synthase.70  Thus 
MTAN plays a vital role in both AI-1 and AI-2 biosynthesis. According to the MTAN catalytic 
mechanism as proposed by Schramm group, it undertakes catalysis through an early and late 
transition states (TS) involving formation of ribosyl oxacarbenium ions.112 Based on the 
oxacarbenium ion transition state of MTAN catalyzed reactions, early and late TS analogs were 
synthesized. The 5'-thio-substituted immucillin (ImmA) mimic the early TS where the glycosylic 
bond is partially broken whereas the second generation DADMe-immucillin analogs mimic a late 
TS in which ribose moiety is completely broken from adenine (Scheme 4).112 
Schramm and coworkers 113 designed and synthesized a series of TS analogs (Scheme 4). The 
TS analogs 76-84 inhibit MTAN with KI in nM range when tested in Streptococcus pnuemoniae 
(Figure 16). Early TS analogs 76 and 77 inhibited with KI of 60 nM and 40 nM, respectively. The 
DADMe-Immucillin analogs 80 and 84, mimicking the late TS inhibited with KI values of 24 nM 
and 2.3 nM, respectively.113 In order to improve the potency of TS analogs, the Schramm group 
synthesized a series of azetidine analog resembling late TS. Methylthio azetedine 85 inhibits E. 
coli and S. pneumonia MTAN with KI value of 0.84 nM and 150 nM, respectively. 
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Scheme 4. (A) 5’-Methylthioadenosine/AdoHcy nucleosidase catalyzed hydrolysis of 5'-
methylthioadenosine and S-adenosylmethionine (B) Proposed transition state of 5’-
Methylthioadenosine/AdoHcy nucleosidase along with aza TS analogs.113  
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The compound 86 was shown to have KI of 0.45 and 84 nM with E. coli and S. pneumonia 
MTAN, respectively.114  When 80 (MT-DADMe-Immucillin-A), 81 (EtT-DADMe-Immucillin-
A) and 82 (BuT-DADMe-Immucillin-A) were tested in V. cholerae MTAN, they were found to 
be slow-onset, tight-binding inhibitors of with IC50 values of 27, 31 and 6 nM, respectively. The 
DADMe-Immucillins 80 and 82 also inhibited E. coli MTAN with IC50 in nM range. These 
results clearly validated the use of MTAN inhibitors as potential drug molecules.57 
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Figure 16. Transition state analogs of 5’-Methylthioadenosine/AdoHcy nucleosidase 
1.2.2.3. Modulation of AI-2 receptor (LuxP/LsrB)   
As described earlier, many bacteria use AI-2 as interspecies signaling molecule but different 
bacteria recognize different forms of AI-2. For example, V. harveyi recognizes borate ester of S-
THMF while S. typhimurium recognizes R-THMF as AI-2.45 The sensor protein for V. harveyi is 
LuxP and LsrB in case of S. typhimurium. The crystal structures of the binding proteins along 
with their AI-2s revealed a substantial difference in the residues at the binding pocket between 
LuxP and LsrB explaining the selective preference of LuxP for the anionic borate ester and LsrB 
for the neutral R-THMF).45 As AI-2 binding proteins play a significant role in QS cascade, 
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compounds which can inhibit LuxP or LasrB receptors or which can mimic the structures of AI-2 
will provide substantial information on the binding site. This might open new doors for 
development of novel QS inhibitors. 
The crystal structure of LuxP with AI-2 was solved by Bassler et al.44 Certain degree of 
flexibility within the binding pocket of LuxP was observed. Encouraged by such results, the 
Janda group synthesized eight DPD structural analogs 87-94 and tested in V. harveyi strain 
MM30 (a LuxS mutant that is unable to synthesize DPD) (Figure 17).115 The results of the 
activity studies suggested a cleft in the binding pocket responsible for accommodation of 
structurally diverse molecules. Boron binding, presence, position and stereochemistry of hydroxyl 
group were suggested to be critical for optimum activity.  
AI-2 agonists  
The DPD is an unstable molecule and difficult to isolate and purify. Because of this reason 
studies on AI-2 QS were performed using LuxS mutants as the source of DPD. Employment of 
mutants lacks the accurate control on concentrations of DPD used. To overcome these practical 
limitations and to study binding of AI-2 at the receptor, many groups have obtained DPD and its 
analogs by synthetic route.116-119 Recently Doutheau et al. synthesized bis-(O)-acetylated DPD 
(Ac2-DPD), a precursor to DPD, 96 (Figure 17). The Ac2-DPD is stable at physiological pH and 
also in concentrated solutions. The esterases present in vivo hydrolyze 96 to provide DPD. 
However, Ac2-DPD was found to be less potent than DPD in BB170 strain of V. harveyi 
bioluminescence assay and MET844 strain of S. typhimurium β-galactosidase assay, presumably 
because of the difference in rates of hydrolysis to release DPD. It has comparable activity to DPD 
in biofilm formation when assayed in the B. cereus strain 407.120 As replacement of hydrogen 
atoms with fluorine atom often results in modulation of biological and metabolic properties, the 
Doutheau lab also reported a trifluoro methyl analog of DPD, 95 (Figure 17). However, 95 was 
found to be less potent than the natural substrate.121 
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Figure 17. Various DPD agonists resembling DPD, furanosyl DPD or its borate ester AI-2  
Janda et al. found that S-THMF-carbonate, 97 produced from the complexation of furanosyl 
form of S-DPD with carbonate, acts as AI-2 agonists by inducing bioluminescence in V. harveyi 
strain MM30 (Figure 17). Among the several metal salts tested to identify the potential of metal 
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ions complexes of furanosyl DPD other than boron to act as QS modulators, cesium carbonate 
was able to induce bioluminescence. Interestingly, carbonate anion rather than the metal ion was 
found responsible for the QS modulatory activity. The agonistic activity of S-THMF-carbonate 
was conceivable, as it fits perfectly in the binding pocket of LuxP mimicking the borate 
complex.122 
Steinberg et al. synthesized several oxaborazolidine analogs resembling the structure of AI-2. 
Compounds 98 and 99 (Figure 17) displayed co-agonistic activity in V. harveyi strain BB170 
(which lacks luxN, the sensor for AI-1) and also in strain BB77 (which lacks luxS and luxM, the 
synthases for AI-1 and 2, respectively). These results demonstrated the involvement of 
oxaborazolidines specifically in AI-2 signal transduction by their ability to act synergistically 
with DPD or AI-2.123 
Recently Janda et al. reported C1-Alkyl substituted DPD analogs as modulators of AI-2 QS 
(Figure 17). These compounds were evaluated in S. typhimurium strain Met844 with a lacZ-lsr 
fusion (lacks luxS, the DPD synthase) for the induction of β-galactosidase activity, with and 
without external DPD (lacZ encodes for the enzyme β-galactosidase which is under the control of 
promoter lsr. The lsr activation is, in turn influenced by AI-2). Propyl-DPD, 101 was found to be 
an antagonist while ethyl derivative, 100 has no activity. Interestingly when tested in V. harveyi 
MM32 (lacks AI-1 sensor, LuxN and DPD synthase, LuxS) all the derivatives showed agonistic 
activity only in presence of DPD by inducing luminescence. Propyl-DPD, 101 and azido-DPD, 
103 (Figure 17) were found to be active by seven fold when compared to DPD.124 Meijler et al. 
and Sintim et al. also synthesized alkyl DPDs independently and also observed similar agonistic 
activity in V. harveyi assays, supporting the results observed by the Janda group.125,126 However, 
no definite trend was observed with respect to the effect of C1-chain length or ring size on 
synergism with AI-2 induced bioluminescence.126 
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The Janda group also performed a short and efficient synthesis of natural product fimbrolide, 
a known QS inhibitor (53) and studied its inhibitory effects on AI-2 mediated QS in comparison 
with the C1-substituted DPD analogs.127 Hexyl-DPD, 102 was found to be more potent than 
fimbrolide 53, in inhibiting bioluminescence of V. harveyi (Figure 17) 
Recently Wang et al. reported para-substituted phenylboronic acid derivatives, 104-108 
(Figure 18) as antagonists of AI-2 mediated QS in V. harveyi strain MM32 which shows 
bioluminescence only with addition of external DPD. Only para substituted phenyl boronic acids 
were found to exhibit strong antagonism (IC50 in single digit µM range) whereas derivatives 
substituted with amino, carboxyl and alkyl groups possessed no comparable activity. Analogs 
with no ionizable functional groups and low pKa values were found to possess strong antagonism 
for LuxP receptor. It was proposed that, analogs which existed as tetrahedral borates at neutral 
pH, mimic the natural substrate and exhibit antagonism.60 
AI-2 antagonists  
Wang group also reported pyrogallols as antagonists to AI-2 signal protein in V. harveyi 
strain MM32.128 Since the natural substrate, AI-2 in V. harveyi is a diol-borate complex, it was 
rationalized that diols which could bind to borate tightly and  mimic the structural geometry of 
AI-2 and LuxP  complex, could be antagonists.129-131 Among the fifteen aromatic polyols tested, 
pyrogallols, 109-113 possessing nonionizable functional groups were found to be more potent 
inhibitors with IC50 values in single digit µM range (Figure 18). From the structure based virtual 
screening of a library of compounds against the crystal structure of LuxP heterocyclic sulfones, 
114 and 115 were identified as AI-2 QS inhibitors.132  
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Figure 18. Pyrogallols and heterocyclic sulfones as DPD analogs.129-131  
Coenye et al. reported nucleoside analogs as AI-2 signal transduction inhibitors.133 The most 
active compound found from their screening was an adenosine derivative substituted at C3ˈby p-
methoxyphenylpropionamide moiety, 116 and its deadenylated derivative 117 (Figure 19). 
Interestingly, though structurally 116 resembles SAdH, the microbiological assays performed on 
V. harveyi mutant strains revealed the molecular target of 116 to be LuxPQ which is involved in 
AI-2 signal transduction (which is upstream of AI-2 production). Adenosine derivative, 116 also 
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reduced the AI-2 mediated QS behaviors like starvation response, biofilm formation, pigment and 
protease production in various Vibrio species.  
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Figure 19. 3-Amino-3-deoxy sugar and nucleoside inhibitors.133 
Using V. harveyi strain BB170 which lacks the sensor for AI-1, Pillai et al. discovered a 
series of fatty acids obtained from poultry meat wash to be inhibitors of AI-2 mediated QS.134 
Linoleic acid, 118a oleic acid, 118b palmitic acid, 118c and stearic acid, 118d  (Figure 20) at 0.1, 
1, and 10 mM concentrations resulted in AI-2 inhibition ranging from approximately 25% to 
99%.  
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Figure 20. Fatty acids as AI-2 mediated QS inhibitors in V. harveyi.134 
Recently Bentley et al. investigated inhibition of interspecies QS by sequestration of AI-2-
using LsrK. The LsrK is a AI-2 kinase enzyme which phophorylates AI-2 into phosphoAI-2 
which in turn modulates QS by activating lsr regulated gene expression in S. typhimurium and  
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E. coli. 61 It was rationalized that by providing LsrK externally, AI-2 could be phosphorylated ex 
in vivo and should be incapable of entering the cells to induce QS. Quorum quenching was 
observed, when LsrK was added to cultures of E. coli which generates AI-2 and S. typhimurium 
which detects AI-2, suggesting the utility of LsrK as broad range quorum quencher. 
1.3. Aza sugars 
As part of my dissertation deals with aza sugar analogs of SRH in which ribosyl oxygen is 
replaced with nitrogen atom, I would like also to summarize recent developments in the 
chemistry of biologically active aza sugars. Synthetic strategies pertaining to the synthesis of 4-
aza-SRH analogs will be discussed (Detailed synthesis of aza sugars was  reviewed by Pearson et 
al.135) 
Aza sugars are polyhydroxy alkaloids that mimic natural sugars. They are carbohydrate 
analogs in which the ring oxygen is replaced by a nitrogen atom. They are also called the imino 
sugars.136 Naturally available aza sugars identified so far are classified based on the type of ring 
structure as: (1) polyhydroxy piperidines (e.g., nojirimycin), (2) pyrrolidines (e.g., CYB 3, 
nectricin), (3) indolizidines, (e.g., swaianosonine) (4) pyrrolizidines, (e.g., alexin) and (5) 
nortropanes (e.g., calystegine A3). Representative structures belonging to each class are depicted 
in Figure 21.135  
Aza sugars are found to act as glycosidase inhibitors because of their resemblance to natural 
sugars. Glycosidase and glycotransferases are set of enzymes which control metabolism and 
biosynthesis of oligosaccharides and glycoconjugates. Such carbohydrate derivatives are essential 
for vital biological functions like cell adhesion, cell-cell recognition, cell growth, maintenance of 
immune system, oncogenesis, tumor metastasis etc. Therefore, inhibitors of glysosidases are 
widely sought after, as they can provide novel antiviral, antibacterial, anticancer, antidiabetic, 
antiHIV-AIDS agents.  
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Figure 21. Representative examples of naturally occurring aza sugars belonging to different 
structural class.135,137 
 
For example, N-hydroxyethyl-1-deoxynojirimycin (Miglitol)138 and N-butyl-1-
deoxynojirimycin (Miglustat)139 are approved drugs against type-2 diabetes and Gaucher’s 
disease, respectively (Figure 22). Furthermore, castanospermine is found to show potent antiviral 
activity,140 swainsonine141 displays anticancer activity, and the bicyclic indoline derivative, 
lentiginosine142 is an amyloglucosidase inhibitor.  
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Figure 22. Examples of aza sugars with proven biological application.138-140,142 
1.3.1. Transition state analogs of glycoside hydrolases 
According to TS theory, the catalytic proficiency of an enzyme is derived from its capacity to 
lower activation energy and stabilization of the TS. Altered substrates which mimic the TS of the 
enzyme bind to the enzyme with greater affinity than the natural substrate as they are proposed to 
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catch all the binding interactions available.143 Such non-natural substrates also assist in 
understanding the mechanism of enzyme catalysis and thereby facilitate the development of 
potent inhibitors. As a result of the wide utility of glycoside hydrolases in vital biological 
functions, there has been huge interest in developing inhibitors. 
Glycoside hydrolases catalyze cleavage of glycosidic bond in sugar via formation of an 
oxacarebenium ion which is in the half chair conformation at the anomeric center (at the TS) 
leading to either retention (retaining glycosidases) or inversion of configuration (inverting 
glycosidases) of anomeric center. Two carboxylic residues at the active site acting as acid/base 
and a molecule of water catalyze hydrolysis. 
1.3.1.1. Cleavage mechanism of glycosidases 
The proposed mechanism of catalysis for retaining glycosidases of  sugars (119a) involves: 
(i) protonation of anomeric oxygen with acidic groups present at the active site (119b, Figure 23), 
(ii) generation of oxocarbenium ion 119c after removal of ROH from the anomeric carbon (the 
glycosyl cation 119c is proposed to exist as oxocarbenium ion 119h in half chair conformation), 
(iii) subsequent formation of an ester bond at the anomeric center with the active site carboxylate 
(119d from Figure 23), and (iv) formation of hemiacetal product 119e with the retention of 
anomeric configuration by nucelophilic displacement of ester group with the enzyme bound water 
molecule (Figure 23).137 
Retaining glycosidases 
The first step of catalysis is similar to the retaining glycosidases where general acid 
protonates the anomeric oxygen. In the later step, however inverting glycosidases differ from the 
retaining glycosidases. In case of retaining glycosidases, ester intermediate precedes nucleophilic 
attack by naked water molecule generating the product, while inverting glycosidases act by 
Inverting glycosidases 
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nucleophilic attack of the carboxylate directed water molecule at the anomeric center to generate  
the hemiacetal product 119f, hence inversion of configuration (Figure 23).  
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Figure 23. Cleavage mechanism of (a) retaining and (b) inverting glycosidases. (c) Resonance 
forms of oxocarbenium ion in half chair confirmation.137 
 
1.3.1.2. Aza sugars as transition state analogs 
The design of TS inhibitors focuses on either emulating the supposed half chair geometry or 
the charge at the TS or both. Since the charge build up occurs in different places at the TS, 
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mimics with charge at various positions were designed. TS analogs are broadly categorized 
according to the charge build up and geometry.137 
 Since the proposed glycosidases mechanism of catalysis was shown to have protonated 
exocyclic oxygen in early TS (119b in Figure 23), analogs mimicking the charge at the anomeric 
oxygen were synthesized. Most potent inhibitors in this category are sugars which possess a 
nitrogen atom in place of anomeric oxygen.137 The protonated amine can mimic the early TS. 
Trehalase inhibitor, trehazolin 120a and chitinase inhibitor, allosimidine 120b (Figure 24) are 
examples of this class of inhibitors.144 
(a) Inhibitors mimicking positive charge at anomeric oxygen 
(b) Inhibitors mimicking positive charge at ring oxygen 
As late TS involves formation of glucosyl oxacarbenium ion in half chair conformation with 
charge either at anomeric carbon (119g) or at ring oxygen (119h), TS analogs mimicking either 
geometry or charge at the ribocarboxenium ion were designed. Most potent α-glucosidase 
inhibitor, 1-deoxynojirimycin145 120c (KI = 18 µM) which contains nitrogen in place of ring 
oxygen (resembles oxacarbenium ion upon protonation) and mannosidase inhibitor, imidazolo 
pentose146 120d (Figure 24) (resembles half chair geometry) are examples of this class of 
inhibitors. 
  
The TS analogs resembling intermediates 119c or 119a which possess charge at the anomeric 
carbon were also developed.137 The most potent inhibitors of glycoside hydrolases fall into the 
category of 119c mimics. For example, β-glycosidase inhibitor, isofagomine 120e (KI = 0.11 µM) 
contains nitrogen at the psuedo anomeric position (Figure 24). The difference in selectivity of 
isofagomines and 1-deoxynojirimycin by α and β-glucosidases was attributed to the location of 
their active site residues. In case of α-retaining glucosidase TS, active site carboxylate group is at 
the top of the sugar ring and charge is located at the endocyclic oxygen where as in case of β-
(c) Inhibitors mimicking positive charge at anomeric carbon  
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retaining TS, active site carboxylate group is present beneath the sugar ring and charge is located 
at the anomeric carbon.147  
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Figure 24. Aza sugar based transition state analogs of glycosylases.137 
(d) Inhibitors mimicking positive charge at multiple places   
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Inhibitors with charge distributed over to multiple atoms at the TS (Figure 23) combining the 
electronic properties of the charged TS intermediates 119b, 119c and 119h as well as half chair 
confirmation were also developed. Such TS analogs mimic TS more closely because of the 
charge at various positions:  
(i) The amidine analog 120f  resembling both endo cyclic and exocyclic charge on oxygen 
(119b and 119h) was found to be strong β-glucosidase inhibitor with KI of 8 µM.148 
(ii) The imiadazole derivative 120g which mimic both half chair confirmation and charge at the 
anomeric center was also developed.  As tetrazoles have pKa value of -4 and cannot be expected 
to be fully protonated in the active site. Compound 120g inhibited α-glucosidase and α-
galactosidase with a KI of about 1.5 µM.149  
(iii) The 1-azafagomine 120h possessing endocyclic nitrogen similar to 1-deoxynojirimycin 
and exocyclic nitrogen at the pseudo anomeric position like isofagomine displayed strong 
inhibition of both α- and β-glucosidases (α-glucosidase with KI = 6.9 µM and β-glucosidase with 
KI = 0.32 µM, respectively) (Figure 24).150 
(iv) The hydrazine analog 120i, a hybrid of isogalactofogamine and and aminogalactose was 
found to be inhibitor of galactosidase (α-glalactosidase with KI = 73 µM and β-galactosidase with 
KI = 410 µM) (Figure 24).151 Such analog mimics glucosyl cation 119c and intermediate with 
protonated anomeric oxygen 119b.  
(e) Inhibitors which does not imitate charge
From the kinetic isotope effects and TS structure, it was suggested that the anomeric carbon 
is sp2-hybridized.152 Moreover such observation was attested by potent inhibition observed by 
lactam and lactone analogs although they only mimic the hybridization but not the charge. 
However except for lactam analog 120j153 and 120k 154 which inhibit xylanase with KI = 0.34 µM 
and with KI = 18 nM, respectively, in general, this class of inhibitors are the weakest of all the 
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classes of inhibitors described earlier. The weak inhibition was attributed to the mimicry of 
geometry alone rather than the charges at the TS (Figure 24). 
Recently Schramm et al. prepared various femtomolar and picomolar TS mimics of 5’-
methylthioadenosine nucleosidase (MTAN), which also bear ring nitrogen in place of oxygen and 
mimic the oxacarebenium ion formed at the TS.113 For more description of these MTAN 
inhibitors refer to section 1.2.2.2. 
1.3.2. Hemiaminal sugar chemistry  
As the proposed 4-aza-SRH analogs are structurally hemiaminal congeners (N,O-acetal or 
azahemiacetal) of ribose sugar (polyhydroxylated pyrrolidine), in this section I will discuss in 
brief,  the chemistry of the biologically relevant hemiaminal sugars. Hemiaminals as hemiacetals 
and hemithiols exist in equilibrium as a mixture of open chain aldehyde and closed ring forms 
whose individual percentage varies depending on pH, conformation of sugar, leaving group 
strengths, anomeric effect and ionic strength of the solvent medium (Scheme 5). The chemistry of 
N,O acetals of sugars is found to be complex.  
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Scheme 5. Structures of ribose, 4-thioribose and 4-azaribose in their respective open (aldehyde) 
and closed ring forms 
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Nectricine (Figure 21) is a fungal metabolite isolated from Nectria lucida. It exists solely as 
an imine sugar while its ribose epimer 4-epi-nectricine exist as a complex equilibrium mixture 
consisting of dimer, imine and hemiaminal forms.155 These isomers transform interchangeably 
depending on the pH and concentration of the aqueous solution (Scheme 6). At pD 7-7.5, in 1M 
solution, it exists as a mixture of 4-aza-4-deoxyribopyranoside 121a and its dimeric form 121d in 
equal ratio. At pD 9-11, dimer 121d was observed as a single entity. While at more basic pD (13-
14) dimer 121d and dehydrated hemiaminal 121c (imine) forms coexist in equilibrium. 
Interestingly when the 1 M solution was diluted by 20 times at pD 7-7.5, hemiaminal 121b 
appeared along with imine 121c and pyranoside 121a.156 
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Scheme 6. 4-Amino-4-deoxyribofuranoside in its equilibrium forms at variable pH.156 
The naturally occurring hemiaminal sugar nojiricmycin is a highly potent glycosidase 
Nojiricmycin 
inhibitor relative to its 1-deoxy analog (Figure 21 and 24). It is weakly basic with pKa value of 
5.3 in water.145As it exists purely in its closed ring form (hemiaminal), it does not react with 
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ninhydrin reagent. The chemical shifts and J values of anomeric proton signals of nojirimycin in 
D2O are 5.3 (J = 2.5) for α- anomer and 5.79 (J = 10.0) for β-anomer. Because of the complex 1H 
NMR, nojirimycin is characterized by converting it into its 1-deoxy analog using catalytic 
reduction. 
 Siastatin B (gem-diamine, 1-N-imino sugar) (122a, Scheme 7) is a glycosidase inhibitor in 
which anomeric hydroxyl is replaced by nitrogen.157 The protonated form of siastatin B 122a was 
proposed to mimic the hexopyranosyl cation formed at the TS. As a result of the potent inhibitory 
activity of siastatin B, trifluoromethyl derivative of siastatin B, 122b was synthesized and tested 
for enzymatic inhibition at various pH.158 A time-dependent alteration of 122b was observed at 
pH 5. From the spectral studies, the hemiaminal 122c, imine 122d, enolate 122e and ketone 122f 
formation was revealed (Scheme 7). The similar equilibrium mixture was also observed 
previously in case of hemiaminal 4-epi-nectricine.  
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2. RESEARCH OBJECTIVE 
The overall aim of this study is the design, synthesis and biological evaluation of (a) novel 4-
aza-S-ribosyl-L-homocysteine (4-aza-SRH) analogs and (b) 2-deoxy-2-substituted-S-ribosyl-L-
homocysteine analogs as potential inhibitors of LuxS enzyme which is involved in interspecies 
QS. Also targeted are γ-lactam and their reduced cyclic hemiaminal analogs, bearing the 
additional alkylthiomethyl substituent as AHL mediated intraspecies QS antagonists in P. 
aeruginosa and V. harveyi.  
QS is a population dependent bacterial communication phenomenon utilized by number of 
pathogenic bacteria to direct symbiosis, virulence and biofilm formation. The recent increase in 
prevalence of bacterial strains resistant to antibiotics emphasizes the need for the development of 
new generation of antibacterial agents. Interruption of QS, as a strategy to combat pathogenesis is 
a viable option as it does not affect bacterial growth but only virulence, leading to less incidence 
of microbial resistance. The LuxS is a bacterial enzyme present in more than 60 species and 
responsible for biosynthesis of AI-2, a sensor molecule utilized for intraspecies bacterial 
communication. As a result, inhibitors of LuxS enzyme should inhibit AI-2 synthesis and 
consequently AI-2 mediated QS, giving rise to a new generation of antibacterial agents. 
Intraspecies communication in Gram negative bacteria is mediated largely by AHLs using “R” 
type sensor proteins. Human opportunistic Gram negative pathogen, Pseudomonas aeruginosa 
regulates virulence factor production, biofilm formation via las and rhl mediated QS. Thus, 
inhibition of these QS systems can result in attenuation of virulence. For these reasons, inhibition 
of AHL sensors protein, LasR, can serve as attractive target for the design of antimicrobial 
therapy. 
Initially, I have taken effort to synthesize 4-aza-S-ribosyl-L-homocysteine (SRH) analogs 
with sugar ring oxygen replaced by nitrogen atom (e.g., 143). The nitrogen atom in 4-aza-SRH 
compound should have the ability to mimic the interactions created by oxygen atom present in 
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natural substrate with the LuxS enzyme. The 4-aza-SRH will allow to study of the effect of N,O-
acetal function vs O,O-acetal present in the natural substrate. Since the hemiaminal sugar analogs 
are weak bases at physiological pH, they exist predominantly in cyclic hemiaminal form. I 
envisaged that upon enzyme mediated protonation of anomeric hydroxyl group and dehydration, 
the resulting imine derivatives might act as suicide inhibitors by reacting with proximal 
nucleophiles in the protein. The 4-aza-SRH may also undergo LuxS mediated catalysis and 
release aza analogs of 4,5-dihydroxy-2,3-pentanedione (DPD), a precursor to the novel aza-AI-2 
analog. 
In order to interfere with the enzyme mediated sugar ring opening, 4-aza-SRH is further 
modified at the anomeric carbon to afford analogs bearing pyrrolidine (e.g., 129), lactam (e.g., 
141), endocyclic imine (e.g., 158), and cyclic nitrone (e.g., 153) functionality (Figure 24). I 
rationalized that 1-deoxy-4-aza-SRH 129, could inhibit the enzyme mediated ring opening 
because of the lack of hydroxyl group at the anomeric carbon and hence can act as a competitive 
inhibitor. In the case of the lactam analog of SRH 141 in which C1-hydroxyl is replaced by 
carbonyl group, I rationalized that its interaction with LuxS might also result in competitive 
inhibition because of the increase in stability of amide bond towards the hydrolysis. Moreover 
since carbonyl group has the ability to act as good hydrogen bond acceptor and can tautomerize 
into the enolic form, new insights into LuxS binding should be unraveled. In order to attest the 
hypothesis of the covalent adduct formation between 4-aza-SRH derived imine intermediates and 
the enzyme, an imine analog of 4-aza-SRH bearing methyl group at C1 (158) is also targeted.  
Since the nitrone group is a better electrophile than imine, the proposed covalent adduct 
formation is also investigated using the nitrone analog of SRH (153). 
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Figure 25. Novel 4-aza-SRH analogs proposed in this study  
In my second approach towards design of LuxS inhibitors, I aimed at designing and 
synthesizing SRH analogs modified at C2. Such analogs might prevent the first aldo-keto 
isomerization and hence inhibit formation of 2-keto intermediate. In this series, I plan to target 2-
deoxy-SRH, 2-deoxy-2-fluoro-S-arabinosyl-L-homocysteine ([2-F]SAH) 194 and S-arabinosyl-L-
homocysteine (187, SAH) (Figure 25). The [2-F]SAH might also undergo nucleophilic attack at 
C2 by the active site Cys-84 residue, to form a covalent adduct with the enzyme, leading to 
irreversible inhibition. In case of SAH, because of the reversal of stereochemistry at C2-hydroxyl, 
proton abstraction from C2 by Csy84 might be forbidden since proton transfers were proved to 
occur stereochemically. Moreover, such mechanism based inhibitors might also provide 
information on structural features necessary for inhibition and further explain the role of active 
site residues in catalysis. 
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The next goal of my research was to develop modulators of intraspecies QS regulated by 
AHLs. Though several AHL mimics were discovered to be potent QS inhibitors, the utility of 
such compounds to act as drug targets is limited because of the instability of lactone ring. For this 
reason, the development of non-native AHL ligands has emerged as a promising new strategy to 
regulate QS in Gram-negative bacteria. Only a few examples of inhibitors with the altered lactone 
ring structure of AHL have been reported. Though the effect of caprolactam analogs were 
explored before, detailed studies on γ-lactams were not conducted. In order to study effect of 
nonnative γ-lactam ring on QS and also to find common structural requirements for inhibition of 
LuxS and AHL-mediated QS, I undertook an effort to synthesize γ-lactam and their reduced 
cyclic hemiaminal analogs, bearing the additional alkylthiomethyl substituent (from C3-C12) (e.g., 
160). I envisioned that lactam ring being an isoster of lactone ring, will be more stable to basic 
environments when compared to AHLs. Thus, these analogs are expected to act as potential QS 
inhibitors in Gram negative bacteria. 
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3. RESULTS AND DISCUSSION 
3.1. Design and synthesis of 4-aza-S-ribosyl-L-homocystiene analogs 
3.1.1. Pyrrolidine analog  
The first targeted azasugar analog of SRH was pyrrolidine analog 129 lacking the hydroxyl 
group at C1 (Scheme 8).  Since the analog 129 could be protonated but could not undergo ring 
opening, I predicted that the initial step of the LuxS-catalyzed reaction could be precluded. The 
protected 1,4-dideoxy-1,4-imino-D-ribitol 123 served as a convenient starting material which was 
prepared from commercially available D-gulonic-γ-lactone.159 However, attempted mesylation of 
the N-benzyl protected 123 instead of providing 5-O-mesyl precursor for coupling with 
homocysteine resulted in the formation of piperidine byproduct 130 as a mixture of two 
diastereomers at C5 (~3:1).  Analogous rearrangements of pyrrolidines into piperidines through 
ring enlargement via aziridine type intermediates are known.160,161 We found that either 
replacement of the benzyl protection group with the Boc group at ring nitrogen or oxidation of the 
iminoribitol to ribonolactam (e.g., 131, vide infra) reduced basicity of nitrogen enough to prevent 
ring enlargement providing stable 5-O-mesyl derivatives. Thus, silylation of 123 with tert-butyl-
dimethylsilyl chloride (TBDMSCl) afforded 124 and catalytic hydrogenolysis (5% Pd/C) of 124 
in the presence of (Boc)2O affected removal of benzyl group and protection with Boc in a one-pot 
reaction161,162 yielding 125 (99% from 123). Desilylation of 125 produced 126 (70%), which upon 
mesylation gave stable 127 (96%). Nucleoplilic displacement of mesylate with thiolate generated 
from protected L-homocystine54 with tris(2-carboxyethyl)phosphine hydrochloride afforded 128 
(86%). Using water soluble tris(2-carboxyethyl)phosphine for the generation of homocysteine 
reagent not only improved the yields but also simplified purification as compared to the 
previously described analogous substitution which employed  tributyl54 and triethylphoshines59 
for the reduction of homocystine. Treatment of 128 with TFA effected simultaneous removal of 
the N-Boc, acetonide and t-butyl ester protection groups to give 4-azaSRH analog 129 (66%). 
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 Scheme 8. Synthesis of pyrrolidine analog of 4-aza-SRH  
3.1.2. Lactam analog 
Next, lactam-type SRH analog 141 with the amide oxygen at C1 was targeted. As the flat 
planar carbonyl group in amides might mimic the keto intermediate and also fail to undergo ring 
opening, lactam 141 can act as competitive inhibitor. I also speculated that the lactim tautomer 
can mimic the anomeric hydroxyl resulting in binding affinity comparable to the natural substrate. 
Thus, regioselective oxidation of the 5-O-TBDMS-azasugar 124 (hydroxypyrrolidine) at C1 with 
RuO2/NaIO4 under EtOAc/H2O biphasic conditions163 produced lactam 131 (65%). Minor 
quantity (18%) of the corresponding N-benzoylpyrrolidinone byproduct was also formed because 
of the additional oxidation of the benzylic protons (Scheme 9). Desilylation of 131 with TBAF 
produced 132 (97%). Treatment with MsCl and replacement of 5-mesylate group from 135 with 
protected Hcy gave 137 (70%). Treatment of 137 with TFA effected removal of all acid-labile 
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protection groups to yield 140 (48%). Attempts to remove N-benzyl protection [e.g., H2/Pd-C or 
Pd(OH)2-C, Na/NH3(liq), BCl3] from 137 were unsuccessful.  
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Scheme 9. Synthesis of lactam and hemiaminal analogs of 4-aza-SRH  
To overcome this setback the synthetic approach was undertaken with acid-labile Boc protection 
group at nitrogen. Thus, RuO2-catalyzed oxidation of 125 gave 133 (60%) as a sole product and 
subsequent desilylation with TBAF afforded 134 (77%). Although mesylation of 134 to provide 
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136 was unsuccessful we were able to prepare 136 by oxidation of 127with RuO2/NaIO4. 
Coupling of 136 with thiolate generated from L-Hcy resulted in 138 with loss of Boc group at 
sugar nitrogen. Deprotection with TFA followed by TFA/H2O yielded lactam 141 (58%).   
3.1.3. Hemiaminal analog 
The hemiaminal 143 (Scheme 9) which possess ring nitrogen in place of oxygen in SRH, was 
synthesized to explore its effect on LuxS binding, LuxS catalyzed ring opening and degradation. 
Thus, direct reduction of the unprotected amide 138 (or 141) with super hydride164 failed to yield 
143. However, treatment of 138 with (Boc)2O/DMAP gave fully protected lactam 139 which 
upon treatment with LiBEt3H produced hemiaminal 142. Deprotection with TFA and TFA/H2O 
gave desired 4-azaSRH 143 as a mixture of complex mixture of several isomers. Interestingly, 
analogous N,O-acetals were reported to be stable under conditions required for coupling with 
nucleoside bases.163  
3.1.3.1. Benzyloxime derivative of hemiaminal sugar 
In order to support our hypothesis that the hemiaminal analog 143 could be converted to the 
open aldamine form during the first step of LuxS catalysis,  limited model studies were performed 
with hemiaminal 4-amino-4-deoxy-α/β-D-ribofuranose 146a156 (Scheme 10). Thus, previously 
described N-Boc protected lactam 133 was reduced with LiBEt3H to afford protected hemiaminal 
144. Desilylation with TBAF yielded 145, which was treated with TFA to give deprotected 
hemiaminal 146a as a mixture of α/β anomers. Subsequent treatment of 146a with O-
benzylhydroxylamine gave desired oxime derivative 147 as a single product. The formation of 
oxime 147 suggested that though hemiaminal 146a is the major isomer at neutral pH, equilibrium 
could be shifted towards open aldehyde form 146b by derivatization. Such results clearly 
supported the plausible conversion of hemiaminal analog 143 to its open aldehyde form. 
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Reagents and conditions (a) LiEt3BH/THF, THF/-78 oC; (b) TBAF/THF/rt; 
(c) (i) TFA/0 oC (ii) TFA/H2O/0 oC; (d) BnO-NH2/Pyridine/rt.
d NH2
OHOH
HO O
b 144R = Si (100%)
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Scheme 10. Benzyl oxime derivative of 4-azaribose 
3.1.4. Nitrone analog  
A nitrone analog of SRH was also targeted. As nitrones are more electrophilic than imines 
such analog might act as a suicide inhibitor by forming a covalent adduct with proximal 
nuclepophilic groups in the protein. Thus, treatment of the 1,4-iminoribitol 148 with SeO2/H2O2 
gave nitrone 149165 (73%) as a white crystalline solid (Scheme 11). Desilylation and subsequent 
mesylation yielded 151 (56%). Treatment of the mesylated sugar 151 with protected Hcy afforded 
a nitrone-type SRH analog 152 (43%). Deprotection of 152 with TFA produced unstable 
homocysteine derivative 153 (40%).  
3.1.5. Imine analog 
To explore possibility of the LuxS-mediated addition of water across carbon-nitrogen double 
bond an imine-type analog of SRH 158 (Scheme 12) was targeted. It is noteworthy that addition 
of water to imine 158 might result in the in situ generation of the hemiaminal of type 143. Thus, 
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the precursor, 1-methyl iminocyclitol 154 was prepared by the Moriarty rearrangement166 of L-
lyxo sugar to give the D-riboazasugar. 
N
OO
RO
R
124 R'  = TBDMS, R = Bn
148 R'  = TBDMS, R = H (80%)
b N
OO
RO
O
149 R' = TBDMS (73%)
150 R' = H (42%)
d
N
OO
MsO
O
151 (56%)
N
OHOH
SHO
NH2
O
153 (40%)
e
f N
OO
O
St-BuO
NHBoc
O
152 (43%)
Reagents and conditions (a) H2/Pd-C/EtOH/rt; (b) SeO2/H2O2/Me2CO/-4 °C; (c) 
TBAF/THF/-4 °C; (d) MsCl/Et3N/CH2Cl2/ -4 °C; (e) BocNHCH(CH2CH2SH)CO2t-
Bu/LDA/DMF/-20 °C; (f) (i) TFA/-4°C; (ii) TFA/H2O/-4 °C.
O
a c
 
Scheme 11. Synthesis of nitrone analog of 4-aza-SRH 
The imine 154166 was converted into 5-O-mesyl derivative 155 (85%), which was coupled with 
protected L-Hcy to give 156 (Scheme 12, 85%). Treatment of 156 with TFA gave isopropylidene 
protected 157. The protons at the C1-methyl group were found to be exchangeable with 
deuterium within a few hours when compound 157 was dissolved in D2O. Treatment of 157 with 
aqueous TFA (9:1) yielded fully deprotected 158 in quantitative yield. As in the case of 157, 
protons at C1-methyl group of 158 were exchangeable with deuterium. These exchange indicate 
that 1,4-ketimine-SRH analog 158 might undergo enzyme-catalyzed hydrolysis to generate a 4-
aza-SRH analog with a methyl ketone rather than an aldehyde at C1. This change might affect the 
regioselectivity and rate of the first isomerization step in the LuxS-catalyzed reaction. I also 
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showed that the methyl group protons in 154 are not susceptible to exchange even if 154 was 
dissolved in D2O for several hours.   
NRO N
St-BuOOC
NHBoc
a
Reagents: (a) MsCl/Et3N/CH2Cl2; (b) BocNHCH(CH2CH2SH)CO2t-
Bu/LDA/DMF; (c)  TFA d) TFA/H2O
b
154 R = H
155 R = Ms (85%)
O O OO
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Scheme 12. Synthesis of imine analog of 4-aza-SRH  
3.1.6. γ-lactams with alkylthiomethyl substitution at carbon γ and their N,O-acetal counterparts 
 As part of the second objective of my dissertation, I have designed and synthesized γ-lactams 
and cyclic azahemiacetals, bearing alkylthiomethyl substituent with different length of carbon 
chain (C3-C12) as AHL mediated QS inhibitors. Although, previously ε-lactam (caprolactam) 
analogs were reported to lack LuxR binding,76 studies on γ-lactams were not performed. In order 
to further investigate the effects of non-native lactam scaffold on QS, novel γ-lactam ligands were 
designed. As lactam rings are more stable to basic conditions than lactones, these nonnative 
lactam analogs might prove to be potent inhibitors. Moreover, the γ-lactam and cyclic 
azahemiacetal ligands were further modified in a way that they resemble SRH. 
Initially, 5-S-alkylthio derivatives of lactam 160 differing in alkyl chain length were prepared 
(Scheme 13). The key substrate (S)-5-(bromomethyl)-2-pyrrolidone (159) was conveniently 
derived from L-pyroglutamic acid167 (Scheme 13). Displacement of bromide in 159 with sodium 
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propanethiolate produced γ-lactam with propylthiomethyl substitution at carbon γ (160a, 96%). 
As it was demonstrated previously that the length of side chain is also critical for determining the 
agonistic and antagonistic activity,168 I also synthesized analogs containing various chain lengths. 
Higher homologated analogs 160b-d with C6, C9 and C12 alkyl straight chains were prepared 
analogously to 160a. A set of reduced form of lactam analogs which contain a hydroxyl group 
instead of a keto group at C2 were also prepared. Attempted reduction of lactams 160 with 
LiBEt3H were unsuccessful, however reduction of the N-Boc protected lactams 161a-d proceeded 
smoothly to afford hemiaminals (N,O-acetals) 162a-d. Subsequent deprotection with 
trifluoroacetic acid gave N,O-acetal counterparts of γ-lactams (163a-d) as a mixture of at least  
four isomers along with the open chain aldehyde form (25%; 1H NMR). The existence of 
hemiaminal moiety is proved by treatment of this mixture with O-benzylhydroxylamine which 
produced the desired oxime derivative.  
H
NBr
O
R
N
OSR'a
Reagents: (a) R'SH/NaH/DMF; (b )(Boc)2O/DMAP/CH2Cl2; (c) LiEt3BH/THF/CH2Cl2; 
(d) TFA
160a-d R = H  (85-96%)
161a-d R = Boc (88-97%)
b
R
N
OHSR'
162a-d R = Boc  (85-97%)
163a-d R = H (quantitaive)d
159
a = C3H7, b = C6H13 
c = C9H19, d = C12H25
c
 
Scheme 13. Synthesis of γ-lactams and the corresponding hemiaminal analogs with thioalkyl side 
chain 
 
3.1.7. (5S)-(hexyl- or nonylthiomethyl)-3,4-dihydroxypyrrolidin-2-ones and their 
hemiaminal congeners 
To increase the polarity/solubility of the lactam and azahemiacetal analogs in the testing 
media, aza analogs with hydroxyl groups at C3 and C4 were also prepared. The N-Boc protected 
1,4-dideoxy-1,4-imino-D-ribitol 126, readily prepared from the commercially available D-
gulonic-γ-lactone, served as a convenient starting material for the synthesis of dihydroxy lactams 
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164/165 (Scheme 14).159,162,169 Mesylation of compound 126 with MsCl and triethylamine gave 
127. Coupling of the  mesylate 127 with sodium hexane- and nonanethiolate produced 5-S-alkyl 
thioethers 164 and 165 in high yields which were deprotected with TFA to give (5S)-(hexyl- or 
nonylthiomethyl)-3,4-dihydroxypyrrolidin-2-ones 166 and 167 (Scheme 14). Reduction of 164 
and 165 with LiBEt3H afforded hemiaminals 168 and 169 and subsequent deprotection with TFA 
afforded 5-S-(hexyl or nonyl)-3,4-dihydroxypyrrolidin-2-ols 170 and 171 as a complex mixture of 
azahemiacetals existing in equilibrium with dehydrated form (imine) as well as with open 
aldehyde and dimeric forms, as reported for such class of 4-azaribofuranoses.156 
3.2. Design and synthesis of S-ribosyl-L-homocysteine and its C2 modified analogs 
3.2.1. S-Ribosyl-L-homocysteine  
The SRH, required for our enzymatic study, was synthesized according to the methods 
described previously with few modifications that made the synthesis more efficient and bench 
friendly.170 First of all, I have used ribose sugar derivative (required for coupling to 
homocysteine) with bromide as a leaving group instead of the activated hydroxyl. Secondly 
homocysteine thiolate was generated by using our previously published method109 employing 
triscarboxyethylphosphine hydrochloride (TCEP) as water soluble reducing agent of disulfide 
bond rather than in situ generated homocysteine thiolate by Mitsunobu reaction between sugar 
and homocystine.170 Thus, bromo ribose 172171 upon treatment with protected Hcy afforded 173 
in 72% yield (Scheme 15). Subsequent standard deprotection yielded natural substrate SRH 174 
in 50% yield.  
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Scheme 14. Synthesis of ribolactams and their hemiaminal congeners 
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Scheme 15. Synthesis of S-ribosyl-L-homocysteine 
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3.2.2. 2-Deoxy S-ribosyl-L-homocysteine 
The 2-deoxySRH 180 (Scheme 16), because of the lack of hydroxylic group at the second 
position, should not undergo the first aldose-ketose isomerization step and hence block 2-keto 
intermediate formation and DPD release. Thus, the 2-deoxyribose was converted to methyl 2-
deoxy-α/β-D-erythro-pentofuranoside, 175 with methanol and H2SO4.172 Treatment of 175  with 
MsCl and NEt3 gave compound 176 (43%) which  upon protection with the benzoyl group at C3 
afforded 177 (95%) (Scheme 16). Coupling of mesyalted derivative 177 with protected Hcy gave 
2-deoxySRH derivative 178. However, attempted removal of of Boc protection under acidic 
conditions failed to produce the desired 2-deoxySRH. Nonetheless, the methyl 2-deoxySRH 
analog, 179 (37%) was obtained by coupling of the mesylated sugar 175 with racemic D/L-
homocysteine in aqueous NaOH.109  
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(c)BocNHCH(CH2CH2SH)CO2t-Bu/LDA/DMF/rt; (d) NH2CH(CH2CH2SH)CO2H/NaOH/H2O/65 oC 
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Scheme 16. Synthesis of 2-deoxy-S-ribosyl-L-homocysteine 
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3.2.3. S-Arabinosyl-L-homocysteine  
 I next explored synthesis of S-arabinosyl-L-homocysteine (SAH) 187 (Scheme 17). As it was 
found earlier that the xylo analog 73,109 with the inversion of stereochemistry at C3 was the most 
potent of C3 modified sugars (as the proton shuttle is stereospecific), it will be interesting to 
explore the effect of  inversion of stereochemistry at C2 (SAH). Thus, selective mesylation of 
acetonide protected 181173 gave 182 (33%). Subsequent benzoylation of the free hydroxyl at C3 
afforded 183 in 63% yield. However, coupling of the mesylated sugar 183 with protected 
homocysteine was unsuccessful. In another approach, the mesylated sugar 183 was converted to 
bromo compound 184 (47%) by treatment with NaBr/DMF171 (Scheme 17). Subsequently, bromo 
sugar 184 was coupled to the thiolate of Hcy to afford protected SAH intermediate 185 in a very 
low yield. However, such reaction was not reproducible and the targeted SAH 187 was not 
obtained in desired purity to perform enzymatic study.  
3.2.4. 2-Fluoro-2-deoxy-S-arabinosyl-L-homocysteine  
As it is well known that introduction of fluorine atom brings change in physical, chemical 
and biological properties of a molecule, I next focused on synthesis of [2-F]SAH 194 (Scheme 
18). Such a compound can potentially act as competitive inhibitor as it could bind to LuxS but 
because of the lack of hydroxyl group at C2, should not undergo carbonyl shift from C1 to C2 to 
form 2-keto intermediate. Alternatively [2-F]SAH might undergo nucleophilic attack by Cys-84 
forming a covalent adduct between inhibitor and protein, resulting in irreversible inhibition of the 
enzyme. Thus, benzoylation of the triisopropylsilyl (TIPS) protected 2-deoxy-2-fluoroarabinose 
188174 at anomeric hydroxyl, produced 189 (77%). 
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Scheme 17. Synthesis of S-arabinosyl-L-homocysteine (SAH) 
Desilylation of 189 with NH4F gave the corresponding 2-deoxy-2-fluoroarabinose 190 (37%) 
which upon mesylation afforded 191 (65%) (Scheme 18). However, attempted coupling of 
mesylated sugar 191, under various conditions failed to produce desired protected 2-fluoro analog 
of SRH 192. In another approach, selective acid mediated mono desilylation of 189 with 
TFA/H2O and subsequent mesylation afforded 5-O-mesyl-3-O-TIPS protected mesyl sugar. 
Unfortunately, attempts to couple this sugar with Hcy were unsuccessful. Therefore, desired [2-
F]SAH 194 was not obtained. 
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 Scheme 18. Synthesis of 2-deoxy-2-fluoro-S-arabinosyl-L-homocysteine 
3.3. Biological evaluation of targeted quorum sensing modulators 
3.3.1. Quorum sensing assays of γ-lactams with alkylthiomethyl substitution at carbon γ and 
their N,O-acetal counterparts 
 
3.3.1.1. Screening against las and rhl signaling in P. aeruginosa 
To determine the effect of the γ-lactam (160, 166 and 177) (Figure 26) and their 
corresponding hemiaminal analogs (163, 170  and 171) (Figure 26) on the P. aeruginosa las and 
rhl AHL-mediated pathways, las- and rhl-dependent β-galactosidase reporters were 
independently expressed with their respective receptor proteins in E. coli as previously described 
by Dr.Kalai Mathee’s research group at FIU.15 As expected and in agreement with published data, 
exogenous 3-oxo-C12-AHL and C4-AHL activated the las and rhl β-galactosidase reporters, 
respectively. The AHL treated controls (3-oxo-C12-AHL in case of las and C4-AHL in case of rhl) 
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in absence of inhibitor are considered as 100% active (Figure 26). Also, no activity was observed 
in absence of exogenous AHL. The effect of the synthesized γ-lactam and their corresponding 
hemiaminal analogs on the las and rhl reporter activity was also compared with the effect of 
addition of the DMSO as a solvent (Figure 26). 
Screening against las signaling
Compounds 160a, 163a were initially screened at a concentration of 100 µg/mL (0.57 mM) 
for their activity against the las system (Figure 26). Hemiaminal 163a was found to enhance las 
reporter activity by 15% while lactam 160a inhibited las activity approximately by 28%. 
Inhibition was dependent upon the addition of 2 μM of 3-oxo-C12-AHL. However, hemiaminal 
163a significantly stimulated (approximately 2.3-fold) las reporter activity at 50 µg/mL and 
inhibited las reporter activity by 69% and 89% at 150 and 200 µg/mL, respectively. In contrast, 
lactam 160a inhibited las activity at all concentrations tested. Cell growth was not inhibited by 
the addition of lactam and hemiaminal compounds at the tested concentrations.  
  
Among other lactam analogs tested, percent inhibition increased in a concentration dependent 
manner. Inhibition potency also increased as the alkylthio chain length increased. Specifically, 
nonylthio lactam 160c and dodecylthio lactam 160d were found to possess greatest inhibition at 
all concentrations tested. At the lowest concentration tested (50 µg/mL), 160c inhibited 28% 
while 160d inhibited 48%. On the contrary, among the cyclic hemiaminals analogs, no general 
trend was observed between chain length and percent inhibition. As with 163a, hemiaminal 163b 
also stimulated QS at 50 µg/mL but with much lesser potency, however inhibited 100% at all 
higher concentrations tested. Hemiaminals containing nonyl side chain (163c) and dodecyl chain 
(163d) showed moderate activity. The ribolactam analogs (166 and 167) and their cyclic 
hemiaminal counterparts (170 and 171) were found to inhibit las activity at all concentrations 
tested but only with moderate potency with hemiaminals being slightly more active. 
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Figure 26. Effect of lactam and hemiaminal analogs on PlasI-lacZ expression in Escherichia coli. The compounds were tested at 50 -200 
µg/mL concentrations against 2 μM of 3-oxo-C12-AHL. PlasI-lacZ activity is depicted as percent activity relative to the DMSO treated control 
in presence of AHL. Significance was determined by a paired two-tailed Student t-test and is denoted as follows: *p-value < 0.05, † p-value < 
0.02, ‡ p-value < 0.01. The p value < 0.05 correspond to 5% (< 0.02 corresponds to 2% and, < 0.01 corresponds to 1%) chance of rejecting the 
null hypothesis when it is true. Rejection of null hypothesis infers that the result is statistically significant. Each trial was performed as a 
triplicate.  
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 The hexylthio lactam 160b and nonylthio lactam 160c stimulated rhl QS activities at higher 
concentrations with moderate potency with hexylthio lactam 160b being most active (Figure 27; 
Table 2). Propylthio lactam 160a and dodecylthio lactam 160d were inactive at the concentrations 
tested. In contrast, cyclic hemiaminals with shorter alkylthio chain (163a and 163b) inhibited rhl 
activity, while analogs with longer alkyl chain (163c and 163d) were inactive. The hexylthio 
hemiaminal 163b completely inhibited rhl signaling at concentrations of 100 µg/mL and higher. 
The strong inhibition observed with propylthio 163a and hexylthio 163b hemiaminal analogs 
having the side chain lengths similar to C4-AHL is in agreement with the structure activity 
relationship reported for various synthetic AHL mimetics targeting RhlR.75,175 Except for 
ribolactam 166 which stimulated rhl signaling, all the ribolactam analogs (167) and their cyclic 
hemiaminal counterparts (170/171) were inactive in rhl signaling system (Figure 27; Table 2)  
Screening against rhl signaling 
Thus, in this dissertation novel lactam and the corresponding hemiaminal analogs as las and 
rhl signaling modulators were reported. Studies of structural features other than the AHL scaffold 
as tools to understand the R type protein interaction with AHLs are limited, only a few examples 
of inhibitors with the altered lactone ring structure of AHL have been reported (for more 
discussion on AHL mimics with altered lactone ring, refer to section 1.2.1.3.). For example, 
Smith et al. reported 3-oxo-C12-(2-aminocyclohexanone) (Figure 8, 39) as a strong antagonist of 
LasR system,87 while Muh et al. identified two LasR inhibitors having a phenyl and tetrazole ring 
(Figure 11, 49 and 50, respectively), with IC50 in nM range (Figure 11).96 It is noteworthy that γ-
thiolactone analogue of 7b (Figure 9) showed inhibition of LuxR while the corresponding ε-
lactam (caprolactam) analog was reported to lack LuxR binding.78 The targeted optically pure γ-
lactams and cyclic hemiaminals were capable of either inhibiting or, in some cases, inducing P. 
aeruginosa QS pathways. Though, such analogues had moderate antagonism (dodecylthio lactam 
160d had 48% inhibition at 0.16 mM and hexylthio hemiaminal 163b had 100% inhibition at 0.38 
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mM) when compared to previously reported inhibitors (with IC50 values in submicromolar), the 
novel lactam scaffold might serve as stable alternative to lactone present in AHL and further 
facilitate future generation of AHL mimics. 
 
Figure 27. Effect of lactam and cyclic hemiaminal analogs on PrhlA-lacZ expression in E. coli. 
The compounds were tested at 50-200 µg/mL concentrations against 2 μM of C4-AHL. PrhlA-lacZ 
activity is depicted as percent activity relative to the DMSO treated control in presence of AHL. 
Significance was determined by a paired two-tailed Student t-test and is denoted as follows: *p-
value < 0.05, †p-value < 0.02, ‡p-value < 0.01. The p-value < 0.05 corresponds to 5%, (< 0.02 
corresponds to 2% and < 0.01 corresponds to 1%) chance of rejecting the null hypothesis when it 
is true. Rejection of null hypothesis infers that the result is statistically significant. 
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Table 2. Effect of lactam and cyclic hemiaminal analogs on rhl signaling 
Concentration (µg/ mL) 50 100 150 200 
Compound Percent Activitya,b ± Standard Deviation 
No inhibitor 100 ± 0 100 ± 0 100 ± 0 100 ± 0 
No AHL      0.29 ± 0.4
c    
C.viminalis 33± 6d    
160a 104 ± 24 118 ± 0.8 104 ± 13 108 ± 17 
160b 126 ± 8 126 ± 29 130 ± 31 145 ± 19‡ 
160c 95 ± 3 115 ± 30 108 ± 12 137 ± 46 
160d 103 ± 7 106 ± 6 109 ± 8 106 ± 5 
163a 121 ± 6 138 ± 3 41 ± 1† 9 ± 1‡ 
163b 26 ± 0.2 0.2 ± 0.3† 0 ± 0‡ 0 ± 0* 
163c 93 ± 12 80 ± 13 100 ± 11 99 ± 3 
163d 98 ± 13 93 ± 27 91 ± 8 96 ± 5 
166 132 ± 36 129 ± 10 148 ± 9 161 ± 7‡ 
167 106 ± 3 117 ± 8‡ 115 ± 11 135 ± 5‡ 
170 94 ± 8 105 ± 3 109 ± 12 116 ± 18 
171 98 ± 5 127 ± 14* 116 ± 9 121 ± 14 
a Effect of lactam and cyclic hemiaminal derivatives on PrhlA-lacZ expression in E. coli tested at 
50-200 µg/mL concentrations against 2 μM of C4-AHL. PrhlA-lacZ activity is depicted as percent 
activity relative to the DMSO treated control in presence of AHL. b *p-value < 0.05, †p-value < 
0.02, ‡p-value < 0.01 according to a paired, two-tailed Student t-test.  b Activity in absence of AHL 
was considered negligible. d 20 µL water extract of Callistemon.viminalis was shown to have anti 
QS activity as expected and reported previously.191 
3.3.1.2. Screening against bioluminescence in V. harveyi  
The lactam (160, 166 and 167) and hemiaminal derivatives (163, 170 and 171) were also 
tested for their effect on QS mediated luminescence of wild type V. harveyi MAV. None of the 
analogs had any effect on growth (Table 3). In case of luminescence assay, γ-lactams and their 
hemiaminal counterparts displayed two patterns showing (i) inhibition of luminescence as found 
for lactam compounds 160b, 166 and 167 and hemiaminals 163b, 163c and 170), and (ii) no 
effect at the concentrations tested, as observed with propylthio γ-lactam 160a as well as with 
160d, 163c, 163d and nonylthio ribohemiaminal 171 (Table 3). In order to identify the pathway 
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of inhibition of luminescence (as three QS systems operate in Vibrio harveyi), the synthetic 
ligands were also tested against V. harveyi strains BB170 and BB152 lacking AI-1 (AHL) sensor. 
Such tests revealed similar luminescence data as found for wild type. The analogs which showed 
bioluminescence inhibition (160b, 160c, 163b, 166, 167 and 170) when tested against light 
producing enzyme, luciferase displayed identical trend in reduction of bioluminescence (personal 
communication of Dr. Makemson at FIU). In conclusion, luminescence and lucifersase assays 
revealed that the inhibition of luminescence was not mediated by QS but by luciferase.  
Table 3. Effect γ-lactam and hemiaminal analogs on V. harveyi MAV bioluminescence and 
growth 
 
Aza analogs % Inhibition 
Luminescence 
% Inhibition of 
Growth 
Conc 
X 10-4M 
160a 0 0 3.5 
160b 99.8 0 3.5 
160c 64 0 3.1 
160d 0 0 2.7 
163a 75 0 2.2 
163b 99.7 0 1.2 
163c 0 0 3.1 
163d 0 0 2.7 
166 29 0 3.2 
167 80 0 2.8 
170 52 0 3.2 
171 0 0 2.7 
aCompounds dissolved in water or DMSO served as a control and % inhibition is calculated 
relative to the solvent control. Bioluminescence was recorded in light units (1 LU = 1.08 x 108 
q/s/mL) and all measurements were obtained in a single trial. 
3.3.2. Inhibition studies of 4-aza-SRH analogs against LuxS enzyme 
Bacillus subtilis LuxS preparation and preliminary inhibition studies of selected 4-aza-SRH 
analogs against LuxSBs were performed by Dr. Pei’s research group at Ohio State University 
using published protocols.54,58 The LuxS activity assay was based on quantitative detection of the 
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liberated homocysteine released from the  natural substrate SRH which is readily detected by 
Ellman’s reagent (DTNB).176 The DTNB reacts with free thiol (homocysteine) rapidly and 
quantitatively to form a chromophore, 5-thionitrobenzoic acid (TNB) whose absorbance can be 
measured at 412 nm (ε412 = 14,150 M-1cm-1) (Scheme 19). From activity assay, LuxS was found 
to show saturation kinetics toward SRH with a KM value of 1.05 μM and a Vmax value of 1.8 x 10-4 
μM/min (fitted into Michaleis-Menten equation V = (Vmax[S]/(KM + [S]) (Table 4; Figure 28). 
Table 4. Rate of LuxS catalysis at various concentrations of natural substrate  
[SRH] µM dA/min (rate) 
44.5 0.0185 
26.7 0.0178 
8.9 0.0153 
4.4 0.0141 
2.2 0.0126 
 
Inhibition of 4-Aza-SRH analogs was determined in a manner similar to the activity assay  
except for addition of various concentrations of inhibitors to the reaction mixture besides DTNB, 
SRH and LuxSBs. Rate of the reaction and KM values in presence of aza analogs were calculated 
and mechanism of inhibition was determined. Percentage activity of LuxS in presence of 
inhibitors was reported relative to the percentage activity of SRH alone (i.e., without inhibitor 
activity percentage was considered 100%). From the 4-aza-SRH derivatives tested, pyrrolidine 
analog 129, lactam analog 140, and propylthio γ-lactam analog 160a were found to act as 
competitive inhibitors of moderate potency. 
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Scheme 19. LuxS activity assay for detection of the released homocysteine employing DTNB  
 
Figure 28. Lineweaver-Burk plot of Co-LuxS enzyme with SRH (data were fitted into the 
Michaelis-Menten equation V = Vmax[S]/(KM + [S])) 
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Because of the absence of the hydroxylic group at C1, 1-deoxy-4-aza-SRH 129 (Figure 30) 
should not undergo enzyme mediated ring opening which is the very first step in the LuxS-
mediated catalysis, but might still be able to bind to LuxS (because of the ability to bind at 
homocysteine pocket and chelate to the metal ion via C2 and C3 hydroxyls) hence act as 
competitive inhibitor. Supporting our hypothesis, pyrrolidine analog 129 acted as a competitive 
inhibitor with KI value of 49 µM and IC50 value of 0.8 mM (Figure 29). Weak inhibition of 129 
was probably the result of loss of the binding energy derived from C1-hydroxyl. This hydroxylic 
group was originally shown to interact with several active site residues (Ser-6, His-11 and Arg-
39) via hydrogen bonding in the co-crystal structure of C84A-LuxSBs with 2-ketone 
intermediate.49 Because of the positively charged ring nitrogen (~pKa = 6.6), the conformational 
change in sugar ring might have also resulted in improper fit into the active site.  
 
Figure 29. Dose response curve of pyrrolidine analog 129 against LuxS enzyme 
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Figure 30. Activity of the selected 4-aza-SRH analogs against LuxS enzyme 
Lactam-type SRH analog 141 (Figure 30) with the amide oxygen at C1 was tested next as 
LuxS inhibitor. Apart from its inability to open the sugar ring, the lactam ring was chosen mainly 
because the planar amide group resembles the carbonyl group existing in aldose form of SRH or 
the C2 keto group present in 2-keto intermediate. Secondly the carbonyl of lactam might also 
form new interactions at the active site via hydrogen bonding. Thirdly, the carboxamide moiety 
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has the potential to tautomerize to a lactim form so as to generate a hydroxylic group at C1 which 
mimics the natural substrate.177,178 Lactam 141 was found to be a competitive inhibitor with KI 
value of 37 µM and IC50 value of 0.66 mM (Figure 31; Table 5). As expected, the corresponding 
lactam analog 140 with benzylic group at the ring nitrogen was found to be inactive. This may be 
the result of the steric bulkiness caused by benzylic group preventing access to LuxS active site. 
Table 5. Rate and percentage activity of LuxS at different concentrations of analogs 129 and 141 
 
Compound  Concentration (µM)  dA/min (rate) % Activity 
129 0 0.01012 100 
129 200 0.00865 85.5 
129 400 0.00659 65.1 
129 800 0.00500 49.4 
129 1600 0.00392 38.7 
129 3200 0.00261 25.8 
 
141 
 
0 
 
0.00936 
 
100 
141 80 0.00833 89 
141 160 0.00728 78 
141 320 0.00578 62 
141 655 0.00462 49 
141 1310 0.00306 33 
 
 
Figure 31. Dose response curve of lactam analog 141 against LuxS enzyme 
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As the lactam analog 141 was found to inhibit LuxS, further modification of the lactam 
analog by removing hydroxylic groups at C2 and C3 was performed to provide 2,3-dideoxy 
lactam analog of SRH (e.g., 195; Figure 30).179 Lactam 195 was found to be inactive. The lack of 
the vicinal hydroxyl groups might have totally eradicated LuxS binding ability, probably because 
of the large difference in polarity and absence of metal chelation. The hemiaminal analog 196 
(Figure 30) was also devoid of activity confirming the significance of C2 and C3 hydroxylic 
groups for LuxS binding. These findings are consistent with the structural requirements for LuxS 
binding and activity as reported in literature.58 
Hemiaminal analog of 4-aza-SRH 143 (Figure 30) was tested to study the effect of N,O-acetal 
function vs O,O-acetal present in natural substrate on the LuxS catalyzed reaction. As only open 
aldehyde form of SRH is catalytically active, ring opening of SRH should serve as an important 
step to study catalysis of LuxS enzyme. The LuxS was reported to bind to cyclic ribofuranose 
form of SRH (O,O-hemiacetal) and catalyze ring opening. I envisaged that because of the 
intrinsic difference in leaving group property of amine when compared to hydroxylic group 
(existing in natural substrate), the hemiaminal analog 143 can interfere with enzyme mediated 
ring opening and therefore act as LuxS inhibitor. In case of natural substrate SRH, (O,O-
hemiacetal), the enzyme catalyzes protonation of the ring oxygen, leading to the sugar ring 
opening. On the other hand, as the pKa of hemiaminal 143 is around 5.8180 at physiological pH, 
the enzyme mediated protonation of 143 is speculated to occur preferentially at anomeric 
hydroxyl as opposed to ring nitrogen, resulting in loss of water to give imine 197. The imine 
intermediate 197 might act as suicide inhibitor (path (a) in Scheme 20) by forming a covalent 
adduct with proximal nucleophilic groups (for example Cys84). Alternatively it can also 
tautomerize to give 2-keto-4-aza-SRH 200 (path (b) in Scheme 20) via formation of enamine 199 
(Amadori rearrangement).158 The keto byproduct 200 might also serve as competitive inhibitor 
because of its structural resemblance to the 2-keto SRH intermediate. The LuxS-mediated N,O-
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acetal ring opening leading to the open chain aldamine and ultimately to the formation of aza 
analog of DPD 201 ((S)-1,2-dihydroxy-4-iminopentan-3-one) has to be also considered (path (c) 
in Scheme 20). The acyclic imine analog of DPD 201 may cyclize to give furan derivative 203a 
(aza analog of pro-AI-2). The imine analog of pro-AI-2 might also tautomerize to give eneamine 
202 or can hydrolyze to provide DPD. Because of the electron withdrawing nature of α-
substituents, it is speculated that the imine tautomer is less favorable when compared to 
enamine.181 A time-dependent inhibition of this N,O-acetal analog with IC50 value of 60 µM was 
observed with 4-aza-SRH 143 (Figure 32; Table 6). Chemical equilibration among hemiaminal, 
open aldehyde, imine and enamine forms of 143 might be responsible for time-dependent 
inhibition. The complex kinetics of this analog precluded determination of KI value. Further work 
is necessary to determine the exact mechanism of inhibition and to support the formation of the 
aza DPD analog as well as the detection of enzyme substrate complex. 
 
Figure 32. Dose response curve of hemiaminal analog 143 against LuxS enzyme 
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Scheme 20. Plausible mechanism of interaction of hemiaminal analog of SRH 143 with LuxS. 
Production and complexation of aza-DPD analogs. 
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Table 6. Rate and percentage activity of LuxS at different concentrations of analogs 143 and  
160a 
Compound Concentration (µM) dA/min (rate) % Activity 
143 0 0.01028 100 
143 20 0.00917 89 
143 40 0.00777 76 
143 50 0.00665 65 
143 60 0.00548 53 
143 80 0.00395 38 
143 100 0.00322 31 
143 200 0.00196 19 
 
160a 
 
0 
 
0.00967 
 
100 
160a 100 0.00935 97 
160a 200 0.00896 93 
160a 400 0.00906 94 
160a 800 0.00862 89 
160a 1600 0.00830 86 
160a 3200 0.00720 74 
160a 6069 0.00638 66 
160a 12138 0.00457 47 
 
In order to further investigate the effect of imine group on the inhibition of LuxS, I also 
synthesized 1-methyl imino SRH analog 158. Imino sugars with endocyclic C=N structural motif 
were described to act as potential suicide inhibitors because of the strong electrophilic nature of 
imine bond.186 Three plausible ways of interaction of this analog with LuxS are speculated. 
Firstly, nucelophilic residues at the active site might covalently bond to imine carbon, resulting in 
irreversible inhibition (pathway (a) in Scheme 21). Secondly, imine analog 158 can also 
tautomerize to give methyl 2-keto-4-aza-SRH 208 analogous to path (b) described for hemiaminal 
143 in Scheme 20. As a third plausible pathway, 158 can transform in situ into the 
ketohemiaminal 209 by nucleophilic attack of the enzyme bound water (pKa = 10) across imine 
bond. Ring opening of the hemiaminal should generate ketone 208 which might be coordinated 
by Co+2 and converted to an aza analog of DPD 211 with an additional methyl group at C1 (path 
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(c) in Scheme 20). The imine 209 might also tautomerize to eneamine 212 or cyclize to give furan 
derivative 213. Unfortunately, inhibition assay determined no activity for the imine 158. This 
may be because of its misfit into the polar active site of LuxS owing to hydrophobic CH3 at C1. 
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Scheme 21. Plausible mechanism of interaction of cyclic imine analog of SRH 158 with LuxS 
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 In order to find structural requirements for inhibition of both intra species (AHL mediated) 
and inter species QS (AI-2 mediated), the propylthio γ-lactam analog 160a and its hemiaminal 
counterpart 163a, which were earlier found to be AHL mediated QS inhibitors in P. aeruginosa 
(Section 3.4.1.2), were tested for LuxS inhibition as well. The propylthio-lactam analog 160a 
displayed very weak inhibition with KI value of 0.71 mM and IC50 value of 11 mM (Figure 33). 
The reduced hemiaminal counterpart 163a was devoid of inhibition (Table 6). These data were 
consistent with the LuxS inhibition results found for 2,3-dideoxy SRH analogs, 195 and 196 
which were also inactive. Depletion of inhibition might be because of the loss of binding energy 
derived from: (i) binding of C1-hydroxylic group at the active site, (in case of lactam analog), (ii) 
homocysteine moiety, and (iii) metal ligation to hydroxylic groups owing to missing C1, C2 and 
C3 hydroxylic groups and homocysteine. However, no common structural motif was found as 
propylthio compounds were inactive, probably owing to the large intrinsic differences in the 
active sites of LasR and LuxS. 
 
Figure 33. Dose response curve of propylthio lactam analog 160a against LuxS enzyme 
The LuxS inhibition studies with 4-aza-SRH analogs were also attempted in our laboratory 
with histidine-tagged LuxS protein. E. coli BL21(DE3)/pLuxS strain was kindly provided by Dr. 
Zhou from Northeastern University. The protein was isolated and purified by Dr. Wang’s 
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research group at FIU by following published methods.47 Such purified HTCo-LuxSBs protein 
showed characteristics identical to the properties described in the literature.50 For example, 
presence of purple color and UV-VIS absorption bands at 630, 580 and 530 nm.50 Moreover 
cobalt incorporation into apo-enzyme was confirmed by determination of cobalt concentration 
(12.87 mM) using ICP-MS analysis in the laboratory of Dr.Cai at FIU. However, testing results 
of this protein are still not conclusive. The inhibition studies with 2-deoxy analog 179 and nitrone 
analog 153 will be investigated in future.  
3.3.3. Complexation studies with aza-DPD 
Since 4-aza-SRH 143 was proposed to release aza analog of DPD 201 upon LuxS mediated 
catalysis (pathway (c), Scheme 20), an additional model study was performed to investigate the 
possibility of  formation of aza-DPD analog 201 and its plausible cyclisation and binding with 
borate to form aza-AI-2, 203c or diol complex 203d (Scheme 22). The differential affinity of 
borate binding towards amino alcohol (as in pro-aza-AI-2 203b) vs cis-diols (as in pro-AI-2, S-
THMF, Scheme 2) was measured employing 11Boron NMR binding studies. The aminoethanol 
205, cis-2-aminocyclopentanol and ethanediol 204 in borate solution were used as model 
compounds, to simulate the complexation of 203b. Treatment of either 2-aminoethanol or cis-2-
aminocyclopentanol with saturated borate solution in D2O at pH 7.3 or in benzene solution 
showed broad peaks on 11B NMR spectra which were inconclusive of complexation as reported 
for the related vicinal aminoalcohols with borate.182 On the contrary, 11B NMR data for D- ribose 
was consistent with literature values for 2:1 and 1:1 sugar/borate complexes (Figure 34).183 
Taylor et al. showed that NH2C(CH2OH)3 has less tendency to form borate complexes than the 
corresponding triols with alkyl substituents (instead of amino group), although mono-chelate and 
bis-chelate borate complexes with vicinal hydroxyl groups were formed.185  
With 11B NMR 
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Scheme 22. Borate binding study of ethanediol and aminoethanol 
 
Figure 34. 11Boron NMR spectrum of D-ribose in saturated borate solution in D2O at pH 7.8. 
Peaks at 18.92 ppm (C), 12.92 ppm (D) and 1.01 (E) ppm correspond to borates B(OH)4-, 
B3O3(OH)4- and B5O6(OH)4-, respectively.184 
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 Energy minimization calculations [density functional theory (DFT)] were performed 
between 2,3-borate ester (AI-2) and 3,4-borate ester of the cyclic DPD by Dr.Mebel from FIU 
(Figure 35). The relative energy of 2,3-diester (AI-2) was found to be lower than that of the 
corresponding 3,4-diester. However, in case of aza analogues, DFT calculations between aza-AI-
2 203c and 3,4-borate ester 203d showed that complex 203 had lower energy than aminoalcohol 
complex 203c. Such results indicate once more the preferential affinity of boron for diols as 
compared to aminoalcohols. 
With DFT calculations 
 
Figure 35. DFT calculations for borate esters of 203b (Figure 35A) and S-THMF (Figure 35B) 
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4. EXPERIMENTAL PROCEDURES 
4.1. General procedures 
 The 1H (400 or 600 MHz) and 13C (100 MHz) spectra were determined with solutions in 
CDCl3 unless otherwise noted. The 11B (192.6 MHz) NMR spectra were recorded in D2O. Mass 
spectra (MS) were obtained with atmospheric pressure chemical ionization (APCI) or ESI 
technique and HRMS in AP-ESI or TOF-ESI mode. The TLC was performed with Merck 
kieselgel 60-F254 sheets products were detected with 254 nm light or by visualization with 
Ce(SO4)2/(NH4)6Mo7O24∙4H2O/H2SO4/H2O reagent. Merck kieselgel 60 (230-400 mesh) was used 
for column chromatography. The HPLC purifications were performed using XTerra® preparative 
RP18 OBDTM column (5µm 19 x 150 mm) with gradient program using CH3CN/H2O as a mobile 
phase. Reagent grade chemicals were used, and solvents were dried by reflux over and distillation 
from CaH2 (except THF/potassium) under argon. Using SPSS analytical software two-tailed 
Student t-test was performed and p values were generated. 
The aza sugars synthesized in this dissertation are treated as SRH analogs throughout the 
manuscript and therefore numbering of carbons starts at anomeric position. However, in the 
experimental section, the numbering of carbons for aza sugars either follows sugar nomenclature 
or heterocyclic nomenclature depending on the nature of the sugar (Figure 36). 
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Figure 36. Two systems of nomenclatures used in the dissertation 
4.2. Synthesis of the inhibitors  
N-Benzyl-5-O-tert-butyldimethylsilyl-1,4-dideoxy-1,4-imino-2,3-O-isopropylidene-D-
ribitol (124). To a stirred solution of 123159 (150 mg, 0.57 mmol) in anhydrous CH2Cl2 (5 mL) at 
rt under Ar atmosphere was added DMAP (7 mg, 0.05 mmol) and imidazole (93 mg, 1.36 mmol) 
followed by TBDMSCl (0.68 mmol, 103 mg). The mixture was then stirred for 10 h and 
partitioned (CH2Cl2//NaHCO3/H2O). The organic layer was washed (brine), dried (MgSO4) and 
evaporated. The residue was column chromatographed (15% EtOAc/hexane) to give 124187 (204 
mg, 98%) as a colorless oil. 1H NMR δ -0.13 (s, 3, CH3), 0.00 (s, 3, CH3), 0.83 (s, 9, t-Bu), 1.26 
(s, 3, CH3), 1.49 (s, 3, CH3), 2.65 (dd, J = 2.7, 10.3 Hz, 1, H1), 2.94 ('q', J =, 2.2 Hz, 1, H4), 3.04 
(dd, J = 5.5, 10.3 Hz, 1, H1'), 3.57 (dd, J = 4.1, 10.6 Hz, 1, H5), 3.64 (d, J = 13.4 Hz, 1, Bn), 3.71 
(dd, J = 10.6, 4.3 Hz, 1, H5'), 3.94 (d, J = 13.4 Hz, 1, Bn), 4.49 (dd, J = 2.0, 6.5 Hz, 1, H3), 4.58 
('dt', J = 2.7, 6.2 Hz, 1, H2), 7.13-7.23 (m, 5, Bn); 13C NMR δ -5.50, (CH3), -5.43, (CH3), 18.16 
(t-Bu), 25.20 (CMe2), 25.72 (CH3), 25.91 (CH3), 27.20 (CMe2), 56.91 (Bn), 59.28 (C1), 63.15 
(C5), 68.93 (C4), 79.44 (C2), 83.33 (C3), 111.86 (CMe2), 128.22, 128.47, 126.83, 139.41 (Bn); 
MS (APCI) m/z 378 (100, MH+). 
N-tert-Butoxycarbonyl-1,4-dideoxy-1,4-imino-2,3-O-isopropylidene-5-O-tert-
butyldimethylsilyl-D-ribitol (125). A solution of 124 (145 mg, 0.38 mmol), triethylamine (76.7 
mg, 0.106 mL, 0.76 mmol), di-tert-butyldicarbonate (126 mg, 0.57 mmol) and 5% Pd/C (300 mg) 
in ethanol (6 mL) was stirred under an atmosphere of hydrogen at room temperature for 6 h. The 
reaction mixture was filtered through Celite to remove the catalyst. The Celite was washed with 
ethanol (5 mL) and washings and the filtrate were combined and evaporated. The residue was 
partitioned (EtOAc//NaHCO3/H2O). The organic layer was washed (brine), dried (MgSO4) and 
evaporated. The crude product was column chromatographed (20  → 30% EtOAc/hexane) to give 
125 (147 mg, 99%) with data as reported.164  
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N-tert-Butoxycarbonyl-1,4-dideoxy-1,4-imino-2,3-O-isopropylidene-D-ribitol (126). 
TBAF (1 M/THF, 0.25 mL, 0.25 mmol) was added to a stirred solution of 125 (66 mg, 0.17 
mmol) in THF (5 mL) at ambient temperature. After stirring for 30 min, the reaction mixture was 
partitioned (EtOAc//NaHCO3/H2O). The organic layer was washed (brine), dried (MgSO4) and 
evaporated. The residue was column chromatographed (50 → 60% EtOAc/hexane) to give 126 
(32 mg, 70%) with data as reported.169 
N-tert-Butoxycarbonyl-1,4-dideoxy-1,4-imino-2,3-O-isopropylidene-5-O-
methanesulfonyl-D-ribitol (127). Procedure A. Triethylamine (66 mg, 92 µL, 0.66 mmol) and 
MsCl (37.6 mg, 25 µL, 0.33 mmol) were added drop wise to stirred solution of 126 (60 mg, 0.22 
mmole) in anhydrous CH2Cl2 (6 mL) at 0ºC (ice-bath). After 5 min, ice-bath was removed and the 
reaction mixture was allowed to stir at ambient temperature for 30 min. The reaction mixture was 
quenched with saturated NaHCO3/H2O and was extracted with CH2Cl2. The organic layer was 
washed (brine), dried (MgSO4) and evaporated to give 127 (73 mg, 96%) as a mixture (~3:2) of 
two rotamers of sufficient purity to be directly used in next step: 1H NMR δ 1.28 (s, 3, CH3), 1.42 
(s, 12H, t-Bu, CH3), 2.96 (s, 1.2, Ms), 2.98 (s, 1.8, Ms), 3.39 (dd, J = 4.8, 12.5 Hz, 0.4, H1), 3.46 
(dd, J = 4.8, 12.5 Hz, 0.6, H1), 3.69 (d, J = 12.5 Hz, 0.6, H1'), 3.82 (d, J = 12.5 Hz, 0.4, H1'), 
4.10-4.14 (m, 0.4, H4), 4.22-4.30 (m, 0.6, H4), 4.22-4.29 (m, 1.4, H5,5'), 4.45 (dd, J = 4.1, 10.1 
Hz, 0.6, H5), 4.65 ('d', J = 5.9 Hz, 1, H3); 4.72 ('t', J = 5.3 Hz, 1, H2); 13C NMR (major rotamer) 
δ 24.93 (CMe2), 26.93 (CMe2), 29.59 (t-Bu), 37.09 (Ms), 52.51 (C1), 62.39 (C4), 68.94 (C5), 
79.20 (C2), 80.43 (t-Bu), 81.68 (C3), 112.07 (CMe2),154.24 (CO); 13C NMR (minor rotamer) δ 
24.93 (CMe2), 26.93 (CMe2), 29.59 (t-Bu), 37.48 (Ms), 53.11 (C1), 62.64 (C4), 68.59 (C5), 78.54 
(C2), 80.64 (t-Bu), 82.53 (C3), 112.07 (CMe2), 153.63 (CO); MS (APCI) m/z 252 [100, (MH2-
Boc)+], 352 (10, MH+) 
S-(N-tert-Butoxycarbonyl-1,4-imino-2,3-O-isopropylidene-1,4,5-trideoxy-D-ribitol-5-yl)-
N-tert-butoxycarbonyl-L-homocysteine tert-butyl ester (128). Procedure B. Step a. H2O (0.4 
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mL) and tris(2-carboxyethyl)phosphine hydrochloride (140 mg, 0.5 mmol) were added to a stirred 
solution of N,N'-di(tert-butoxycarbonyl)-L-homocystine di(tert-butyl) ester54 (250 mg, 0.4 mmol) 
in anhydrous DMF (4 mL) at ambient temperature under Ar atmosphere. After 24 h, the reaction 
mixture [TLC (EtOAc/hexane, 2:8) showed conversion of disulfide (Rf 0.55) into thiol (Rf 0.65)] 
was partitioned between EtOAc, and saturated NaHCO3/H2O. Aqueous layer was extracted with 
EtOAc, and the combined organic layer was washed with brine, dried (MgSO4), and concentrated 
to give N-tert-butoxycarbonyl-L-homocysteine tert-butyl ester54 (240 mg, 99%) as colorless oil of 
sufficient purity to be directly used in next step. Step b. LDA (2.0 M/THF and heptanes; 85 µL, 
0.17 mmol) was added drop wise (10 min) to a stirred solution of freshly prepared thiolate from 
step a (200 mg, 0.6 mmol) in anhydrous DMF (5 mL) under a vigorous stream of argon at 0 ºC 
(ice-bath). After an additional 10 min, 127 (100 mg, 0.2 mmol) in anhydrous DMF (5 mL) was 
added via a syringe. After 15 min ice-bath was removed and the reaction mixture was stirred for 
24 h at ambient temperature. Ice-cold saturated NH4Cl/H2O was added and the resulting 
suspension was diluted with EtOAc. The organic layer was separated and the aqueous layer was 
extracted with EtOAc. The combined organic layer was washed (brine), dried (MgSO4) and 
evaporated. The residue was column chromatographed (40 → 50% EtOAc/hexane) to give 128 
(130 mg, 86%) as a mixture of rotamers (~1:1): 1H NMR δ 1.29 (s, 3, CH3), 1.41 (s, 12H, t-Bu, 
CH3), 1.44 (s, 18H, t-Bu), 1.79-1.92 (m, 2, H8,8'), 2.39-2.80 (m, 4, H5,5',7,7' ), 3.37 (dd, J = 4.2, 
11.7 Hz, 0.5, H1 ), 3.43 (dd, J = 4.5, 11.7 Hz, 0.5, H1 ), 3.70 (d, J = 12.6 Hz, 0.5, H1'), 3.84 (d, J 
= 12.8 Hz, 0.5, H1'), 3.99-4.05 (m, 0.5, H4), 4.11-4.17 (m, 0.5, H4), 4.18-4.29 (m, 1, H9), 4.56 
(dd, J = 5.6, 10.4 Hz, 0.5, H3), 4.60 (dd, J = 5.6, 10.4 Hz, 0.5, H3), 4.69 (d, J = 4.8 Hz, 0.5, H2), 
4.71 (d, J = 4.8 Hz, 0.5, H2), 5.06 (br. d, J = 7.3 Hz, 0.5, NH), 5.29 (br. d, J = 6.1 Hz, 0.5, NH); 
13C NMR δ 24.97 (CMe2), 26.93 (CMe2), 27.91 (C7), 28.01 (t-Bu), 28.34 (t-Bu), 28.43 (t-Bu), 
32.18 (C5), 32.57 (C8), 32.92 (C8), 33.22 (C5), 51.73 (C1), 52.42 (C1), 53.48 (C9), 62.76 (C4),  
63.16 (C4), 78.47 (C2), 78.50 (t-Bu), 79.21 (C2), 79.23 (t-Bu), 80.00 (t-Bu), 80.10 (t-Bu), 83.49 
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(C3), 84.07 (C3), 111.85 (CMe2), 154.09 (CO), 154.93 (CO), 155.36 (CO), 171.25 (CO), 171.46 
(CO); MS (APCI) m/z 547 (100, MH+). 
S-(1,4,5-Trideoxy-1,4-imino-D-ribitol-5-yl)-L-homocysteine (129). Procedure C. Step a. 
Compound 128 (39 mg, 0.07 mmol) in TFA (4.0 mL) was stirred at 0 ºC for 3 h. Volatiles were 
evaporated and coevaporated with toluene to give an oily residue, which was used in next step. 
Step b. Product from step a was treated with TFA/H2O (9:1, 4.0 mL) for 1 h at 0 ºC. Volatiles 
were evaporated and the crude product was purified on RP-HPLC (5% CH3CN/H2O for 50 min at 
2.5 mL/min; tR = 12 min) to give 129 (12 mg, 66%) as a colorless oil: 1H NMR (D2O) δ 2.00-2.15 
(m, 2, H8,8'), 2.61-2.71 (m, 2, H7,7'), 2.77 (dd, J = 10.4, 14.5 Hz, 1, H5), 3.05 (dd, J = 4.3, 14.5 
Hz, 1, H5'), 3.24 (dd, J = 1.9, 13.0 Hz, 1, H1), 3.43 (dd, J = 4.0, 13.0 Hz, 1, H1'), 3.59 (ddd, J = 
4.3, 8.7, 10.4 Hz, 1, H4), 3.76 (t, J = 6.2 Hz, 1, H9), 4.04 (dd, J = 4.1, 8.7 Hz, 1, H3), 4.29 (ddd, J 
= 1.9, 4.0, 4.1 Hz, 1, H2); 13C NMR (D2O) δ 26.81 (C8), 30.06 (C7), 30.62 (C5), 49.16 (C1), 
53.55 (C9), 59.48 (C4), 69.48 (C2), 74.34 (C3), 174.02 (COOH); MS m/z 251 (100, MH+). 
HRMS (TOF MS-ESI) m/z calculated for C9H18N2O4S [M+H]+ 251.106; found 251.1063. 
1-Benzyl-5-chloro-3,4-dihydroxy-3,4-O-isopropylidinepiperidine [130(3S,4S,5R/S)]. 
Treatment of 122 (50 mg, 0.19 mmol) with MsCl (31.9 mg, 21.9 μL, 0.28 mmol) by Procedure A 
[column chromatography (20 → 30% EtOAc/hexane)] gave 130 (25 mg, 46%) as a 3:1 mixture of 
diastereomers: The major isomer had: 1H NMR δ 1.30 (s, 3, CH3), 1.50 (s, 3, CH3), 2.13-2.19 (m, 
1, H2), 2.49 (dd, J = 3.7, 13.3 Hz, 1, H6), 2.87 (dd, J = 1.7, 12.0 Hz, 1, H2'), 3.05 ('dt', J = 2.1, 
13.3 Hz, 1, H6'), 3.50 (d, J = 13.4 Hz, 1, Bn), 3.61 (d, J = 13.4 Hz, 1, Bn), 3.93-3.99 (m, 2, H3,5), 
4.19 (dd, J = 3.7, 7.5 Hz, 1, H4), 7.20-7.25 (m, 5, Bn); 13C NMR δ 26.18 (CMe2), 28.43 (CMe2), 
53.54 (C6), 56.53 (C2), 58.48 (C5), 61.52 (Bn), 73.77 (C4), 79.52 (C3), 112.80 (CMe2), 127.26, 
128.40, 128.92, 137.16 (Bn); MS m/z 282 (100, MH+[35Cl]), 284 (40, MH+ [37Cl]); HRMS (TOF 
MS-ESI) m/z calculated for C15H2035ClNO2 [M+H] + 282.1255; found. 282.1259. 
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N-Benzyl-5-(tert-butyldimethylsiloxymethyl)-3,4-dihydroxy-3,4-O-
isopropylidenepyrrolidin-2-one [131(3R,4R,5S)]. Procedure D. RuO2×H2O (4.3 mg, 0.032 
mmol) was added to a stirred solution of NaIO4 (83 mg, 0.39 mmol) in H2O (1 mL) at ambient 
temperature. After 5 min, a solution of 124 (50 mg, 0.13 mmol) in EtOAc (1 mL) was added drop 
wise and the reaction mixture was continued to stir for 12 h. Water (10 mL) and EtOAc (10 mL) 
were added and the separated aqueous layer was furthermore extracted with EtOAc (2 × 10 mL). 
The combined organic layers were washed (brine), dried (MgSO4) and evaporated. The residue 
was column chromatographed (50 → 60% EtOAc/hexane) to give 131 (33 mg, 65%) and N-
benzoylpyrrolidinone as a byproduct (10 mg, 18%). Compound 131 had: 1H NMR δ 0.01 (s, 6, 
CH3), 0.84 (s, 9, t-Bu), 1.35 (s, 3, CH3), 1.42 (s, 3, CH3), 3.51 (t, J = 2.1 Hz, 1, H5), 3.62 (dd, J = 
2.0, 10.9 Hz, 1, H6), 3.69 (dd, J = 2.3, 10.9 Hz, 1, H6'), 3.93 (d, J = 15.2 Hz, 1, Bn), 4.50 (d, J = 
5.6 Hz, 1, H4), 4.69 (d, J = 5.6 Hz, 1, H3), 5.00 (d, J = 15.2 Hz, 1, Bn), 7.22-7.32 (m, 5, Bn); MS 
m/z 392 (100, MH+).13C NMR δ -5.67, (CH3), -5.56, (CH3), 18.11 (t-Bu), 25.79 (t-Bu), 25.81 
(CMe2), 27.26 (CMe2), 44.19 (Bn), 60.22 (C6), 62.02 (C5), 76.66 (C4), 78.01 (C3), 111.69 
(CMe2), 127.71, 128.18, 128.73, 135.59 (Bn), 171.89 (CO)The N-Benzoyl-5-(tert-
butyldimethylsiloxymethyl)-3,4-dihydroxy-3,4-O-isopropylidene-2-pyrrolidinone byproduct had: 
1H NMR δ 0.01 (s, 3, CH3), 0.05 (s, 3, CH3), 0.87 (s, 9, t-Bu), 1.40 (s, 3, CH3), 1.51 (s, 3, CH3), 
3.83 (dd, J = 1.5, 10.7 Hz, 1, H6), 4.19 (dd, J = 2.2, 10.7 Hz, 1, H6'), 4.58 ('t', J = 1.8 Hz, 1, H5), 
4.65 (d, J = 5.5 Hz, 1, H4), 4.76 ( d, J = 5.5 Hz, 1, H3), 7.38-7.43 (m, 2, Bn), 7.51 ('dt', J = 1.3, 
6.7 Hz, 2, Bn), 7.54-7.58 (m, 1, Bn), 13C NMR δ -5.72, (CH3), -5.58, (CH3), 18.16 (CH3), 25.34 
(CMe2), 25.82 (t-Bu), 27.22 (CMe2), 61.68 (C5), 62.12 (C6), 76.30 (C4), 78.67 (C3), 112.09 
(CMe2), 127.87, 128.73, 132.15, 134.11 (Bn) 170.56 (CO), 171.66 (CO); MS (APCI) m/z 406 
(100, MH+). 
N-Benzyl-3,4-dihydroxy-5-(hydroxymethyl)-3,4-O-isopropylidenepyrrolidin-2-one 
[132b(3R,4R,5R)]. TBAF (1 M/THF, 0.18 mL, 0.18 mmol) was added drop wise to a stirred 
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solution of 131 (49 mg, 0.12 mmol) in THF (10 mL) at 0 °C. After 5 min, the ice-bath was 
removed and reaction mixture was allowed to stir at ambient temperature for 2 h. The reaction 
mixture was quenched with water and volatiles were evaporated. The residue was partitioned 
(EtOAc//NaHCO3/H2O). The organic layer was washed (brine), dried (MgSO4) and evaporated. 
The residue was column chromatographed (80  → 90% EtOAc/hexane) to give 132188 as a white 
solid (33 mg, 97%): 1H NMR δ 1.37 (s, 3, CH3), 1.47 (s, 3, CH3), 3.35 (s, 1, OH), 3.54 ('t', J =, 
1.8 Hz, 1, H5), 3.64 (d of m, J = 5.0, 11.8 Hz, 1, H6), 3.85 (br. d, J = 12.0 Hz, 1, H6'), 4.08 (d, J 
= 15.2 Hz, 1, Bn), 4.64 (d, J = 5.6, Hz, 1, H4), 4.77 (d, J = 5.2 Hz, 1, H3), 5.04 (d, J = 15.2 Hz, 1, 
Bn), 7.29-7.37 (m, 5, Bn); MS (APCI) m/z 310 (100, [MH+MeOH] +). 
N-(tert-Butoxycarbonyl)-5-(tert-butyldimethylsiloxymethyl)-3,4-dihydroxy-3,4-O-
isopropylidene-pyrrolidin-2-one [133(3R,4R,5R)]. Oxidation of 125 (90 mg, 0.23 mmol) with 
NaIO4 (126 mg, 0.7 mmol) and RuO2xH2O (8 mg, 0.05 mmol) by Procedure D [column 
chromatography (50 → 60% EtOAc/hexane)] gave 133 (56 mg, 60%) as a colorless oil with data 
as reported.164  
N-(tert-Butoxycarbonyl)-3,4-dihydroxy-5-(hydroxymethyl)-3,4-O-isopropylidene-
pyrrolidin-2-one [134(3R,4R,5R)]. Desilylation of 133 (50 mg, 0.12 mmol) with TBAF (1 
M/THF, 0.14 mL, 0.14 mmol), as described for 132, [column chromatography (70 → 80% 
EtOAc/hexane)] gave 134 (27 mg, 77%) as a colorless oil: 1H NMR δ 1.36 (s, 3, CH3), 1.46 (s, 
12, t-Bu, CH3), 3.88 (dt,  J = 3.9, 5.3 Hz, 1, H5), 4.03 (dd, J = 4.1, 11.4 Hz, 1, H6), 4.19 (dd, J = 
3.8, 11.4 Hz, 1, H6'), 4.57 (dd, J = 5.3, 5.7 Hz, 1, H4), 4.63 (d, J = 5.7 Hz, 1, H3); 13C NMR δ 
25.66 (CMe2), 26.98 (CMe2), 27.60 (t-Bu), 56.68 (C5), 66.63 (C6), 76.70 (C3), 77.02 (C4), 83.28 
(t-Bu), 112.37 (CMe2), 152.98 (CO), 173.71 (CO); MS (APCI) m/z 320 (100, [MH+MeOH] +). 
N-Benzyl-3,4-dihydroxy-3,4-O-isopropylidene-5-
[(methanesulfonyloxy)methyl]pyrrolidin-2-one [135(3R,4R,5R)]. Mesylation of 132 (67 mg, 
0.24 mmol) with MsCl (41.0 mg, 27 µL, 0.36 mmol) by Procedure A gave 135 (83 mg, 97%) as a 
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colorless oil of sufficient purity to be used directly in next step: 1H NMR δ 1.30 (s, 3, CH3), 1.36 
(s, 3, CH3), 3.07 (s, 3, Ms), 3.65 (t, J = 2.7 Hz, 1, H5), 4.06 (d, J = 15.2 Hz, 1, Bn), 4.16 (dd, J = 
2.2, 11.0 Hz, 1, H6), 4.22 (dd, J = 3.0, 11.0 Hz, 1, H6'), 4.51 (d, J = 5.6 Hz, 1, H4), 4.69 (d, J = 
5.6 Hz, 1, H3), 4.92 (d, J = 15.2 Hz, 1, Bn), 7.18-7.30 (m, 5, Bn); MS (APCI) m/z 388 (100, 
[MH+ MeOH] +), 356 (40, MH+). 
N-(tert-Butoxycarbonyl)-3,4-dihydroxy-3,4-O-isopropylidene-5- 
[(methanesulfonyloxy)methyl]pyrrolidin-2-one [136(3R,4R,5R)]. Oxidation of 127 (80 mg, 
0.32 mmol) with NaIO4 (172 mg, 0.96 mmol) and RuO2×H2O (8.5 mg, 0.064 mmol) by procedure 
D [column chromatography (EtOAc)] gave 136 (78 mg, 95%) as a colorless oil: 1H NMR δ 1.37 
(s, 3, CH3), 1.44 (s, 3, CH3), 1.54 (s, 9, t-Bu), 3.01 (s, 3, Ms), 4.39-4.43 ('m', 2, H5,6), 4.58 (d, J = 
5.4 Hz, 1, H4), 4.64 (dd, J = 3.1, 11.2 Hz, 1, H6'), 4.70 (d, J = 5.5 Hz, H3); 13C NMR δ 25.62 
(CMe2), 27.04 (CMe2), 27.97 (t-Bu), 37.70 (Ms), 59.18 (C5), 67.03( C6), 74.54 (C4), 77.54 (C3), 
84.72 (t-Bu), 112.75 (CMe2), 149.66 (CO), 170.20 (CO); MS (APCI) m/z 297 [100, (MH2-
Boc+MeOH)+]. 
S-[(N-Benzyl-3,4-dihydroxy-3,4-O-isopropylidene-pyrrolidin-2-one-5-yl)methyl]-N-tert-
butoxycarbonyl-L-homocysteine tert-butyl ester [137(3R,4R,5S)]. Treatment of 135 (85 mg, 
0.24 mmol) with lithium homocysteinate (104 mg, 0.36 mmol) by Procedure B [column 
chromatography (60 → 70% EtOAc/hexane)] gave 137 (94 mg, 70%) as a colorless oil. 1H NMR 
δ 1.28 (s, 3, CH3), 1.37 (s, 12, t-Bu, CH3), 1.39 (s, 9, t-Bu), 1.74-1.86 (m, 1, H8), 1.95-2.17 (m, 1, 
H8'), 2.46-2.57 (m, 2, H7,7'), 2.69-2.73 (m, 2, H6,6'), 3.59-3.71 (m, 1, H5), 3.86 (d, J = 15.0 Hz, 
1, Bn), 4.17-4.18 (m, 1, H9), 4.43 (d, J = 5.7 Hz, 1, H4), 4.79 (d, J = 5.5 Hz, 1, H3), 4.97 (d, J = 
15.0 Hz, 1, Bn), 5.05 (br. d, J = 7.1 Hz, 1, NH); 7.17-7.27 (m, 5, Bn); 13C NMR δ 25.63 (CMe2), 
27.04 (CMe2), 27.99 (t-Bu), 28.31 (t-Bu), 29.02 (C7), 33.13 (C6), 33.18 (C8), 44.40 (Bn), 53.08 
(C9), 60.34 (C5), 77.19 (C4), 77.48 (C3), 79.90 (t-Bu) 82.35 (t-Bu), 112.09 (CMe2), 127.94, 
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128.16, 128.80, 135.18 (Bn), 152.98 (CO), 171.11 (CO), 171.35 (CO); MS m/z 551 (100, MH+). 
HRMS (AP-ESI) m/z calculated for C28H43N2O7S [MH]+ 551.2785; found 551.2792.  
S-[(3,4-Dihydroxy-3,4-O-isopropylidenepyrrolidin-2-one-5-yl)methyl]-N-tert-
butoxycarbonyl-L-homocysteine tert-butyl ester [138(3R,4R,5S)]. Treatment of 136 (70 mg, 
0.19 mmol) with lithium homocysteinate (83 mg, 0.28 mmol) by Procedure B [column 
chromatography (70% → 80% EtOAc/hexane)] gave 138 (40 mg, 45%) as a light yellow oil. 1H 
NMR δ 1.36 (s, 3, CH3), 1.43 (s, 9, t-Bu), 1.45 (s, 12, t-Bu, CH3), 1.82-1.90 (m, 1, H8), 1.97-2.06 
(m, 1, H8'), 2.58 ('t', J = 7.4 Hz, 2, H7,7'), 2.64-2.72 (m, 2, H6,6'), 3.83 ('t', J = 5.8 Hz 1, H5), 
4.23-4.24 (m, 1, H9), 4.48 (d, J = 4.4 Hz, 1, H4), 4.69 (d, J = 4.6 Hz, 1, H3), 5.21 (br. d, J = 7.9 
Hz, 1, NH); 13C NMR δ 25.55 (CMe2), 26.98 (CMe2), 27.98 (t-Bu), 28.43 (t-Bu), 29.16 (C7), 
32.88 (C8), 33.78 ( C6), 53.15 (C9), 60.38 (C5), 75.90 (C4), 77.52 (C3), 79.98 (t-Bu) 82.36 (t-
Bu), 112.41 (CMe2), 149.88 (CO), 155.94 (CO), 170.37 (CO), 171.15 (CO); MS (APCI) m/z 461 
(100, MH+).  
 S-[N-(tert-Butoxycarbonyl)-3,4-dihydroxy-3,4-O-isopropylidenepyrrolidin-2-one-5-
yl)methyl]-N-tert-butoxycarbonyl-L-homocysteine tert-butyl ester [139(3R,4R,5S)]. 
Procedure E.  DMAP (18.8 mg, 0.15 mmol) and (Boc)2O (46.4 mg, 0.21 mmol) were added to a 
stirred solution of compound 138 (27 mg, 0.06 mmol) in CH2Cl2 (2 mL) at ambient temperature 
under Ar atmosphere. After 48 h, the reaction mixture was quenched with H2O (5 mL) and 
partitioned (CH2Cl2//NaHCO3/H2O). The organic layer was washed (brine), dried (MgSO4) and 
evaporated. The residue was column chromatographed (30 → 40% EtOAc/hexane) to give 139 
(30 mg, 93%) as a colorless oil: 1H NMR δ 1.36 (s, 3, CH3), 1.43 (s, 9, t-Bu), 1.45 (s, 3, CH3), 
1.46 (s, 9, t-Bu), 1.54 (s, 9, t-Bu), 1.82-1.87 (m, 1, H8), 2.02-2.04 (m, 1, H8'), 2.49-2.55 (m, 1, 
H7), 2.58-2.62 (m, 1, H7'), 2.70 (dd, J = 7.1, 14.2 Hz, 1, H6), 2.95 (dd, J = 2.5, 14.2 Hz, 1, H6'), 
4.22-4.24 (m, 1, H9), 4.23 (dd, J = 2.5, 7.1 Hz, 1, H5), 4.46 (d, J = 5.5 Hz, 1, H4), 4.80 (d, J = 5.5 
Hz, 1, H3), 5.08 (br. d, J = 7.9 Hz, 1, NH); 13C NMR δ 25.56 (CMe2), 26.93 (CMe2), 27.98 (t-Bu), 
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28.33 (t-Bu), 28.42 (t-Bu ), 28.91 (C7), 33.21 (C8), 36.58 (C6), 53.15 (C9), 60.39 (C5), 77.52 
(C4), 75.90 (C3), 82.28 (2x t-Bu), 84.11 (t-Bu), 112.41 (CMe2), 149.88 (CO), 155.50 (CO), 
170.37 (CO), 171.15 (CO); MS (ESI) m/z 583 (100, [M+Na]+). 
S-[N-Benzyl-3,4-dihydroxypyrrolidin-2-one-5-yl)methyl]-L-homocysteine 
[140(3R,4R,5S)]. Treatment of 137 (40 mg, 0.07 mmol) with TFA by Procedure C (step a, 3 h) 
gave crude 140 as colorless oil. RP-HPLC purification (5% CH3CN/H2O for 30 min followed by 
gradient 5 → 90% CH3CN/H2O for 30 min at 2.5 mL/min; tR = 45 min) gave 140 (12 mg, 48%): 
1H NMR (D2O) δ 1.88-2.01 (m, 2, H8,8'), 2.47-2.51 (m, 2, H9,9'), 2.61 (dd, J = 8.4, 14.0 Hz, 1, 
H6), 2.72 (dd, J = 3.9, 14.0 Hz, 1, H6'), 3.47 (dd, J = 3.6, 8.3 Hz, 1, H5), 3.68 (ˈtˈ, J = 5.8 Hz, 1, 
H9), 4.26 (dd, J = 5.3 Hz, 1, H4), 4.27 (d, J = 14.7 Hz, 1, Bn), 4.62 (d, J = 5.2 Hz, 1, H3), 4.68 (d, 
J = 14.7 Hz, 1, Bn), 7.23-7.36 (m, 5, Bn); 13C NMR (D2O) δ 27.71 (C7), 30.31 (C8), 30.75 (C6), 
45.18 (Bn), 53.58 (C9), 63.87 (C5), 70.03 (C4), 70.14 (C3), 128.03, 128.07, 128.02, 135.12 (Bn), 
173.88 (CO), 174.73 (CO); MS (APCI) m/z 355 (50, MH+). HRMS (AP-ESI) m/z calculated for 
C16H22N2O5S [M+Na]+ 377.1147; found 377.1156. 
S-[(3,4-Dihydroxypyrrolidin-2-one-5-yl)methyl]-L-homocysteine [141(3R,4R,5S)]. 
Treatment of 138 (30 mg, 0.065 mmol) with TFA by Procedure C (step a, 3 h) gave crude 141 as 
colorless oil. RP-HPLC purification (5% CH3CN/H2O at 2.5 mL/min; tR = 16 min) gave 141 (10 
mg, 58) %): 1H NMR (D2O) δ 2.00-2.18 (m, 2, H8,8'), 2.65-2.67 (m, 3, H6,7,7'), 2.73-2.74 (m, 1, 
H6'), 3.63 ('t', J = 6.5 Hz, 1, H5), 3.85 ('t', J = 5.8 Hz, 1, H9), 4.19 ('d', J = 5.2 Hz, 1, H4), 4.47 (d, 
J = 5.2 Hz, 1, H3); 13C NMR (D2O) δ 26.21 (C7), 28.53 (C8), 32.70 (C6), 58.83 (C5), 51.07 (C9), 
69.71 (C3), 70.46 (C4), 170.87 (CO),176.10 (CO); MS (ESI) m/z 265 (100, MH+). 
S-[N-(tert-Butoxycarbonyl)-3,4-dihydroxy-3,4-O-isopropylidenepyrrolidin-2-ol-5-
yl)methyl]-N-tert-butoxycarbonyl-L-homocysteine tert-butyl ester [142(3R,4R,5S)]. 
Procedure F. LiEt3BH (1 M/THF; 125 μL, 0.12 mmol) was added to a stirred solution of 139 (28 
mg, 0.05 mmol) in anhydrous THF (1 mL) at -78ºC under N2 atmosphere. After 30 min, the 
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solution was quenched with water and volatiles were evaporated. The residue was partitioned 
(EtOAc//NaHCO3/H2O), washed (brine) and dried (MgSO4). The resulting oil was 
chromatographed (40% EtOAc/hexane) to give 142 [26 mg, 92%; mixture of anomers (α/ β, 3:2) 
which appear as a set of rotamers (1:1)] as colorless oil:  1H NMR δ 1.30 (s, 3, CH3), 1.43 (s, 12, 
t-Bu, CH3), 1.46 (s, 9, t-Bu), 1.48 (s, 9, t-Bu), 1.83-1.94 (m, 1, H8), 2.03-2.10 (m, 1, H8'), 2.51-
2.62 (m, 3, H7,H7',6), 2.83 (dd, J = 3.7, 13.5 Hz, 0.6, H6'), 2.92 (dd, J = 3.5, 13.7 Hz, 0.4, H6'), 
3.45 (dd, J = 3.5, 10.6 Hz, 0.3, H5), 3.99-4.28 (m, 2.7, H5), 4.57 (d, J = 5.8 Hz, 0.6, H4), 4.59 (d, 
J = 5.9 Hz, 0.4, H4), 4.66 (d, J = 6.7 Hz, 0.4, H3), 4.72 (d, J = 5.8 Hz, 0.6, H3), 5.09 (br. d, J = 
7.2 Hz, 0.6, NH); 5.32 (br. d, J = 7.8 Hz, 0.4, NH), 5.39 (s, 0.4, H2), 5.50 (s, 0.6, H2); 13C NMR δ 
(major isomer) 24.82 (CMe2), 26.68 (CMe2), 27.99 (t-Bu ), 28.31 (t-Bu), 28.38 (t-Bu), 29.68 (C7), 
32.85 (C8), 34.68 (C6), 53.21 (C9), 63.86 (C5), 82.76 (C3), 84.44 (C4), 87.13 (C2), 81.22 (2 × t-
Bu), 82.31 (t-Bu), 112.65 (CMe2), 154.31 (CO), 155.39 (CO), 171.25 (CO); MS (ESI) m/z 585 
(100, [M+Na]+). 
S-[3,4-Dihydroxypyrrolidin-2-ol-5-yl)methyl]-L-homocysteine 143(3R,4R,5S)]. Treatment 
of 142 (24 mg, 0.04 mmol) with TFA by Procedure C (step a, 1 h; step b, 10 h at 0 °C) gave 
crude 143. The RP-HPLC (5% CH3CN/H2O at 2.5 mL/min; tR = 14 min) yielded 143 [8 mg, 72%; 
as mixture of anomers, (α/ β, 3:2)] as a slightly yellow oil: 1H NMR (D2O) δ 2 .15-2.24 (m, 1, 
H8), 2.26-2.37 (m, 1, H8'), 2.75-2.82 (m, 2, H7,H7'), 2.84-2.98 (m, 1, H6,6'), 3.09-3.17 (m, 1, 
H6,6'), 3.55-3.69 (m, 0.6, H5), 3.76-3.83 (m, 0.4, H5), 4.15-4.21 (m, 2, H3,4,9), 4.23-4.25 (m, 
0.4, H3), 4.34 (dd, J = 4.8, 6.3 Hz, 0.6, H4), 5.27 (d, J = 2.6 Hz, 0.6, H2); 5.41 (d, J = 2.2 Hz, 0.4, 
H2); 13C NMR δ (major isomer) 25.83 (C7), 28.66 (C8), 30.72 (C6), 51.28 (C9), 58.76 (C5), 
71.98 (C4), 72.96 (C3), 86.54 (C2), 171.15 (CO); MS (ESI) m/z 267 (50, MH+),  
249 (100, [M-17] +) 
N-(tert-Butoxycarbonyl)-5-(tert-butyldimethylsiloxy)-2,3-O-isopropylidene-4-amino-4-
deoxy-α/β-D-ribofuranose (144). Reduction of 133164 (68 mg, 0.17 mmol) with LiEt3BH (1 
  
 
97 
M/THF; 0.43 mL, 0.43 mmol) in anhydrous THF (2 mL) at -78 ºC by the procedure F gave 144164 
(68 mg, 100%) as a colorless oil with data as reported. 
N-(tert-Butoxycarbonyl)-2,3-O-isopropylidene-4-amino-4-deoxy-α/β-D-ribofuranose 
(145). Desilylation of 144 (55 mg, 0.13 mmol) with TBAF (1 M/THF, 0.19 mL, 0.19 mmol), as 
described for 132, [column chromatography (50 → 60% EtOAc/hexane)] gave 145 (α/β, 3:2; 39 
mg, 96%) as a colorless oil: δ 1H NMR δ 1.30 (s, 3, CH3), 1.40 (s, 3, CH3), 1.46 (s, 5.4, t-Bu), 
1.49 (s, 3.6, t-Bu), 2.87 (br. s, 0.4, OH), 3.15 (br. s, 0.6, OH), 3.6-3.77 (m, 1.6, H5,5'), 3.84-3.90 
(m, 0.8, H5',OH), 4.10 ('s', 0.6, H4), 4.27 ('s', 0.4, H4), 4.30 (br. s, 0.6, OH), 4.55 (d, J = 5.9 Hz, 
1, H3), 4.73 (d, J = 5.9 Hz, 0.4, H2), 4.77 (d, J = 5.9 Hz, 0.6, H2), 5.36 (d, J = 5.7 Hz, 0.4, H1), 
5.51 (s, 0.6, H1); 13C NMR (α anomer) δ 24.58 (CMe2), 26.58 (CMe2), 28.33 (t-Bu), 62.61 (C5), 
65.84 (C4), 81.87 (C2), 81.34 (t-Bu), 85.31 (C3), 86.40 (C1), 111.39 (CMe2), 154.29 (NHCO); 
13C NMR (β anomer) δ 24.69 (CMe2), 26.66 (CMe2), 28.33 (t-Bu), 62.61 (C5), 65.84 (C4), 81.21 
(C2), 81.34 (t-Bu), 86.40 (C3), 86.53 (C1), 111.39 (CMe2), 153.53 (CO); MS (APCI) m/z  272 
(50, [M-17] +), 213 (100, [MH-Boc-OH+CH3CN]+). 
4-Amino-4-deoxy-α/β-D-ribofuranose (146a). Treatment of 145 (27 mg, 0.09 mmol) with 
TFA by Procedure C (step a, 5 h; step b, 6 h at 0°C) gave crude 146a (13 mg, 92% as a light 
yellow oil of a mixture of anomers (α/β, 0.65:0.35):  1H NMR (D2O) 3.37-3.38 (m, 0.35, H4), 
3.41-3.44 (m, 0.65, H4), 3.61-3.63 (m, 0.65, H3), 3.70 (dd, J = 6.0, 13.1 Hz, 0.35, H5), 3.71 (dd, 
J = 2.1, 12.8 Hz, 0.65, H5), 3.83 (m, 0.35, H3), 3.91 (dd, J = 3.0, 4.0 Hz, 0.35, H2), 3.95 (dd, J = 
2.8, 13.5 Hz, 0.35, H5'), 4.01 (dd, J = 3.0, 12.8 Hz, 0.65, H5'), 4.05 ('t', J = 3.4 Hz, 0.65, H2), 
4.69 (d, J = 1.3 Hz, 0.35, H1), 4.97 (d, J = 4.0 Hz, 0.65, H1); 13C NMR (major rotamer) δ 50.13 
(C4), 58.86 (C5), 65.61 (C2), 69.84 (C3), 94.05 (C1); 13C NMR (minor rotamer) δ 49.85 (C4), 
61.50 (C5), 63.56 (C2), 69.79 (C3), 94.05 (C1); MS (APCI) m/z 150 (100, MH+). 
4-Amino-4-deoxy-D-ribose O-Benzyloxime (147). A solution of 146a (13 mg, 0.09 mmol) 
and O-benzylhydroxylamine hydrochloride (43 mg, 0.27 mmol) in anhydrous pyridine (4 mL) 
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was stirred under an atmosphere of nitrogen at room temperature for 12 h. Pyridine was 
evaporated to give 147 of sufficient purity for spectroscopic analysis: 1H NMR (MeOD) δ 3.52 
('dt', J = 4.1, 8.4 Hz, 1, H4), 3.79 (dd, J = 3.8, 11.5 Hz, 1, H5), 3.85 (dd, J = 4.4, 8.7 Hz, 1, H3), 
3.94 (dd, J = 8.4, 11.5 Hz, 1, H5'), 4.13 (dd, J = 6.8, 8.7 Hz, 1, H2), 4.92-5.16 (Bn, 2H, signal 
within the envelope of the solvent peaks but cross peaks to each other protons observed in COSY 
and confirmed by HETCOR), 7.41 (H1, signal within the envelope of Bn protons but cross peaks 
to H2 observed in COSY), 7.35-7.47 (m, 5H, Bn) ); 13C NMR δ 56.20 (C4), 58.81 (C5), 71.22 
(C3), 71.56 (C2), 77.01 ( Bn), 128.91, 129.30, 129, 139.07 (Bn); MS (ESI) m/z 255 (60, MH+). 
5-O-tert-Butyldimethylsilyl-1,4-dideoxy-1,4-imino-2,3-O-isopropylidene-D-ribitol (148). 
To a solution of 124 (109 mg, 0.28 mmol) in EtOH (6 mL) was added 5% Pd/C (300 mg) and 
stirred under an atmosphere of H2 at room temperature for 6 h. The mixture was filtered through 
celite to remove the catalyst. The celite bed was washed with ethanol (5 mL) and washings and 
the filtrate were combined and evaporated. The residue was column chromatographed (30% 
EtOAc/hexane) to give 148187 as a colorless oil (70 mg, 80%): 1H NMR δ 0.04 (s, 3, CH3), 0.04 
(s, 3, CH3), 0.87 (s, 9, t-Bu), 1.32 (s, 3, CH3), 1.46 (s, 3, CH3), 2.33 (s, 1, NH), 2.98 ('d', J = 2.6 
Hz, 2, H1,1'), 3.20 ('dt', J = 0.6, 5.8 Hz, 1, H4), 3.52 (dd, J = 5.9, 10.3 Hz, 1, H5), 3.62 (dd, J = 
5.1, 10.3 Hz, 1, H5'), 4.63 (dd, J = 0.8, 5.8 Hz, 1, H3), 4.68 ('dt', J = 2.6, 5.8 Hz, H2) MS (APCI) 
m/z 288 (100, MH+). 
5-O-tert-Butyldimethylsilyl-1,N-didehydro-1,4-dideoxy-1,4-imino-2,3-O-isopropylidene-
D-ribitol N–Oxide (149). A stirred solution of 148 (70 mg, 0.24 mmol) and SeO2 (0.01 mmol, 
1.1 mg) in acetone (3 mL) was cooled to -4 °C under N2 atmosphere and H2O2 (25%) was added 
slowly (3-4 h) until the reaction was completed (monitored by TLC). Volatiles were evaporated 
and the residue was partitioned (EtOAc//NaHCO3/H2O).The organic layer was collected, washed 
(brine) and dried (MgSO4). The resulting solid was chromatographed (50% EtOAc/hexane) to 
give 148 (54 mg, 73%) as a white crystalline solid with data as reported.165  
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1,N-Didehydro-1,4-dideoxy-1,4-imino-2,3-O-isopropylidene-D-ribitol N-Oxide (150). 
Desilylation of 149 (155 mg, 0.51 mmol) with TBAF (1 M/THF, 0.77 mL, 0.77 mmol) at -4 °C as 
described for 132 [column chromatography (10%→ 20% MeOH/CHCl3)] gave 150 (40 mg, 42%) 
as a white crystalline solid: 1H NMR δ 1.34 (s, 3, CH3), 1.41 (s, 3, CH3), 3.87 (dd, J = 2. 1, 19. 6 
Hz, 1, H5), 4.02-4.03 (m, 1, H4), 4.14 (dd, J = 2.3, 11.9 Hz, 1, H5'), 4.96 (d, J = 6.2 Hz, 1, H3), 
5.21 ('dt', J = 1.4, 6.2 Hz, 1, H2), 6.90 (br. s, 1, H1); 13C NMR δ 25.66 (CMe2), 27.15 (CMe2), 
58.87 (C5), 77.16 (C3), 78.85 (C4), 80.78 (C2), 111.50 (CMe2), 134.63 (C1); MS (ESI) m/z 186 
(100, [M-1]+). 
1,N-Didehydro-1,4-dideoxy-1,4-imino-2,3-O-isopropylidene-5-O-methanesulfonyl-D-
ribitol N–Oxide (151). Treatment of 150 (40 mg, 0.21 mmol) at -4 °C with MsCl (26 µL, 0.32 
mmol) by Procedure A [column chromatography (80% → 90% EtOAc/hexane)] gave 151 (24 
mg, 56%) as a colorless oil: 1H NMR δ 1.37 (s, 3, CH3), 1.46 (s, 3, CH3), 3.04 (s, 3, Ms), 4.23- 
4.24 (m, 1, H4), 4.55 (dd, J = 1.8, 11.1 Hz, 1, H5), 4.83 (dd, J = 2.4, 11.1 Hz, 1, H5'), 4.91 (dd, J 
= 1.1, 6.3 Hz, 1, H3), 5.25 ('dt', J = 1.5, 6.4 Hz, 1, H2), 6.99 (s, 1, H1); 13C NMR δ 25.56 (CMe2), 
27.07 (CMe2), 37.42 (Ms), 65.54 (C5), 75.78 (C3), 77.75 (C4), 78.43 (C2), 112.64 (CMe2), 
134.10 (C1); MS (APSI) m/z 266 (100, MH+).  
S-(1,N-Didehydro-1,4-dideoxy-1,4-imino-2,3-O-isopropylidene-D-ribitol-5-yl N-Oxide)-
N-tert-butoxycarbonyl-L-homocysteine tert-butyl ester (152). Treatment of 151 (24 mg, 0.09 
mmol) with L- homocysteinate (38 mg, 0.13 mmol) by Procedure B (step a and b, 8 h at -20°C) 
and purification by column chromatography (80% → 90% EtOAc/Hexane) gave 152 as a 
colorless oil (24 mg, 43%): 1H NMR δ 1.44 (s, 9, t-Bu ), 1.45 (s, 3, CH3),1.46 (s, 9, t-Bu), 1.81-
1.90 (m, 1, H8), 1.96-2.09 (m, 1, H8'), 2.52-2.70 (m, 2, H7,H7'), 3.07 (dd, J = 3.5, 14.4 Hz, 1, 
H5), 3.14 (dd, J = 5.2, 14.4 Hz, 1, H5'), 4.20-4.31 (m, 2, H4,9), 4.71 (d, J = 6.2 Hz, 1, H3), 5.06 
(br. s, 1, NH), 5.31 ('dt', J = 1.4, 6.4 Hz, 1, H2), 6.97 (s, 1, H1); 13C NMR δ 25.64 (CMe2), 26.07 
(CMe2), 28.00 (t-Bu), 28.32 (t-Bu), 29.07 (C7), 32.00 (C5), 32.81 (C8), 53.07 (C9), 77.94 (C3), 
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78.96 (C2), 79.13 (C4), 79.82 (t-Bu), 82.24 (t-Bu), 111.96 (CMe2), 133.43 (C1), 155.39 (CO), 
171.09 (CO); MS (APCI) m/z 461 (100, MH+). 
S-(1,N-Didehydro-1,4-dideoxy-1,4-imino-D-ribitol-5-yl N–Oxide)-L-homocysteine (153). 
Treatment of 152 (72 mg, 0.15 mmol) with TFA by Procedure C (step a, 5 h; step b, 6 h at 0 °C) 
gave crude 152. Purification by HPLC (5% CH3CN/H2O for at 2.5 mL/min; tR = 10-14 min) 
afforded 153 (16 mg, 40 %) as a white solid: 1H NMR (D2O) δ 2.01-2.17 (m, 2, H8,8'), 2.83-2.89 
(m, 2, H7,7'), 2.97 (dd, J = 6.3, 14.4 Hz, 1,H5), 3.06 (dd, J = 3.8, 14.4 Hz, 1, H5'), 3.73-3.77 (m, 
1, H9), 4.08-4.22 (m, 1, H4), 4.40 (dd, J = 3.2, 6.0 Hz, 1, H3), 4.89-4.96 (m, 1, H2), 7.25 (s, 1, 
H1); 13C NMR δ 27.63 (C7), 29.87 (C5), 30.51 (C8), 53.73 (C9), 70.42 (C3), 78.26 (C4), 80.71 
(C2), 141.80 (C1), 173.92 (CO); MS (APCI) m/z 265 (50, MH+). HRMS (AP-ESI) m/z calculated 
for C9H16N2NaO5S [MH+Na]+ 287.0678; found 287.0664. 
 1,N-Didehydro-1,4-dideoxy-1,4-imino-2,3-O-isopropylidene-5-O-methanesulfonyl-1-
methyl-D-ribitol (155). Treatment of 154166 (48.5 mg, 0.26 mmol) with MsCl (0.031 mL, 45 mg, 
0.39 mmol) in the presence of Et3N (0.11 mL, 80 mg, 0.79 mmol) by Procedure A [3 h; column 
chromatography (EtOAc → 10% MeOH/EtOAc)] gave 155 (59 mg, 85%) as a colorless oil: 1H 
NMR δ 1.38 (s, 3, CH3), 1.39 (s, 3, CH3), 2.16 (d, J = 1.0 Hz, 3, N=CMe), 3.00 (s, 3, Ms), 4.38 (s, 
1, H4), 4.39 (dd, 1, J = 3.6, 11.2 Hz, 1, H5), 4.53 (dd, J = 4.2, 11.3 Hz, 1, H5'), 4.64 (d, J = 5.8 
Hz, 1, H3), 4.95 ('q', J = 5.6 Hz, 1, H2); 13C NMR δ 17.08 (N=CMe), 25.70 (CMe2), 26.84 
(CMe2), 37.37 (Ms), 69.68 (C5), 74.97 (C4), 79.77 (C3), 87.42 (C2), 112.37 (CMe2),  177.04 
(C=N); MS (APCI) m/z 264 (100, MH+). 
S-(1,N-Didehydro-1,4-dideoxy-1,4-imino-2,3-O-isopropylidene-1-methyl-D-ribitol-5-yl)-
N-(tert-butoxycarbonyl)-L-homocysteine tert-butyl ester (156). Treatment of 155 (49.5 mg, 
0.19 mmol) with protected L-Hcy (82 mg, 0.284 mmol) by Procedure B (step a and b, 36 h) gave 
124 mg of yellowish oily residue. Crude product was column chromatographed (50 → 60% 
EtOAc/hexane) to give 156 as an colorless oil (73 mg, 85%): 1H NMR δ 1.35 (s, 3, CH3 ), 1.35 (s, 
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3, CH3), 1.43 (s, 9, t-Bu), 1.46 (s, 9, t-Bu), 1.84 ('sx', J = 7.3 Hz, 1, C8), 1.98-2.07 (m, 1, H8'), 
2.11 (d, J = 1.1 Hz, 3, N=CMe), 2.54 ('t', J = 7.6 Hz, 2, H7,7'), 2.65 (dd, J = 6.4, 13.5 Hz, 1, H5), 
2.87 (dd, J = 4.4, 13.5 Hz, 1, H5'), 4.17-4.27 (m, 1, H9), 4.33 (br. 't', J = 4.6 Hz, 1, H4), 4.48 (d, J 
= 5.6 Hz, 1, H2) 4.96 (d, J = 5.6 Hz, 1, H3) 5.13 (br. d, J = 7.7 Hz, 1, NH); 13C NMR δ 16.97 
(N=CMe), 25.72 (CMe2), 26.79 (CMe2), 27.99 (t-Bu), 28.30 (t-Bu), 29.16 (C7), 33.12 (C8), 35.32 
(C5), 53.34 (C9), 76.46 (C4), 79.75 (t-Bu), 81.80 (C2), 82.11 (t-Bu), 87.27 (C3), 111.91 (CMe2), 
155.32 (CO), 171.23 (CO), 174.67 (N=C); MS (APCI) m/z 459 (100, [MH]+); HRMS (TOF MS-
ESI) m/z calculated for C22H38N2O6S [MH]+ 459.2523; found 459.2523. 
S-(1,N-Didehydro-1,4-dideoxy-1,4-imino-2,3-O-isopropylidene-1-methyl-D-ribitol-5-yl)-
L-homocysteine (157). Treatment of 156 (62 mg, 0.136 mmol) with TFA by Procedure C (step a, 
ambient temperature) gave 157 (41 mg, 99%) as a colorless oil: 1H NMR (D2O) δ 1.38 (s, 3, 
CH3), 1.41 (s, 3, CH3), 2.10-2.20 (m, 1, H8), 2.22-2.31 (m, 1, H8'), 2.57 (br. s, 3 → 0, exchanged 
with D2O within few hours, N=CMe), 2.75 (t, J = 7.3 Hz, 2, H7,7'), 2.99 (d, J = 6.2 Hz, 2, H5,5'), 
4.17 (t, J = 6.4 Hz, 1, H9), 4.73 ('t', J = 6.3 Hz, 1, H4), 4.91 (d, J = 5.4 Hz, 1, H2), 5.64 (d, J = 5.3 
Hz, 1, H3); 1H NMR (DMSO) δ 1.28 (s, 3, CH3), 1.30 (s, 3, CH3), 1.95-2.07 (m, 2, H8,8'), 2.08 (s, 
3, N=CMe), 2.60 (dd, J = 7.4, 13.6 Hz, 1, H5) 2.65 ('t', J = 7.9 Hz, 2, H7,7'), 2.82 (dd, J = 5.2, 
13.7 Hz, 1, H5'), 4.01 (br. s, 1, H9), 4.21 ('t', J = 5.8 Hz, 1, H4), 4.51 (d, J = 5.5 Hz, 1, H2), 5.10 
(d, J = 5.5Hz, 1, H3), 7.28 (br. s, 3, +NH3); 13C NMR (D2O) δ 15.45 ('q', J = 20 Hz, N=CCD3), 
23.99 (CMe2), 25.44 (CMe2) 27.41 (C7), 29.46 (C8), 31.63 (C5), 51.36 (C9), 71.15 (C4), 78.97 
(C2), 83.97 (C3), 114.23 (CMe2), 171.45 (COOH), 191.73 (N=CCD3); 13C NMR (DMSO) δ 
16.53 (N=CCD3), 25.38 (CMe2), 26.59 (CMe2), 27.47 (C7), 30.07 (C8), 33.24 (C5), 50.94 (C9), 
74.75 (C4), 80.76 (C2), 86.05 (C3), 111.13 (CMe2), 170.67 (CO), no signal (N=CCD3); MS 
(APCI) m/z 303 (100, MH+). 
S-(1,N-Didehydro-1,4-dideoxy-1,4-imino-1-methyl-D-ribitol-5-yl)-L-homocysteine (158). 
Treatment of 157 (41 mg, 0.136 mmol) with TFA/H2O by Procedure C (step b, TFA/H2O 4:1, 
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ambient temperature, 12 h) gave homogenous 158 (36 mg, 98%) as a colorless oil: 1H NMR 
(D2O) δ 2.05-2.16 (m, 1, H8), 2.17-2.27 (m, 1, H8'), 2.45 (br. s, 3→0, exchanged with D within 
few hrs, N=CMe), 2.73 (dt, J = 3.3, 7.3 Hz, 2, H7,7'), 2.78 (dd, J = 8.3, 14.4 Hz, 1, H5), 2.92 (dd, 
J = 6.0, 14.3 Hz, 1, H5') 4.14 (t, J = 6.4 Hz, 1, H9), 4.35 ('t', J = 7.1 Hz, 1, H4), 4.37 (d, J = 5.3 
Hz, 1, H2), 5.12 (d, J = 5.5 Hz, 1, H3); 13C NMR (D2O) δ 15.36 ('q', J = 21 Hz, N=CCD3), 26.95 
(C7), 29.32 (C8), 30.73 (C5), 51.31 (C9), 71.62 (C2), 71.92 (C4), 76.75 (C3), 171.36 (CO), 
195.79 (N=CCD3); MS (APCI) m/z 263 (100,MH+). 
5-(Propylthiomethyl)pyrrolidin-2-one [160a(5S)]. Procedure G. Propanethiol (50 μL, 42 
mg, 0.55 mmol) was added dropwise to a stirred suspension of NaH (35 mg, 0.875 mmol, 60% 
mineral oil) in dry DMF (1 mL) under Ar atmosphere at 0°C. After 10 min (till gas evolution has 
ceased), solution of compound 159167 [(5S), 82 mg, 0.46 mmol] in dry DMF (1 mL) was added 
dropwise, and after 15 min the reaction mixture was allowed to warm to ambient temperature. 
After 12 h the resulting mixture was quenched with water at 0 °C, volatiles were evaporated, and 
the residue was column chromatographed (EtOAc → 10% MeOH/EtOAc) to give 160a(5S) (77 
mg, 96%) as a colorless oil: 1H NMR 0.98 (t, J = 7.3 Hz, 3, H9), 1.60 (sx, J = 7.3 Hz, 2, H8,8'), 
1.76-1.87 (m, 1, H4), 2.25-2.34 (m, 1, H4'), 2.34-2.45 (m, 2, H3,3'), 2.52 (t, J = 7.3 Hz, 2, H7,7'), 
2.54 (dd, J = 7.7, 13.2 Hz, 1, H6), 2.68 (dd, J = 5.5, 13.2 Hz, 1, H6'), 3.80 ('q', J = 5.5 Hz, 1, H6), 
6.73 (br. s, 1, NH); 13C NMR δ 13.39 (C9), 23.05 (C8), 26.64 (C4), 30.16 (C3), 34.65 (C7), 38.56 
(C6), 53.90 (C5), 177.95 (CO); MS (APCI) m/z 174 (MH+). HRMS (AP-ESI) m/z calculated for 
C8H15NNaOS [M+Na]+ 196.0772; found 196.0779. 
5-(Hexylthiomethyl)pyrrolidin-2-one [160b(5S)]. Treatment of 159167 [(5S), 823 mg, 4.62 
mmol] in dry DMF (6 mL) with a thiolate soln in dry DMF (6 mL) generated from hexanethiol 
(682 μL, 573 mg, 4.86 mmol), and NaH (204 mg, 5.09 mmol, 60%/mineral oil) by Procedure G 
[column chromatography (80% EtOAc/hexane → 5% MeOH/EtOAc)] gave 160b(5S) (932 mg, 
94%) as a colorless oil. 1H NMR δ 0.90 (t, J = 7.0 Hz, 3, H12), 1.24-1.33 (m, 4, H10,H11), 1.33-
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1.42 (m, 2, H9), 1.58 ('q', J = 7.4 Hz, 2, H8,8'), 1.78-1.87 (m, 1, H4), 2.27-2.46 (m, 3, H4',H3,3'), 
2.53 (dd, J = 8.0, 13.4 Hz, 1, H6), 2.54 (t, J = 7.3 Hz, 2, H7,7'), 2.70 (dd, J = 5.3, 13.2 Hz, 1, 
H6'), 3.81 ('q', J = 6.6 Hz, 1, H5), 6.47 (br. s, 1, NH); 13C NMR δ 14.00 (C12), 22.51 (C11), 26.75 
(C4), 28.47 (C9), 29.72 (C8), 30.10 (C3), 31.37 (C10), 32.67 (C7), 38.74 (C6), 53.77 (C5), 
177.65 (CO); MS (APCI) m/z 248 (75, [MH+MeOH]+), (ESI) m/z 216 (100, MH+). 
5-(Nonylthiomethyl)pyrrolidin-2-one [160c(5S)]. Treatment of 159167 [(5S), 458 mg, 2.58 
mmol] in dry DMF (3 mL) with thiolate soln in dry DMF (7 mL) generated from nonanethiol 
(433 mg, 510 μL, 2.71 mmol) and NaH (114 mg, 2.84 mmol, 60%/mineral oil) in dry DMF (7 
mL) by Procedure G [column chromatography (80% EtOAc/hexane → EtOAc)] gave 160c(5S) 
(652 mg, 98%) as a colorless oil. 1H NMR δ 0.86 (t, J = 7.0 Hz, 3, H15), 1.19-1.29 (m, 10, H10-
H14), 1.29-1.38 (m, 2, H9), 1.54 ('q', J = 7.3 Hz, 2, H8,8'), 1.75-1.85 (m, 1, H4), 2.23-2.43 (m, 3, 
H4',H3,3'), 2.51 (t, J = 7.5 Hz, 2, H7,7'), 2.54 (dd, J = 7.4, 13.2 Hz, 1, H6), 2.65 (dd, J = 5.8, 13.2 
Hz, 1, H6'), 3.78 ('q', J = 6.5 Hz, 1, H5), 6.97 (br. s, 1, NH); 13C NMR δ 14.05 (C15), 22.61 
(C14), 26.59 (C3), 28.78 (C9), 29.17, 29.20, 29.43 (C11-C13), 29.76 (C8), 30.14 (C3), 31.81 
(C10), 32.70 (C7), 38.63 (C6), 53.93 (C5), 177.97 (CO); MS (ESI) m/z 258 (100, MH+). 
5-(Dodecylthiomethyl)pyrrolidin-2-one [160d(5S)]. Treatment of 159167 [(5S), 448 mg, 
2.52 mmol] in dry DMF (3 mL) with thiolate soln in dry DMF (7 mL) generated from 
dodecanethiol (634 μL, 535 mg, 2.65 mmol), and NaH (110 mg, 2.77 mmol, 60%/mineral oil) in 
dry DMF (7 mL) by Procedure G [column chromatography (80% EtOAc/hexane → EtOAc)] 
gave 160d (5S) (637 mg, 85%) as a colorless oil. 1H NMR δ 0.88 (t, J = 7.0 Hz, 3, H18), 1.21-
1.32 (m, 16, H10-H17), 1.32-1.40 (m, 2, H9), 1.57 ('q', J = 7.4 Hz, 2, H8,8'), 1.77-1.87 (m, 1, 
H4), 2.26-2.45 (m, 3, H4',H3,3'), 2.53 (t, J = 7.6 Hz, 2, H7,7'), 2.54 (dd, J = 7.8, 13.2 Hz, 1, H6), 
2.68 (dd, J = 5.4, 13.2 Hz, 1, H6'), 3.80 ('q', J = 6.6 Hz, 1, H5), 6.64 (br. s, 1, NH); 13C NMR δ 
14.08 (C18), 22.66 (C17), 26.70 (C3), 28.81 (C9), 29.19, 29.32, 29.50, 29.57, 29.60, 29.62 (C11-
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C16), 29.77 (C8), 30.11 (C3), 31.89 (C10), 32.69 (C7), 38.71 (C5), 53.83 (C5), 177.74 (CO); MS 
(ESI) m/z 300 (100, MH+). 
N-tert-Butoxycarbonyl-5-(propylthiomethyl)pyrrolidin-2-one [161a(5S)]. Procedure E: 
DMAP (114 mg, 0.93 mmol), and (Boc)2O (398 mg, 1.82 mmol) were added to a stirred solution 
of compound 160a (77 mg, 0.445 mmol) in CH2Cl2 (2 mL) at ambient temperature under Ar 
atmosphere. After 48 h, the reaction mixture was quenched with H2O (5 mL) and partitioned 
between CH2Cl2//NaHCO3/H2O. The organic layer was washed (brine), dried (MgSO4) and 
evaporated. The residue was column chromatographed (30 → 40% EtOAc/hexane) to give 161a 
(5S) (107 mg, 88%) as a colorless oil : 1H NMR δ 0.95 (t, J = 7.3 Hz, 3, H9), 1.50 (s, 9, t-Bu), 
1.58 (sx, J = 7.3 Hz, 2, H8,8'), 1.96-2.04 (m, 1, H4), 2.06-2.17 (m, 1, H4'), 2.40 (ddd, J = 2.6, 9.6, 
17.9 Hz, 1, H3), 2.50 ('dt', J = 4.9, 7.3 Hz, 2, H7,7'), 2.58-2.67 (m, 1, H3'), 2.60 (dd, J = 9.2, 13.5 
Hz, 1, H6), 2.86 (ddd, J = 0.5, 2.8, 13.5 Hz, 1, H6'), 4.20-4.27 (m, 1, H5); 13C NMR δ 13.31 (C9), 
21.91 (C3), 23.12 (C8), 28.03 (t-Bu), 31.17 (C2), 34.80 (C7), 35.35 (C6), 57.50 (C5), 83.06 (t-
Bu), 149.75 (CO), 174.17 (CO); MS (ESI) m/z 274 (10, MH+), 215 (100, [MH-59] +). 
Structure of compound 160a was additionally confirmed by conversion to the correponding 
O-benzyloxime derivative with benzylhydroxylamine hydrochloride (6 equiv.) in anhydrous 
pyridine: MS (ESI) m/z 281 (60, MH+), 158 (100, [M-BnOH]+), (APCI) m/z 281 (100, MH+). 
N-tert-Butoxycarbonyl-5-(Hexylthiomethyl)pyrrolidin-2-one [161b(5S)]. Treatment of 
160b (311 mg, 1.45 mmol) in CH2Cl2 (6 mL) with DMAP (185 mg, 1.52 mmol), and (Boc)2O 
(746 mg, 3.42 mmol) by procedure E [column chromatography (20 → 40% EtOAc/hexane)] gave 
161b (5S) (429 mg, 94%) as a colorless oil. 1H NMR δ 0.89 (t, J = 7.0 Hz, 3, H12), 1.25-1.33 (m, 
4, H10,H11), 1.34-1.42 (m, 2, H9), 1.55 (s, 9, t-Bu), 1.59 ('q', J = 7.4 Hz, 2, H8,8'), 2.01-2.08 (m, 
1, H4), 2.10-2.21 (m, 1, H4'), 2.45 (ddd, J = 2.5, 9.6, 17.9 Hz, 1, H3), 2.56 ('dt', J = 2.9, 7.3 Hz, 2, 
H7,7'), 2.62-2.72 (m, 1, H3'), 2.63 (dd, J = 9.3, 13.5 Hz, 1, H6), 2.91 (dd, J = 2.7, 13.5 Hz, 1, 
H6'), 4.24-4.31 (m, 1, H5); 13C NMR δ 13.99 (C12), 21.97 (C3), 22.51 (C11), 28.07 (t-Bu), 28.42 
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(C9), 29.80 (C8), 31.21 (C3), 31.37 (C10), 32.93 (C7), 35.53 (C6), 57.53 (C5), 83.10 (t-Bu), 
149.82 (CO), 174.10 (CO); MS (APCI) m/z 316 (5, M-1+), (ESI) m/z 315 (15, M+), 256 (100, [M-
59 ]+). 
N-tert-Butoxycarbonyl-5-(nonylthiomethyl)pyrrolidin-2-one [161c(5S)]. Treatment of 
160c (250 mg, 0.97 mmol) in CH2Cl2 (5 mL) with DMAP (125 mg, 1.02 mmol), and (Boc)2O 
(712 mg, 3.27 mmol) by procedure E [column chromatography (20 → 25% EtOAc/hexane)] gave 
161c(5S) (345 mg, 99%) as a colorless oil. 1H NMR δ 0.85 (t, J = 7.0 Hz, 3, H15), 1.19-1.29 (m, 
10, H10-H14), 1.29-1.38 (m, 2, H9), 1.51 (s, 9, t-Bu), 1.55 ('q', J = 7.3 Hz, 2, H8,8'), 1.96-2.04 
(m, 1, H4), 2.06-2.17 (m, 1, H4'), 2.40 (ddd, J = 2.5, 9.6, 17.8 Hz, 1, H3), 2.52 ('dt', J = 3.0, 7.4 
Hz, 2, H7,7'), 2.58-2.67 (m, 1, H3'), 2.60 (dd, J = 9.3, 13.5 Hz, 1, H6), 2.86 (dd, J = 2.6, 13.5 Hz, 
1, H6'), 4.21-4.27 (m, 1, H5); 13C NMR δ 14.04 (C15), 21.94 (C4), 22.60 (C14), 28.03 (t-Bu), 
28.71 (C9), 29.14, 29.18, 29.40 (C11-C13), 29.80 (C8), 31.16 (C3), 31.80 (C10), 32.87 (C7), 
35.50 (C6), 57.48 (C5), 82.99 (t-Bu), 149.77 (CO), 174.01 (CO); MS (APCI) m/z 358 (10, MH+), 
(ESI) m/z  357 (10, M+), 299 (100, [MH-59]+). 
N-tert-Butoxycarbonyl-5-(dodecylthiomethyl)pyrrolidin-2-one [161d(5S)]. Treatment of 
160d (234 mg, 0.78 mmol) in CH2Cl2 (5 mL) with DMAP (100 mg, 0.82 mmol), and (Boc)2O 
(600 mg, 2.75 mmol) by procedure E[column chromatography (15 → 20% EtOAc/hexane)] gave 
161d(5S) (302 mg, 97%) as a solidifying oil. 1H NMR δ 0.87 (t, J = 7.0 Hz, 3, H18), 1.21-1.31 
(m, 16, H10-H17), 1.31-1.40 (m, 2, H9), 1.53 (s, 9, Boc), 1.58 ('q', J = 7.5 Hz, 2, H8,8'), 1.99-
2.06 (m, 1, H4), 2.08-2.20 (m, 1, H4'), 2.43 (ddd, J = 2.5, 9.6, 17.9 Hz, 1, H3),  2.54 ("dt", J = 
2.9, 7.4 Hz, 2, H7,7'), 2.60-2.70 (m, 2, H3'), 2.62 (dd, J = 9.2, 13.5 Hz, 1, H6), 2.89 (dd, J = 2.6, 
13.5 Hz, 1, H6'), 4.23-4.29 (m, 1, H5); 13C NMR δ 14.08 (C18), 21.96 (C4), 22.65 (C17), 28.06 
(t-Bu), 28.75 (C9), 29.18, 29.31, 29.48, 29.56, 29.59, 29.61 (C11-C16), 29.83 (C8), 31.19 (C3), 
31.88 (C10), 32.91 (C7), 35.52 (C6), 57.51 (C5), 83.04 (t-Bu), 149.81 (t-Bu), 174.04 (CO); MS 
(APCI) m/z 300 (25, [M-Boc]+), (ESI) m/z 400 (10, MH+), 341 (100, [MH-59]+). 
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5-(Propylthiomethyl)pyrrolidin-2-ol [162a(5S)]. Procedure F. LiEt3BH (1M soln in THF, 
0.98 mL, 0.98 mmol) was added to a stirred solution of 161a (107 mg, 0.39 mmol) in CH2Cl2 (3 
mL) at -78 ºC under N2 atmosphere. After 30 min, the solution was quenched with MeOH (4 mL) 
and allowed to warm to ambient temperature. Volatiles were evaporated. The residue was 
partitioned (EtOAc// NaHCO3/H2O), washed (brine) and dried (MgSO4). The resulting oil was 
chromatographed (30 → 40% EtOAc/hexane) to give N-tert-butoxycarbonyl-5-
(propylthiomethyl)pyrrolidin-2-ol 162a(5S); 104 mg, 96%] as a colorless oil of the  mixture of 4 
anomers/rotamers: MS (APCI) m/z 274 (10, [M-1]+), 258 (90, [M-17]+), (ESI) m/z 258 (65, [M-
17]+). Procedure D. Compound 162a (104mg, 0.37 mmol) in TFA (4.0 mL) was stirred at rt for 2 
h. Volatiles were evaporated to give 163a as light yellow oil having spectral properties of a 
complex mixture [4 isomers of aza-furanose forms accompanied by 25% of aldehyde (chain 
form), as indicated by 1H and 13C NMR spectra]: MS (ESI) m/z 158 (10, [M-17]+).  
5-(Hexylthiomethyl)pyrrolidin-2-ol [163b(5S)]. Treatment of 161b (178 mg, 0.56 mmol) in 
CH2Cl2 (3 mL) with LiEt3BH (1 M soln in THF, 1.41 mL, 1.41 mmol), by procedure F [column 
chromatography (30 → 40% EtOAc/hexane)] gave N-tert-butoxycarbonyl-5-
(hexylthiomethyl)pyrrolidin-2-ol [162b(5S); 170 mg, 95%)] as a colorless oil as a mixture of 4 
isomers: MS (ESI) m/z 316 (100, [M-1]+), 300 (20, [M-17]+). Treatment of 162b with an excess 
of TFA by Procedure D (step a, 2 h at rt) gave crude 163b as light yellow oil as amixture of 4 
isomers of the aza-furanose form accompanied by 25% of aldehyde (chain form); MS (APCI) m/z 
200 (100, [M-17]+) (ESI) m/z 200 (10, [M-17]+). 
5-(Nonylthiomethyl)pyrrolidin-2-ol [163c(5S)]. Treatment of 161c (227 mg, 0.64 mmol) in 
CH2Cl2 (4 mL) with LiEt3BH (1 M soln in THF, 1.59 mL, 1.59 mmol), by procedure F [column 
chromatography (20 → 30% EtOAc/hexane)] gave tert-Butoxycarbonyl-5-
(nonylthiomethyl)pyrrolidin-2-ol [162c(5S); 220 mg, 96%; as a colorless oil of a complex 
mixture of 4 isomers]: MS (ESI)  m/z 358 (10, [M-1]+), 342 (100, [M-17]+). Treatment of 162c 
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with an excess of TFA by Procedure D (step a, 2 h at rt) gave crude 163c as light yellow oil as a 
mixture of 4 isomers of the aza-furanose forms accompanied by 25% of the aldehyde (chain 
form): MS (APCI) m/z 258 (15, [M-1]+), 242 (100, [M-17]+). 
5-(Dodecylthiomethyl)pyrrolidin-2-ol [163d(5S)]. Treatment of 162d (224 mg, 0.56 mmol) in 
CH2Cl2 (4 mL) with LiEt3BH (1 M soln in THF, 1.4 mL, 1.4 mmol), by procedure F [column 
chromatography (20 → 30% EtOAc/hexane)] gave N-tert-butoxycarbonyl-5-
(dodecylthiomethyl)pyrrolidin-2-ol [162d(5S) (219 mg, 97%) as a solidifying oil of the mixture 
of 4 isomers]: MS (APCI) m/z 400 (50, [M-1]+), 384 (100, [M-17]+). Treatment of 162d with an 
excess of TFA by Procedure D (step a, 2 h at rt) gave crude 163d as light yellow oil as a mixture 
of 4 isomers of aza-furanose form accompanied by 25% of aldehyde (chain form): MS (APCI) 
m/z 301 (5, M+), 300, (20, [M-1]+), 284 (100, [M-17]+). 
N-(tert-Butoxycarbonyl)-3,4-dihydroxy-3,4-O-isopropylidene-5-
(hexylthiomethyl)pyrrolidin-2-one [164 (3R,4R,5S)]. Treatment of 136 (60 mg, 0.16 mmol) in 
dry DMF (0.5 mL) with sodium hexathiolate (generated from hexanethiol (46.8 μL,  0.33 
mmol)/NaH (14mg, 0.35 mmol, 60%/mineral oil) in dry DMF (0.5 mL)] by Procedure G [column 
chromatography (5% → 10% MeOH/EtOAc)] gave 164 (25 mg, 40%) as a colorless oil and N-
Boc deprotected 164 (24 mg, 38%) as a white crystalline solid. Compound 164 had: 1H NMR δ 
0.81 (t, J = 7.0 Hz, 3, H12), 1.16-1.27 (m, 6, H9, 10, 11), 1.30 (s, 3, CH3), 1.39 (s, 3, CH3), 1.44-
1.59 (m, 11, H8,8', t-Bu), 2.36-2.50 (m, 2, H7,7'), 2.76 (dd, J = 6.2, 14.4 Hz, 1, H6), 2.82 (dd, J = 
2.7, 14.4 Hz, 1, H6'), 4.31 (dd, J = 2.7, 6.2 Hz, 1, H5), 4.38 (d, J = 5.5 Hz, 1, H4), 4.78 (d, J = 5.5 
Hz, 1, H3); 13C NMR δ 14.00 (C12), 22.49 (C10), 24.38 (CMe2), 25.46 (CMe2), 27.97 (t-Bu), 
28.30 (C9), 29.63 (C8), 31.33 (C11), 33.67 (C7), 33.85 (C6), 60.84 (C5), 76.09 (C4), 77.63 (C3), 
83.94 (t-Bu), 112.27 (CMe2), 170.59 (CO) 149.80 (CO); MS (APCI) m/z 288 (100, [MH-Boc]+). 
N-Boc deprotected 164 had: 1H NMR δ 0.88 (t, J = 7.0 Hz, 3, H12), 1.25-1.36 (m, 6, H9,10,11), 
1.38 (s, 3, CMe2), 1.48 (s, 3, CMe2), 1.56.-1.62 (m, 2, H8,8'), 2.52.-2.75 (m, 3, H6,7,7'), 2.73 (dd, 
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J = 5.9, 13.4 Hz, 1, H6'), 3.81 ('t', J = 6.1 Hz, 1, H5), 4.50 (d, J = 5.9 Hz, 1, H4), 4.69 (d, J = 5.9 
Hz, 1, H3), 5.94 (s, 1, NH); 13C NMR δ 14.01 (C12), 29.66 (C8), 22.52, 28.49, 31.36 (C9, C10, 
C11), 25.57 (CMe2), 26.94 (CMe2), 33.19 (C7), 33.66 (C6), 58.01 (C5), 76.60 (C4), 79.15 ( C3), 
112.73 (CMe2), 173.23 (CO); MS (APCI) m/z 288 (100, [MH+]). 
N-(tert-Butoxycarbonyl)-3,4-dihydroxy-3,4-O-isopropylidine-5-
(nonylthiomethyl)pyrrolidin-2-one [165(3R,4R,5S)]. Treatment of 136 (60 mg, 0.16 mmol] in 
dry DMF (0.5 mL) with  nonathiolate [generated from nonanethiol (62 μL, 0.33 mmol)/NaH (14 
mg, 0.35 mmol, 60% mineral oil) in dry DMF (0.5 mL)] by Procedure G (column 
chromatography (5% → 10% MeOH/EtOAc) gave 165 (30 mg, 42%) as a colorless oil: 1H NMR 
δ; 0.87 (t, J = 7.0 Hz, 3, H15), 1.25-1.31 (m, 12, H9-H14), 1.36 (s, 3, CMe2), 1.45 (s, 3, CMe2), 
1.56-1.57 (m, 11, H8,8', t-Bu), 2.44-2.54 (m, 2, H7,7'), 2.82 (dd, J = 6.2, 14.4 Hz, 1, H6), 2.91 
(dd, J = 2.7, 14.4 Hz, 1, H6'), 4.38 (dd, J = 2.7, 6.2 Hz, 1, H5), 4.45 (d, J = 5.5 Hz, 1, H4), 4.85 
(d, J = 5.5 Hz, 1, H3); 13C NMR δ 14.07 (C15), 22.64, 28.68, 29.15, 29.22, 29.43, 31.83 (C9-14), 
29.66 (C8), 24.38 (CMe2), 25.46 (CMe2), 26.99 (C9), 27.97 (t-Bu), 33.67 (C7), 33.87 (C6), 60.84 
(C5), 76.09 (C4), 77.61 ( C3), 83.93 (t-Bu), 112.27 (CMe2), 149.80 (CO), 170.58 (CO); MS 
(APCI) m/z 330 (100, [MH2-Boc]+). 
3,4-Dihydroxy-5-(hexylthiomethyl)pyrrolidin-2-one [166(3R,4R,5S)]. TFA/H2O (1 mL, 
9:1) was added to N-Boc deprotected 164 (22 mg, 0.07 mmol) or 164 and the resulting solution 
was stirred at 0 ºC 3 h. Evaporation of volatiles gave light yellow oil that was column 
chromatographed (5 → 10% MeOH/EtOAc) to give 166 (12 mg, 63%) as a colorless oil: 1H NMR 
δ 0.87 (t, J = 7.0 Hz, 3, H12), 1.24-1.39 (m, 6, H9, 10, 11), 1.52-1.59 (m, 2, H8,8'), 2.50-2.55 (m, 
3, H5,7,7'), 2.73 (dd, J = 5.5, 13.6 Hz, 1, H6'), 3.71 ('t', J = 6.4 Hz, 1, H5), 4.21 (d, J = 5.0 Hz, 1, 
H4), 4.44 (d, J = 5.0 Hz, 1, H3), 7.11 (br. s, 1, NH); 13C NMR δ 14.01 (C12),), 29.63 (C8), 14.11, 
22.55, 31.42 (C9,C10,C11), 32.73 (C7), 35.27 (C6), 59.85 (C5), 69.77 (C4), 71.75 ( C3), 175.97 
(CO); MS (APCI) m/z 248 (100, [MH]+). 
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 3,4-Dihydroxy-5-(nonylthiomethyl)pyrrolidin-2-one [167(3R,4R,5S)]. Treatment of 165 
(20 mg, 0.04 mmol) with TFA/H2O (1 mL, 9:1) as described for 164 gave 167 (10 mg, 85%) as a 
colorless oil. 1H NMR 0.88 (t, J = 6.8 Hz, 3, H15), 1.20-1.38 (m, 12, H9-H14), 1.52-1.59 (m, 2, 
H8,8'), 2.49-2.54 (m, 3, H 6,7,7'), 2.70 (dd, J = 5.4, 13.5 Hz, 1, H6'), 3.71('t', J = 5.6 Hz, 1, H5), 
4.25 (d, J = 4.9 Hz, 1, H4), 4.49 (d, J = 4.6 Hz, 1, H3), 7.15 ( br. s, 1, NH); 13C NMR δ 14.07 
(C15), 22.66, 28.84, 29.24, 29.27, 29.65, 31.86 (C9-14), 29.50 (C8), 26.99 (C9), 32.61 (C7), 
34.99 (C6), 60.66 (C5), 69.74 (C4), 72.50 ( C3), 176.24 (CO); MS (APCI) m/z 290 (100, [MH]+). 
3,4-Dihydroxy-5-(hexylthiomethyl)pyrrolidin-2-ol [170(3R,4R,5S)]. Treatment of 164 (40 
mg, 0.1 mmol) in THF (1 mL) with LiEt3BH (1 M/THF, 0.26 mL, 0.26 mmol), by procedure F 
[column chromatography (10 → 20% EtOAc/hexane)] gave N-(tert-butoxycarbonyl)-3,4-
dihydroxy-3,4-O-isopropylidene-5-hexylthiomethyl-pyrrolidine-2-ol [168 (3R,4R,5S)]; 39 mg, 
97%)] as a colorless oil of the mixture of 4 isomers: MS (ESI) m/z 389 (100, [M-17]+). Treatment 
of 168 (39 mg, 0.1 mmol) with TFA/H2O (0.9:0.1 mL) at 0 ºC for 3 h gave a light yellow oil that 
was column chromatographed (5 → 10% MeOH/EtOAc) to give 170 (22 mg, 88%) as a light 
yellow oil.  1H NMR showed a complex mixture of four isomers of the aza-furanose form also 
accompanied by aldehyde (chain form); MS (APCI) m/z 250 (20, [MH]+), 232 (60, [M-17] +). 
3,4-Dihydroxy-5-(nonylthiomethyl)pyrrolidin-2-ol [171(3R,4R,5S)]. Treatment of 165 (40 
mg, 0.09 mmol) in THF (1 mL) with LiEt3BH (1 M/THF, 0.22 mL, 0.22 mmol), by procedure F [ 
column chromatography (10 → 20% EtOAc/hexane)] gave N-(tert-butoxycarbonyl)-3,4-
dihydroxy-3,4-O-isopropylidene-5-nonylthiomethyl-pyrrolidine-2-ol [168(3R,4R,5S)]; 30 mg, 
75%)] as a colorless oil as a mixture of 4 isomers: MS (APCI) m/z 414 (100, [M-17]+), 314 (95 
[MH-Boc-H2O]+). Treatment of 169 (28 mg, 0.06 mmol) with an excess of TFA/H2O (0.9:0.1 
mL) at 0 ºC for 3 h gave a light yellow oil that was column chromatographed (5 → 10%
MeOH/EtOAc) to give 171 (18 mg, 96%) as a light yellow oil. 1H NMR showed a complex 
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mixture of four isomers of the aza-furanose form also accompanied by aldehyde (chain form); 
MS (APCI) m/z 292 (80, [MH] +), 274 (60, [M-17]+). 
S-(Methyl 2,3-O-Isopropylidene-β-D-ribofuranos-5-yl)-N-(tert-butoxycarbonyl)-L-
homocysteine tert-butyl ester (173). Treatment of 172 (170 mg, 0.64 mmol) (prepared according 
to reported methods171 with NMR data as reported189 with lithium homocysteinate (260 mg, 0.89 
mmol) by Procedure B [column chromatography (15 → 20% EtOAc/hexane)] gave 173 (220 mg, 
72%) as a light yellow oil: 1H NMR δ 1.32 (s, 3, CH3), 1.45 (s, 9, t-Bu), 1.47 (s, 12, t-Bu, CH3), 
2.07-2.21 (m, 2, H8,8'), 2.54-2.59 (m, 3, H5,7,7'), 2.77 (dd, J = 6.1, 13.4 Hz, 1, H5'), 4.21-4.25 
(m, 1, H9), 4.23 (dd, J = 6.1, 9.5 Hz, 1, H4), 4.60 (d, J = 5.9 Hz, 1, H3), 4.70 (d, J = 5.9 Hz, 2, 
H2), 5.10 (s, 1, H1), 5.30 (br. s, 1, NH); 13C NMR δ 24.94 (CMe2), 26.42 (CMe2), 27.99 (t-Bu), 
28.31 (t-Bu ), 27.73 (C7), 33.18 (C8), 35.58 (C5), 53.77 (C9), 54.93 (OCH3), 83.32 (C2), 85.26 
(C3), 85.78 (C4), 109.59 (C1), 82.17 (t-Bu), 82.21 (t-Bu), 112.44 (CMe2), 155.32 (CO), 171.05 
(CO); MS m/z 500 (100, [M+ Na]+).  
S-Ribosyl-L-homocysteine. Treatment of 173 (30 mg, 0.06 mmol) with TFA/H2O (9:1, 3 
mL) by Procedure C at 0 oC for 12 h gave SRH 174 (8.4 mg, 50%) as a colorless oil with data as 
reported.170 
Methyl 2-Deoxy-5-O-methanesulfonyl-α/β-D-erythro-pentofuranoside (176). Treatment of 
175172  (550 mg, 3.73 mmol) with MsCl (0.290  mL, 316 mg, 4.1 mmol) in the presence of Et3N 
(1.56 mL, 1.13 g, 11.19 mmol) by Procedure A [3 h; column chromatography (EtOAc → 10% 
MeOH/EtOAc)] gave 176 (α/β, 3:2; 367 mg, 43%): 1H NMR δ 1.99-2.18 (m, 2, H2), 3.06 (s, 1.8, 
Ms), 3.09 (s, 1.2, Ms), 3.39 (s, 1.2, OMe), 3.41 (s, 1.8, OMe), 4.19-4.25 (m, 0.6, H3), 4.25-4.32 
(m, 2.6, H4,5,5'), 4.08-4.14 (m, 0.4, H4), 4.44 (dt, J = 4.5, 5.6 Hz, 0.4, H3), 5.09 (dd, J = 1.6, 5.2 
Hz, 0.4, H1), 5.11 (d, J = 4.6 Hz, 0.6, H1); 13C NMR δ 37.50 (Ms), 37.53 (Ms), 41.05 (C2), 41.31 
(C2), 55.06 (OCH3), 55.16 (OCH3), 69.31 (C5), 70.21 (C5), 71.87 (C4), 72.30 (C4), 83.14 (C3), 
83.99 (C3), 105.49 (C1), 105.55 (C1); MS (APCI) m/z 240 (100, [M+H2O]+). 
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Methyl 3-O-Benzoyl-2-deoxy-5-O-methanesulfonyl-α/β-D-erythro-pentofuranoside (177). 
Procedure H. A mixture of 176  (300 mg, 1.3 mmol), 2,6-lutidine (0.30 mL, 278 mg, 2.6 mmol) 
and catalytic amount of DMAP (7.5 mg, 0.65 mmol) in CH2Cl2 was heated to 35 °C and BzCl 
(0.180 mL, 218 mg, 1.56 mmol) was added to this mixture and stirred overnight.The mixture was 
cooled to room temperature and partitioned (CH2Cl2//NaHCO3/H2O). The organic layer was 
washed (brine), dried (MgSO4) and evaporated. The residue was column chromatographed (25% 
EtOAc/hexane) to give 177 (α/β, 3:2; 440 mg, 95%) isolated by column chromatography. The α–
Anomer had: 1H NMR δ 2.36 (dt, J = 5.3, 10.7, 14 Hz, 1, H2), 2.50 (ddd, J = 2.1, 7.3, 14 Hz, 1, 
H2'), 3.10 (s, 3, Ms), 3.41 (s, 3, OMe), 4.35-4.44 (m, 3, H4,5), 4.49 ( dd, J = 4.4, 9.5 Hz, 1, H5'), 
5.22 (dd, J = 2.1, 5.4 Hz, 1, H1), 5.45-5.49 (m, 1, H3), 7.45-7.96 (m, 5, Harom); 13C NMR δ 37.72 
(Ms), 39.02 (C2), 55.52 (OCH3), 69.80 (C5), 75.01 (C3), 81.73 (C4), 105.49 (C1), 105.87 (C1), 
128.51, 129.70, 133.49 (Carom), 166.45 (OCOPh); MS (APCI) m/z 147 ([MH-Bz-Ms]+).β–Anomer 
had: 1H NMR δ 2.21 (dd, J = 1.2, 14.4 Hz, 1, H2), 2.48 (ddd, J = 5.3, 8.3, 14.4 Hz, 1, H2'), 3.08 
(s, 3, Ms), 3.41(s, 1.0, OMe), 4.37 (q, 1, H4), 4.54 ( d, J = 3.4 Hz, 2, H5), 5.18 (d, J = 5.0 Hz, 1, 
H1), 5.30-5.33 (m, 1, H3), 7.45-8.06 (m, 5, Harom). 
S-(Methyl 3-O-Benzoyl-2-deoxy-β-D-erythro-pentofuranos-5-yl)-N-(tert-
butoxycarbonyl)-L-homocysteine tert-butyl ester (178). Treatment of β-anomer of 177 (427 
mg, 1.29 mmol) with protected L-Hcy (530 mg, 1.8 mmol) by Procedure B (step a and b, 36 h) 
gave 950 mg of oily residue. The crude was column chromatographed (20 → 30% 
EtOAc/hexane) to give 178 as a colorless oil (440 mg, 64%). β–Anomer had: 1H NMR δ 1.39 (s, 
9, t-Bu), 1.42 (s, 9, t-Bu), 1.84-1.89 (m, 1, H8), 2.03-2.09 (m, 1, H8'), 2.10 (dd, J = 1.5, 14.5, 
1,H2), 2.51 (ddd, J = 5.3, 8.4, 14.3 Hz, 1, 2'), 2.63 ('t', J = 7.8 Hz, 2, H7,7'), 2.84 (dd, J = 5.7, 
14.0 Hz, 1, H5), 2.92 (dd, J = 4.4, 13.8 Hz, 1, H5'), 3.36 (s, 3, OMe), 4.17-4.26 (m, 1, H9), 4.35 
(dt, J = 4.3, 5.4 Hz, 1, H4),5.10 ( d, J = 5.0 Hz, 1, H1), 5.13 (br. d, J = 7.9 Hz, 1, NH), 5.20 (ddd, 
J = 2.3, 4.0, 8.3 Hz, 1, H3), 7.42-8.02 (m, 5, Harom); 13C NMR δ 27.88 (t-Bu), 28.31 (t-Bu), 29.03 
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(C7), 33.15 (C8), 34.86 (C5), 39.25 (C2), 54.96 (C9), 55.48 (OCH3), 79.73 (C3), 82.53 (C4), 
104.79 (C1), 82.06 (t-Bu), 83.68 (t-Bu), 128.36, 129.75, 129.86, 133.15 (Carom), 155.36 (CO), 
166.45 (COPh), 171.12 (CO); MS (APCI) m/z 426 (60, [MH2-Boc]+). Treatment of 178 with 
TFA/H2O resulted in a complex mixture indicating decomposition of sugar. Therefore, 2-deoxy-
SRH could not be synthesized from 178. 
S-(Methyl 2-Deoxy-α/β-D-erythro-pentofuranos-5-yl)homocysteine (179) Compound 176 
(65 mg, 0.28 mmol) was added to 1 M NaOH/ H2O (5 mL) and degassed with N2 for 30 min, 
followed by addition of D/L-Homocysteine (56.7 mg, 0.42 mmol) and the suspension was heated 
to 60 °C. After 12 h, the reaction mixture was cooled to room temperature, neutralized with dilute 
HCl to pH 7 and washed with EtOAc (3 × 10 mL).109 The water layer was evaporated and 
purified by HPLC (5% CH3CN/H2O for 35 min at 2.5 mL/min; tR = 13.6 min) to give 179 (α/β, 
3:1; 30 mg, 37%). β–Anomer had: 1H NMR (D2O) δ 1H NMR δ 1.8-1.84 (m, 1, H2), 2.30-2.37 
(m, 1, H2'), 2.02-2.15 (m, 2, H8), 2.61-2.78 (m, 4, H5,5',7,7'), 3.76 ('t', J = 5.8 Hz, 1 H9), 4.05-
4.09 (m, 1, H4), 4.11-4.15 (m, 1, H3), 3.28 (s, 3, OMe), 5.10 (d, J = 5.0 Hz, 1, H1), 5.13 (br. d, J 
= 7.9 Hz, 1, NH), 5.06 (d, J = 4.7 Hz, 1, H1); 13C NMR δ 27.49 (C7), 30.38 (C8), 39.85 (C5), 
39.25 (C2), 53.78 (C9), 54.79 (OCH3), 79.60 (C4), 84.20 (C3), 105.48 (C1), 174.10 (COOH); MS 
(APCI) m/z 266 (100, MH+).  
1,2-O-Isopropylidene-5-O-methanesulfonyl-β-D-arabinofuranoside (182). Treatment of 
181173 (85 mg, 0.44 mmol) with MsCl (0.03mL, 37.7 mg, 0.49 mmol) in the presence of Et3N 
(0.186  mL, 135 mg, 1.34 mmol) by Procedure A [3 h; column chromatography (60 → 70% 
EtOAc/hexane) gave 182 (40 mg, 33%) as a colorless oil: 1H NMR δ 1.32 (s, 3, CH3), 1.55 (s, 3, 
CH3), 3.12 (s, 3, Ms), 4.30 (br. s, 1, H3), 4.25 (ddd, J = 1.9, 5.4, 7.3 Hz, 1, H4), 4.36 (dd, J = 5.4 
10.9 Hz, 1, H5), 4.47 (dd, J = 7.3, 10.9 Hz, 1, H5'), 4.60 (d, J = 3.8 Hz, 1, H2), 5.98 (d, J = 3.8 
Hz, 1, H1); 13C NMR δ 25.81 (CMe2), 26.59 (CMe2) 37.94 (Ms), 68.81 (C5), 75.50 (C3), 85.10 
(C4), 105.49 (C1), 86.38 (C2), 106.13 (C1), 113.0 (CMe2).  
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3-O-Benzoyl-1,2-O-isopropylidene-5-O-methanesulfonyl-β-D-arabinofuranoside (183). 
Treatment of 182 (35 mg, 0.13 mmol) with 2,6-lutidine (0.030 mL, 27.8 mg, 2.6 mmol), DMAP 
(0.75 mg, 0.065 mmol) and BzCl (0.018 mL, 21.8 mg, 0.156 mmol)  in CH2Cl2 by Procedure H 
[12 h; column chromatography (50 → 60% EtOAc/hexane) afforded 183 (52 mg, 63%): 1H NMR 
δ 1.32 (s, 3, CH3), 1.62 (s, 3, CH3), 3.13 (s, 3, Ms), 4.45-4.56 (m, 3, H4,5,5'), 4.80 (d, J = 3.8 Hz, 
1, H2), 5.30 (s, 1, H3), 6.05 (d, J = 3.8 Hz, 1, H1), 7.46-8.01 (m, 5, Harom); 13C NMR δ 25.75 
(CMe2), 26.49 (CMe2), 38.05 (Ms), 68.63 (C5), 77.43 (C3), 84.14 (C2), 83.32 (C4), 106.34 (C1), 
113.23 (CMe2), 128.48, 128.84, 129.81, 133.80 (Carom), 165.41 (OCOPh); MS (APCI) m/z 373 
(10, MH+). 
3-O-Benzoyl-5-bromo-1,2-O-isopropylidene-β-D-arabinofuranoside (184).  Compound 
183 (40 mg, 0.107 mmol) and NaBr (12 mg, 0.117 mmol) were heated in DMF (2 mL) under 
reflux for 12 h. The reaction mixture was poured into ice water (20 mL). The mixture was 
partitioned (CH2Cl3//NaHCO3/H2O). The organic layer was washed (brine), dried (MgSO4) and 
evaporated. The residue was column chromatographed (5 → 10% EtOAc/hexane) to give 184 (18 
mg, 47%): 1H NMR δ 1.34 (s, 3, CH3), 1.59 (s, 3, CH3), 3.62 (dd, J = 6.3, 10.2 Hz, 1, H5), 3.71 
(dd, J = 8.4, 10.3 Hz, 1, H5'), 4.48 ('t', J = 7.6 Hz, 1, H4), 4.74  (d, J = 3.8 Hz, 1, H2), 5.49 (br. s, 
1, H3), 6.03 (d, J = 3.8 Hz, 1, H1), 7.46-8.03 (m, 5, Harom); 13C NMR δ 25.83 (CMe2), 26.85 
(CMe2), 31.35 (C5), 78.43 (C3), 83.32 (C4), 84.47 (C2), 85.39 (C4), 106.32 (C1), 113.14 (CMe2), 
128.54, 129.08, 129.83, 133.64 (Carom), 165.30 (OCOPh). 
S-(3-O-Benzoyl-1,2-O-isopropylidene-β-D-arabinofuranos-5-yl)-N-(tert-
butoxycarbonyl)-L-homocysteine tert-butyl ester (185). Treatment of 184 (7 mg, 0.019 mmol) 
with protected L-Hcy (6.6 mg, 0.02 mmol) by Procedure B (step a and b, 36 h) [column 
chromatographed (20 → 25% EtOAc/hexane)] gave 185 as a colorless oil (5 mg, 18%): 1H NMR 
δ 1.32 (s, 3, CH3), 1.37 (s, 9, t-Bu), 1.38 (s, 9, t-Bu), 1.80-1.87 (m, 1, H8), 1.88-2.02 (m, 1, H8'), 
2.52-2.63 (m, 2, H7,7'), 2.86 (dd, J = 6.9, 13.8 Hz, 1, H5), 2.95 (dd, J = 8.0, 13.8 Hz, 1, H5'), 4.29 
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(br. s, 1, H9), 4.30 ('t', J = 6.6 Hz, 1, H4), 4.66 (d, J = 3.9 Hz, 1, H2), 5.13 (br. d, J = 7.6, 1, NH), 
5.29 (br. s, 1, H3), 5.93 (d, J = 3.9 Hz, 1, H1), 7.37-7.96 (m, 5, Harom); MS m/z 590 (45, 
[M+Na]+).  
1-O-Benzoyl-2-deoxy-2-fluoro-3,5-di-O-triisopropylsilyl-α/β-D-arabinofuranoside (189). 
Procedure G. Treatment of 188174 (540 mg, 1.16 mmol) with 2,6-lutidine (0.26 mL, 248 mg, 
2.32 mmol), DMAP (6.7 mg, 0.58 mmol) and BzCl (0.16 mL, 194 mg, 1.39 mmol) by Procedure 
H [column chromatographed (3 → 5% EtOAc/hexane)] gave 189 (α/β, 1:1; 500 mg, 77 %): 1H 
NMR δ 0.78-1.21 (m, 42H, TIPS), 3.77-3.93 (m, 2, H5,5'), 4.26-4.35 (m, 1, H4), 4.78-4.86 (m, 1, 
H3), 5.16-4.96 (m, 1, H2), 6.46-6.53 (m, 0.5, H1), 6.56-6.62 (m, 0.5, H1), 7.40-7.96 (m, 5, Harom); 
19F NMR δ -188.58 (ddd, J = 11.2, 20.8, 44.7 Hz, 1, F2), -203.26 (dd, J = 15.5, 52.2 Hz, 1, F2); 
(APCI) m/z 569 (100, MH+). 
1-O-Benzoyl-2-deoxy-2-fluoro-α/β-D-arabinofuranoside (190). A mixture of 189 (100 mg, 
0.17 mmol) and NH4F (51.8 mg, 1.4 mmol) was refluxed in methanol for 12 h at 60 °C. The 
reaction mixture was evaporated and column chromatographed to give (75 → 80% 
EtOAc/hexane) 190 (α/ β, 1:1; 17 mg, 37 %): β-Anomer had: 1H NMR δ 3.85 (dd, J = 3.4, 12.4 
Hz, 1, H5), 3.69 (dd, J = 4.1, 12.6, Hz, 1, H5'), 3.99 (dt, J = 3.8, 7.4 Hz, 1, H4), 4.71 (dt, J = 7.2, 
17.0 Hz, 1, H3), 5.12 (dd, J = 1.7, 50.7 Hz, 1, H2), 6.43 (d, J = 1.3 Hz, 1, H1), 7.37-8.01 (m, 5, 
Harom); 13C NMR δ 62.09 (C5), 72.31 (d, J = 21.5 Hz, 1, C3), 82.42 (d, J = 9.6 Hz, 1, C4), 99.83 
(d, J = 38.5 Hz, 1, C1), 100.55 (d, J = 200.9 Hz, 1, C2), 128.60 (d, J = 3.5 Hz), 129.21 (d, J = 7 
Hz), 129.90 (d, J = 7.1 Hz), 133.72 (d, J = 4.3 Hz) (Carom), 171.32 (OCOPh); 19F NMR δ -190.63 
(ddd, J = 11.3, 23.2, 50.6 Hz, 1, F2). α-Anomer had 1H NMR δ 3.81 (ddd, J = 1.74, 3.7, 12.5 Hz, 
1, H5), 3.73 (dd, J = 4.0, 12.6, Hz, 1, H5'), 4.22 (dt, J = 3.8, 5.8 Hz, 1, H4), 4.45 ( ddd, J = 1.7, 
5.8, 23.3 Hz, 1, H3), 5.07 (ddd, J = 5.0, 7.3, 52.6 Hz, 1, H2), 6.49 (d, J = 4.5 Hz, 1, H1), 7.37-
8.01 (m, 5, Harom); 13C NMR δ 61.77 (C5), 75.35 (d, J = 22 Hz, 1, C3), 86.00 (d, J = 4 Hz, 1, C4), 
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93.26 (d, J = 18.1 Hz, 1, C1), 94.53 (d, J = 184.5 Hz, 1, C2), 128.46, 129.49, 130.16, 133.61 
(Carom), 165.1 (OCOPh); 19F NMR δ -190.63 07 (ddd, J = 11.3, 23.2, 50.6 Hz, 1, F2). 
1-O-Benzoyl-2-deoxy-2-fluoro-5-O-methanesulfonyl-α/β-D-arabinofuranoside (191). 
Treatment of 190 (15 mg, 0.05 mmol) with MsCl (5.0 µL, 7.3 mg, 0.06 mmol) in the presence of 
Et3N (21 µL, 15.1 mg, 0.15 mmol) by Procedure A [3 h; column chromatography (60 → 70% 
EtOAc/hexane) gave 191 (α/β, 1:1; 13 mg, 65%) as a crystalline solid : 1H NMR δ 2.98 (s, 3, 
Ms), 3.13 (s, 3, Ms), 4.41 ('br. s', 4, H5,5'), 4.46 (dd, J = 4.1, 6.8 Hz, 1, H4), 4.60 ('q', J = 4.0 Hz, 
1, H4), 5.13 (dd, J = 4.2, 19.6 Hz, 1, H3), 5.26-5.40 (m, 3, H2,3), 6.55 (d, J = 8.0 Hz, 1, H1), 6.56 
(d, J = 5.8 Hz, 1, H1), 7.39-8.10 (m, 10, Harom); 13C NMR δ 37.82 (Ms), 38.31 (Ms), 66.40 (C5), 
67.28 (C5), 77.77 (d, J = 8 Hz, 1,C4), 78.90 (d, J = 23 Hz, 1, C3), 79.35 (d, J = 31 Hz, 1, C3), 
91.79 (d, J = 204 Hz, 1,C2), 92.57 (d, J = 18 Hz, 1,C1), 97.05 (d, J = 37 Hz, 1,C1), 97.07 (d, J = 
186 Hz, 1,C2), 128.31, 128.71, 128.90, 129.97, 130.08, 130.55, 134.06, 134.57 (Carom), 165.41 (d, 
J = 31 Hz, 1, OCOPh), 171.13 (OCOPh): 19F NMR δ -190.14 (ddd, J = 10.0, 19.7, 48.8 Hz, 1, 
F2). 
4.3. Borate complexation study  
The 11B NMR spectra were recorded following the published methods described for the study 
of DPD binding to borate.183 The 11B NMR spectra were recorded at 25 °C using Bruker ultra 
shield™ spectrophotometer equipped with TBI probe 1H/13C/D-BB Z-GRD at 192.6 MHz and 
referenced to Et2O.BF3. The NMR sample tubes (10 mm o.d.) made of poly(tetrafluoroethylene) 
(PTFE) were used for all measurements. All the spectra were recorded by collecting 16 scans. 
The boron binding affinities of aminoalcohols and cis-diols were estimated using 11B NMR either 
by taking compounds of interest and borate in 1:1, 1:2 and 2:1 molar ratios in 0.5 mL of NaHCO3 
in D2O solution at pH 7.8 or 5 mg of compound in saturated borate at pH 7.8 in 0.5 mL of D2O 
solution.  
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4.4. Biological screening methods 
4.4.1. Antiquorum sensing assay 
4.4.1.1. β-galactosidase assay 
An overnight culture of E. coli DH5α harboring the plasmids pSC11, which contains a PlasI-
lacZ translational fusion15 and pJN105L, which contains a PBAD-lasR  expression plasmid190 
grown in LB media (10 g tryptone, 5 g yeast extract, 5 g sodium chloride per liter) supplemented 
with ampillicin (100 μg/ ml) and gentamycin (15 μg/ ml), was diluted to an OD600 of 0.150. At 
this time, arabinose (0.2 % w/v), N-3-(oxododecanoyl)homoserine lactone (3-oxo-C12-AHL; 2 
μM), and either the compound under analysis, water extract from Conocarpus erectus or 
Callistemon viminalis191 or solvent (water or DMSO), were added to the culture (1.5 mL). A 
negative control containing only solvent and arabinose (0.2% w/v) was also assayed.  The 
cultures were incubated with shaking for three hours at 37 °C.  
The conditions for the rhl biomonitor E. coli DH5α harboring pECP61.5 plasmid192, were 
essentially same except that the LB medium was only supplemented with ampillicin (100 μg/ ml), 
the overnight culture was diluted to an OD600 of 0.150, induced with 1 mM isopropyl β-D-
thiogalactoside (IPTG), 2 μM C4-AHL and the compounds or the controls added when the OD600 
reached 1.0. After incubation at 37 °C for 4 hours with shaking, β -galactosidase activity was 
assayed as described previously.193 Assays were repeated at least twice. For each biological 
replicate, experimental triplicates were performed and the average percent activity calculated by 
dividing the average Miller units from the samples containing compound or extract by the 
average Miller units from the sample containing solvent and multiplying by 100. Significance of 
inhibition was determined using a paired two-tailed Student t-test. 
4.4.1.2. Growth and luminescence measurement drop assay 
Growth and luminescence measurement drop assays were conducted by Professor Makemson 
at FIU. The V. harveyi strain B392 (MAV) (or strain BB170 (AI-1-, AI-2+) or strain BB152 (AI-1-
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, AI-2+), was grown in AB medium (75% artificial sea water, 0.3% glycerol, 0.2% casamino 
acids, 0.02 % glycerol-phosphate, 25 mM HEPES buffer) at a pH 7.5194 Growth was measured in 
a Spectronic 20 as OD660nm and luminescence was measured in a calibrated photometer and 
recorded in light units (1 LU = 1.08 x 108 q/s/mL). An overnight culture of V. harveyi was added 
to 45 mL of AB medium to an OD660nm of ~0.03, When the culture was rapidly growing (OD660nm 
~0.05 to 0.07), the culture was split (2.5 mL/ 13x100mm culture tubes) and small amounts (2.5 
µL and 10 µL) of each compound were added to each tube. The compound, dissolved in water or 
DMSO served as a control. Each measurement was obtained from a single trial and luminescence 
without inhibitor was considered 100%. 
4.4.2. LuxS enzyme inhibition studies with 4-aza-SRH analogs 
4.4.2.1. LuxS activity assay 
 The DTNB assay was performed in a buffer containing 50 mM HEPES (pH 7.0), 150 mM 
NaCl and 150 μM DTNB. The concentration of substrate (SRH) varied from 2.2 to 50 μM. The 
reaction was initiated by the addition of 0.8 μM of Co-BsLuxS and monitored continuously at 
412 nm (ε = 14150 M-1 cm-1) in a Perkin-Elmer λ25 UV-VIS spectrophotometer at room 
temperature. The initial rates were recorded from the early regions of the progress curves (3 min 
for BsLuxS reactions) and fitted against Michaelis-Menten equation V = (kcat[E]0 [S]/(KM +[S]) to 
obtain KM and kcat values.   
4.4.2.2. LuxS inhibition assay 
 The LuxS inhibition assay was carried out in a similar manner as the activity assay but with 
varying concentrations of inhibitors and 17.8 μM of SRH (to a total volume of 1.0 mL). The 
inhibitors were dissolved in DMSO and the final DMSO concentration was kept less than 5% as 
to not to interfere with the enzyme activity. Kinetics was started by the addition of 0.8 µM B. 
subtilis LuxS coordinated with cobalt (Co-BsLuxS) and monitored at 412 nm. Slope was 
determined from 0-3 min. To calculate the KI values, the relative activity (V/V0) (V and V0 are the 
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reaction rates in the presence and absence of inhibitors, respectively) was plotted against inhibitor 
concentrations [I] and fitted against the equation: V/V0 = (KM+[S])/{KM(1+ [I]/KI)+[S]}.195 In case 
of hemiaminal 143 which displayed time-dependent inhibition, Co-BsLuxS (1.6 μM) was 
incubated with 143 in buffer (without DTNB) for 30 min at room temperature. The reaction was 
then started by adding SRH and DTNB. The KI* values were obtained in the same way from a 
similar equation: V/V0 = (KM+[S])/KM(1+[I]/KI*)+[S]}.  
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5. CONCLUSION 
I have designed and synthesized various LuxS inhibitors and LasR QS modulators. The 
common synthetic approach involved activation of C5 hydroxyl group of the suitable sugar 
precursor and coupling with either thiolate derived from homocysteine (in case of LuxS 
inhibitors) or alkyl thiols (in case of γ-lactam and hemiaminal analogs). The N-Boc-L-Hcy-CO2t-
Bu was synthesized from commercially available L-homocystine. Reduction of the protected 
homocystine with water soluble tris(2-carboxyethyl)phosphine hydrochloride generated protected 
Hcy thiol. The N-tert-butoxycarbonyl-1,4-dideoxy-1,4-imino-2,3-O-isopropylidene-D-ribitol 124 
served as the common sugar precursor for the synthesis of 4-aza-SRH analogs. Thus, the 
synthesis of pyrrolidine analog 129 was achieved by coupling of the mesylated N-Boc protected 
iminoribitol 127 with thiolate of N-Boc-L-Hcy-CO2t-Bu and subsequent deprotection of acid 
labile groups with TFA.  For the synthesis of lactam analog 141, the mesylated ribolactam 136 
required for coupling to Hcy was produced by selective oxidation of the mesylated aza sugar 127 
with RuO2/NaIO4. The hemiaminal analog 143 was accessed conveniently by the super hydride® 
promoted reduction of the protected lactam analog 139 and subsequent TFA treatment. Oxidation 
of TBDMS protected imino ribitol 148 with SeO2/H2O2 produced nitrone based sugar 149 which 
upon subsequent standard desilylation and mesylation yielded desired activated nitrone sugar 151. 
In case of methyl imino analog 158, the key sugar substrate, D-riboiminocyclitol 154 was 
synthesized from L-lyxo sugar by exo-imino to endo iminocyclitol rearrangement. Such imino 
sugar was subsequently mesylated and coupled to the thiolate of N-Boc-L-Hcy-CO2t-Bu to give 
protected methyl imine analog 157 which upon TFA treatment gave imine analog 158. The 2-
deoxy-SRH analog 179 was synthesized by condensation of the mesylated methyl 2-deoxy-α/β-
D-ribose 176 with Hcy. The mesylated-arabinose intermediate 183, required for coupling to Hcy 
was conveniently accessed from D-arabinose. However, coupling of the mesyl sugar 183 with 
protected Hcy provided protected S-arabinosyl-L-homocysteine (SAH) 187 in very low yields. In 
  
 
120 
case of [2-F]SAH 194, the key sugar precursor 5-O-mesyl-2-fluoroarabinose 188 was synthesized 
from reported 2-fluoroarabino lactone. However coupling of the -O-mesyl derivative 188 with 
Hcy was unsuccessful. 
The γ-lactams with alkylthiomethyl substitution at carbon γ and their N,O-acetal counterparts 
were prepared from the key substrate (S)-5-(bromomethyl)-2-pyrrolidone 159 (derived from L-
pyroglutamic acid). Displacement of bromide in 159 with sodium alkylthiolate produced 5-S-
alkylthio lactams 160 with different lengths of alkyl chain (C3-C12). Reduction with super 
hydride® and subsequent deprotection gave hemiaminal analogs 163. The hexylthio ribolactam 
166 and nonylthio ribolactam 167 were synthesized analogously. Reduction of the protected 
ribolactams with super hydride and subsequent deprotection with TFA provided the hemiaminal 
counterparts 170 and 171. 
The optically pure γ-lactams and corresponding hemiaminals were evaluated for their effect 
on P. aeruginosa AHL-dependent las and rhl QS pathways isolated in E. coli. Lactam analogs 
160 showed selectivity between two QS systems, acting as inhibitors against lasR and moderate 
activators against rhlR, presumably because of the differences in the active sites of their cognate 
R proteins. Antagonism of lasR activity increased with the length of the alkylthio chain. 
Interestingly, the cyclic hemiaminal derivatives with shorter alkylthio chain (163a and 163b) 
were found to stimulate lasr QS systems at lower concentrations while strongly inhibit both QS 
systems at higher concentrations. The ribolactam 166/167 and the corresponding cyclic 
hemiaminal 170/171 analogs inhibited lasR and stimulated rhlR moderately. Although, the 
mechanism of inhibition is still  unknown, it is plausible that the compounds act as competitive 
inhibitors by binding to the QS sensor or affect events downstream, such as the binding of LasR 
(or in some cases, RhlR) to the promoter. Affecting downstream events would require that the 
compound enter the cells, which is unknown. Alternatively, it is established that although the rhl 
signaling molecule, C4-AHL diffuses freely, transport of the las signaling molecule is more 
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complex, involving partitioning into the membrane and transport out of the cell by the MexAB-
OprM efflux pump. Thus, it is also possible that the compounds with longer side chains affect the 
membrane and that the las pathway is more sensitive to these changes.  
The pyrrolidine analog 129, lacking C1-hydroxyl exhibited weak inhibition against LuxS 
enzyme with an IC50 value of 0.8 mM and KI of 49 µM. Similarly, lactam analog 141, which also 
lacked anomeric hydroxyl displayed weak competitive inhibition with IC50 value of 0.6 mM and 
KI of 37 µM, suggesting the significance of anomeric hydroxyl for binding or the requirement of 
substrate to exist in open form. This data were also in agreement with the weak inhibition 
observed previously for 1-deoxy-SRH. However, as the inhibitors 129 and 141 possess KI values 
in similar range (40-60 µM), the inhibition might be because of the binding of the homocystiene 
moiety alone. As expected, the N-benzyl lactam analog 140 had no measurable activity. The large 
nonpolar benzylic group at ring nitrogen might have prevented access of 140 into the active site. 
Similarly 2,3-dideoxy lactam analogs of SRH, 195 and 196  were devoid of activity at tested 
concentrations, underscoring the importance of hydroxyl groups for metal chelation and binding 
at the active site.  
The 4-aza-SRH 143 was found to be a time-dependent inhibitor of moderate potency with an 
IC50 value of 60 µM. However, because of the complex kinetics of 143 observed with the 
enzyme, the KI value could not be determined and the mechanism of time-dependent inhibition 
was not identified. Nonetheless, in order to support the hypothesis of covalent inhibition by 4-
aza-SRH 143 via the dehydrated imine 197, methyl imine analog of 4-aza-SRH 158 was 
independently synthesized and tested. Unfortunately, the1-methyl imine analog of SRH 158 was 
found to be inactive. Lack of anomeric hydroxyl or misfit of iminocyclitols at the active site or 
lack of stability of the compound at the testing conditions might have contributed to the loss of 
activity. However, without further enzymatic studies, the precise effect of imine functionality on 
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LuxS activity could not be concluded at the present time. Also, despite the attempts from various 
research groups, correlation between LuxS enzymatic activity and QS was not found so far. 
In this dissertation, two approaches for identification of QS inhibitors in both interspecies 
(LuxS inhibitors) as well as intraspecies (human pathogen, P. aeruginosa) were addressed. The 
structural and biological data provided by these analogs might contribute to the development of 
more effective QS inhibitors which in turn might impact drug discovery and health care.  
As a result of this dissertation, a future work towards understanding the function of S-
ribosylhomocysteinase (LuxS) should mainly concentrate on synthesis of the aza-DPD analogs as 
well as novel inhibitors of LuxS with modifications at C2 or C4 of the ribose ring of the natural 
substrate. 
Future directions 
Aza-DPD analogs should be prepared to evaluate their modulation of QS activity and might 
also allow study of their complexation with borate. Borate complexation experiments with 
aminoalcohols related to aza-AI-2 should shed the light on understanding the binding preferences 
of borate and might further facilitate the understanding of the mechanism of action of hemiaminal 
143.  
Synthesis and evaluation of C2 modified SRH derivatives as potential LuxS inhibitors might 
assist in understanding the role of acid/base residues at the active site. As [3-F]SRH and [3-
Br]SRH were previously found to be time-dependent LuxS inhibitors due to the LuxS catalyzed 
elimination of halide ion, it will be interesting to study if the mechanism of  interaction of [2-
F]SRH and [2-Br]SRH with LuxS follows the nucleophilic substitution at C2 resulting in 
covalent inhibition or elimination mechanism as observed with C3 analogs. So far, SRH analogs 
with modifications at C1 and C2 and C3 were targeted as LuxS inhibitors. Such substrate analogs 
were proposed to inhibit sugar ring opening, first and second keto-enol tautomerization steps 
associated with LuxS catalysis, respectively. Design and synthesis of C4 modified SRH analogs 
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should permit to study the β-elimination reaction in LuxS catalysis (which is the last step leading 
to the release of DPD and Hcy). Modification of SRH with long alkyl side chains either at C4 or 
C7 might inhibit homodimerization of LuxS and thereby prevent LuxS catalysis. As it is known 
from literature that Hcy binding pocket is far from the sugar binding active site, such SRH 
analogs with hydrophobic alkyl chains should fit into the binding pockets for both sugar and Hcy 
moieties.49 However, the presence of hydrophobic alkyl chain might prevent dimerization and 
hence LuxS catalysis. 
Moreover, structural basis for the time-dependent inhibition observed by 143 can be 
estimated by cocrystallizing LuxS with 143. As this analog exists as a complex mixture of several 
isomers, such study will also reveal the identity of the isomer responsible for inhibition. 
Conformational changes, if any occurred due to the replacement of ring oxygen of SRH with 
nitrogen (as in hemiaminal 143) can also be studied using crystal structural data. 
To confirm the LasR inhibition observed by lactam/hemiaminal analogs, inhibition of LasR 
regulated extracellular virulence factors (pyocyanin and elastase production) in culture fluids of 
P. aeruginosa can be estimated. Lactam/hemiaminal analogs with alkylthiomethyl substitution at 
carbon γ were targeted as QS modulators in this study. As a step forward, analogs with 
alkylthiomethyl substitution at α position can also be synthesized. Since similar α linkage of side 
chain to the lactone ring is found in the native AHL, such analogs might prove to be better QS 
inhibitors than γ substituted analogs. Similar thiolactam analogs can also be prepared and targeted 
as QS modulators.  
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APPENDIX : 1H NMR spectra of the selected compounds. For peak assignments refer to the experimental section. 
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